document incorporate reference document partofformk proxy statement annual meeting iii stockholder hold april file securities exchange commission day close fiscal year cover reporttable content item business item risk factor cautionary factor affect future result item b unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant ii item marketforregistrantscommon equityrelate stockholder matter andissuerpurchasesof equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum financial statement note consolidated financial statement report independent register public accounting firm b supplementary datum item change disagreement accountant account financial disclosure item control procedure management report item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature consent independent register public accounting firm independent auditor consent item business merckcoincmerckorthecompanyisaglobalresearchdrivenpharmaceuticalcompanythat discoversdevelopsmanufacturesandmarketsabroadrangeofinnovativeproductstoimprovehumanandanimal healththecompanysoperationsareprincipallymanagedonaproductsbasisandarecomprisedoftworeportable segment pharmaceutical segment vaccine segment pharmaceutical segment include human health pharmaceutical product market directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell humanhealthpharmaceuticalproductsprimarilytodrugwholesalersandretailershospitalsgovernmentagencie andmanagedhealthcareproviderssuchashealthmaintenanceorganizationspharmacybenefitmanagersandother institutionsthevaccinessegmentincludeshumanhealthvaccineproductsmarketedeitherdirectlyorthrougha joint venture product consist preventative pediatric adolescent adult vaccine primarily admin istere physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity company professional representative communicate effectivenesssafetyandvalueofourpharmaceutical andvaccineproductstohealthcareprofessionalsinprivate practice group practice manage care organization financial information information pharmaceutical segment vaccine segmentseeitemmanagementsdiscussionandanalysisoffinancialconditionandresultsofoperation item financial statement supplementary datum overviewduringmerckbeganrealizingbenefitsfromitsmultiyearstrategicplandesignedto reengineer way company develop distribute medicine vaccine worldwide company benefit evolution new commercial model design align company product research developmentandmarketingeffortsutilizingthelatesttechnologiesandbroadeningitsengagementwithcustomer physician scientific leader need medicine vaccine development pipeline patient soon company work build sustainable research development advantage leverage technology facilitate drug discovery development successfully reduce clinical development cycletime theprogressoftheseeffortsisdemonstratedinpartbythecompanysrevenuegrowthinwhich reflect continued market penetration global rollout gardasil human papillomavirus quadrivalent typesandvaccinerecombinantavaccinetohelppreventcervicalcancerprecancerousandlow gradelesionsvulvarandvaginalprecancersandgenitalwartscausedbyhumanpapillomavirushpvtype andjanuviasitagliptinphosphateamedicine thatenhancesanaturalbodysystemtoimproveblood sugarcontrolinpatientswithtypediabetesandrotateqrotavirusvaccineliveoralpentavalentapediatric vaccine help prevent rotavirus gastroenteritis infant child couple strong performance severalinlineproductsthegrowthintheseproductshasmorethanoffsetrevenuedeclinesassociatedwith loss market exclusivity zocor proscar additionallythecompanycontinue theadvancement ofdrugcandidate throughitspipeline food drug administration fda approve janumet sitagliptin phosphate metforminhydrochlorideanoralantihyperglycemicagentthatcombinesjanuviawithmetformininasingletablet toaddressallthreekeydefectsoftypediabetesandisentressraltegravirafirstinclassintegraseinhibitorfor treatment hiv infection treatmentexperience patient addition january fda approvedemendfosaprepitant dimeglumineforinjection anintravenoustherapy forthe preventionofchemo therapyinducednauseaandvomitingcinvalsothecompanyanticipatesthefdawilltakeactioninon thenewdrugapplicationndaforcordaptivetheproposedtrademarkformkaanextendedrelease erniacincombinedwithlaropiprantanovelflushingpathwayinhibitorforcholesterolmanagementfurther thecompanymadeasupplementalfilingwiththefdainjanuaryforgardasilforanexpandedindicationfor womenthroughageandanticipates makingasupplementalfilingforisentresslaterinforanexpande indication use treatmentnave patient company currently seven candidate phase iii devel opmentandanticipatesmakingndafilingswithrespecttotwoofthecandidatesinmkbsimvastatin combine laropiprant er niacin mk taranabant investigational medication treatment obesity company research development effort fully discuss research development aspartofimplementingthenewcommercialmodelthecompanyisreengineeringitscorebusinesstobe efficient goal reduce aspect cost base realize gross margin improvement reengineering include implementation manufacturing marketing cost saving initiative initial phaseoftheglobalrestructuringprogramannouncedinwasdesignedtoreducethecompanyscoststructure increaseefficiencyandenhancecompetitivenessthescopeofthisinitialphaseincludedtheimplementationofa newsupplystrategybythemerckmanufacturingdivisionoverathreeyearperiodfocusingonestablishinglean supplychainsleveraginglowcostexternalmanufacturingandconsolidatingourmanufacturingplantnetworkas partofthisprogramthroughjanuarymerckhadclosedsoldorceasedoperationsatfivemanufacturingsite preclinical site eliminate approximately position companywide comprise actual headcountreductionsandtheeliminationofcontractorsandvacantpositionsthecompanyhowevercontinuesto hirenewemployeesasthebusinessrequiresthepretaxcostsofthisrestructuringprogramsinceinceptionthrough end billion approximately noncash relate primarily accelerate depreciation facility schedule closure approximately represent separation restructuring relate cost cost million expect approximately million tomillion inatwhichtimetheinitial phaseoftherestructuring programrelate tothe manufacturingstrategyisexpectedtobesubstantiallycompletemerckcontinuestoexpecttheinitialphaseofit cost reduction program combine cost saving company expect achieve marketing administrativeandresearchanddevelopmentexpenseswillyieldcumulativepretaxsavingsoftobillion onnovembermerckenteredintoanagreementthesettlementagreementwiththelawfirm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representative plaintiff counsel state coordinate proceeding resolve state federal myocardial infarction miandischemic strokeisclaim alreadyfiledagainstthecompanyinthe unitedstatesifcertainparticipationconditionsunderthesettlementagreementaremetorwaivedthecompany willpayanaggregatefixedamountofbillionintotwofundsforqualifyingclaimsconsistingofbillion qualify mi claim million qualifying claim enter resolution process settlementprogramasaconsequenceofthesettlementagreementthecompanyrecordedapretaxchargeof billioninthefourthquarterofinadditionthecompanyrecordedapretaxgainofmillionrelating toinsuranceproceedswhichthecompanywasawardedoragreedtoreceivepursuanttonegotiatedsettlementsin previously disclose arbitration company upper level excess product liability insurance carrier relatingtocoverageforcostsincurredinthevioxxproductliabilitylitigationtheseitemsarediscussedmorefully item legal proceeding alsointhefourthquarterofthecompanyrecordedapretaxchargeofmillioninconnection withtheanticipate resolution ofinvestigationsofcivilclaim byfederal andstate authority relate tocertain pastmarketingandsellingactivitiesincludingnominalpricingprogramsandsamplesonfebruarythe company enter definitive agreement resolve investigation item discuss fully item legal proceeding earning common share ep assume dilution share include impactoftheusvioxxsettlementagreementchargecostsassociatedwiththeglobalrestructuringprogramthe charge relate resolution certain civil governmental investigation gain insurance arbitrationawardrelatedtovioxxproductliabilitylitigationcoveragewhichcollectivelyreducedepsbyper shareinadditionepsinreflectsanacquiredresearchchargerelatedtotheacquisitionofnovacardiainc novacardia additional reserve establish solely future legal defense cost vioxx litigation favorable impact gain sale asset product divestiture net gain settlement certain patent dispute item discuss fully note consolidated financial statement product sale sale company product follow million singulair cozaarhyzaar fosamax zocor cosopttrusopt primaxin januvia cancidas vasotecvaseretic maxalt proscar propecia arcoxia crixivanstocrin emend invanz janumet pharmaceutical vaccine gardasil rotateq zostavax proquadmmr iivarivax hepatitis vaccine vaccine presentednetofdiscountsandreturn otherpharmaceuticalprimarilyincludessalesofotherhumanpharmaceuticalproductsandrevenuefromthecompanysrelationshipwith astrazenecalpazlpprimarilyrelatingtosalesofnexiumaswellasprilosecrevenuefromazlpwasbillionbillionand billioninandrespectivelyinotherpharmaceuticalalsoreflectedcertainsupplysalesincludingsupplysale associatedwiththecompanysarrangementwithdrreddyslaboratoriesdrreddysforthesaleofgenericsimvastatin theseamountsdonotreflectsalesofvaccinessoldinmostmajoreuropeanmarketsthroughthecompanysjointventuresanofipasteur msdtheresultsofwhicharereflectedinequityincomefromaffiliate otherprimarilyincludesotherhumanandanimalhealthjointventuresupplysalesandothermiscellaneousrevenue company pharmaceutical product include therapeutic preventive agent generally sell prescriptionforthetreatmentofhumandisordersamongthesearesingulairmontelukastsodiumaleukotriene receptorantagonistforthechronictreatmentofasthmaandforthereliefofsymptomsofallergicrhinitiscozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide company significant hypertension andor heart failure product fosamax alendronate sodium fosamax plus alendronate sodiumcholecalciferol merck osteoporosis product treatment case fosamax prevention osteoporosis zocor simvastatin merck atherosclerosis product cosopt dorzolamide hydrochloride timolol maleate oph thalmic solutionandtrusoptdorzolamide hydrochloride ophthalmic solutionmerckslargestselle ophthal mological product primaxin imipenem cilastatin sodium cancidas caspofungin acetate anti bacterialantifungal product januvia janumet treatment type diabete maxalt rizatriptan benzoate acute migraine product proscar finasteride urology product treatment symptomatic benignprostateenlargementpropeciafinasterideaproductforthetreatmentofmalepatternhairlossarcoxia etoricoxib treatment arthritis pain crixivan indinavir sulfate stocrin efavirenz treatment hivinfection emend aprepitant prevention chemotherapyinduce postoperative nausea vomit invanz ertapenem sodium treatment infection company vaccine product include gardasil vaccine help prevent cervical cancer pre cancerousandlowgradelesionsvulvarandvaginalprecancersandgenitalwartscausedbyhpvtype androtateqavaccinetohelpprotectagainstrotavirusgastroenteritisininfantsandchildrenzostavaxzoster vaccine live vaccine help prevent shingles herpe zoster varivax varicella virus vaccine live oka merck avaccine tohelp prevent chickenpox proquadmeasle mumpsrubella varicellavirusvaccine live pediatric combination vaccine measle mump rubella varicella mmr ii measle mumpsandrubellavirusvaccineliveavaccineagainstmeaslesmumpsandrubellaforafurtherdiscussionof salesofthecompanysproductsseeitemmanagementsdiscussionandanalysisoffinancialconditionand result operation product approvalson march fda approve janumet merck oral antihyper glycemicagentthatcombinesjanuviawithmetformininasingletablettoaddressallthreekeydefectsoftype diabetesjanumethasbeenapprovedasanadjuncttodietandexercisetoimprovebloodsugarglucosecontrolin adultpatientswithtypediabeteswhoarenotadequatelycontrolledonmetforminorsitagliptinaloneorinpatient treat combination sitagliptin metformin onoctoberthefdagrantedisentressacceleratedapprovalforuseincombinationwithother antiretroviralagentsforthetreatmentofhivinfectionintreatmentexperiencedadultpatientswhohaveevidence ofviralreplicationandhivstrainsresistanttomultipleantiretroviralagentsisentressisthefirstmedicinetobe approvedinanewclassofantiretroviraldrugscalledintegraseinhibitorsisentressworksbyinhibitingtheinsertion ofhivdnaintohumandnabytheintegraseenzymeinhibitingintegrasefromperformingthisessentialfunction limitstheabilityofthevirustoreplicateandinfectnewcellsthefdasdecisionwasbasedonaweekanalysis ofclinical trialsinwhichisentressincombination withoptimize backgroundtherapyintreatmentexperienced patientsprovidedsignificantreductionsinhivrnaviralloadandincreasesincdcellcountsinfebruary thecompanyannouncedweekdatathatdemonstratedisentressincombinationwithotherantihivmedicine maintain significant hivviral load suppressionandincrease cdcell countsthrough weeksof therapy compare toplacebo incombination withantihivmedicine intwophaseiiistudiesoftreatmentexperience patientsfailingantiretroviraltherapiespatientsinthestudieshadhivresistanttoatleastonedrugineachofthree classesoforalantiretroviralmedicinesbytheendofthemedicinewasapprovedforuseintheeucanada mexico merck conduct phase iii clinical trial isentress treatmentnave previously untreate hiv population potent antiretroviral activity demonstrate significant change serumlipidsatweekandisentresswasgenerallywelltoleratedinpatientsthecompanyanticipatesmakinga supplemental file fda treatmentnave indication onjanuarythefdaapprovedemendforinjectionmgforthepreventionofcinvemend forinjectionprovidesanewoptionfordayoneoralemendmgaspartoftherecommendedthreedayregiman deliver day protection nausea vomit prior fda decision european union euonjanuarygrantedmarketingapprovalforemendforinjectionknownasivemendintheeuan action apply eu member country norway iceland vioxx product liability settlementon september merck announce voluntary worldwide withdrawal vioxx arthritis acute pain medication company decision effective immediately base new threeyear datum prospective randomize placebocontrolle clinical trial approve adenomatous polyp prevention vioxx onnovemberthecompanyannouncedthatithadenteredintoanagreement thesettlement agreementwiththelawfirmsthatcomprisetheexecutivecommitteeoftheplaintiffssteeringcommitteeofthe federalmultidistrict vioxxlitigationaswellasrepresentativesofplaintiffscounselinthetexasnewjerseyand california state coordinate proceeding resolve state federal myocardial infarction mi ischemic strokeisclaimsfiledasofthatdateintheunitedstatesthesettlementagreementwhichalsoappliestotolle claimswassignedbythepartiesafterseveralmeetingswiththreeofthefourjudgesoverseeingthecoordinationof percent current claim vioxx litigation settlement agreement apply legal resident allege mi occur united states settlement agreement march subject extension plaintiff enroll resolutionprocessthesettlementprogramatleastpercentofeachofallcurrentlypendingandtolledimi claimsiiisclaimsiiieligiblemiandisclaimstogetherwhichinvolvedeathandiveligiblemiandisclaim whichtogetherallegemorethanmonthsofusemerckwillpayanaggregateofbillionintotwofundsfor qualifyingclaimsconsistingofbillionforqualifyingmiclaimsandmillionforqualifyingisclaimsthe companyexpectsthattheparticipationconditionswillbemethoweveriftheyarenotthecompanywillhavethe right waive condition terminate settlement agreement acquisitionson september merck complete acquisition novacardia privately heldclinicalstagepharmaceuticalcompanyfocusedoncardiovasculardiseasethisacquisitionaddedrolofylline mk novacardias investigational phase iii compound acute heart failure merck pipeline joint venturesthe company number joint venture relate pharmaceutical vaccine segment pharmaceutical inthecompanyandscheringploughcorporationscheringploughenteredintoagreementsto createseparateequallyownedpartnershipstodevelopandmarketintheunitedstatesnewprescriptionmedicine inthecholesterolmanagementandrespiratorytherapeuticareasindecemberthecholesterolmanagement partnershipagreementswereexpandedtoincludeallthecountriesoftheworldexcludingjapaninoctober zetiaezetimibe market asezetroloutsidetheunitedstatesthefirstinanewclassofcholesterollowere agentswaslaunchedintheunitedstatesinjulyvytorinmarketedasinegyoutsidetheunitedstatesa combinationproductcontainingtheactiveingredientsofbothzetiaandzocorwasapprovedintheunitedstate thecompanyandscheringploughsellvytorinandzetiathroughtheirjointventurecompanymerck scheringploughpharmaceuticalsthemsppartnershiponjanuarythemsppartnershipannounce primary endpoint result enhance effect combination ezetimibe highdose simvastatinvssimvastatinaloneontheatherosclerotic processinpatientswithheterozygousfamilial hyper cholesterolemia trialthemsppartnershipsubmittedanabstractontheenhancetrialforpresentation atthe american college cardiology meeting march notify acceptance college enhance surrogate endpoint trial conduct patient heterozygous familial hyperchole terolemia rare condition affect approximately population analyse conduct accordance original statistical analysis plan primary endpoint mean change intima mediathicknessmeasuredatthreesitesinthecarotidarteriestherightandleftcommoncarotidinternalcarotid carotid bulb patient treat ezetimibesimvastatin mg versus patient treat simvastatinmgaloneoveratwoyearperiodtherewasnostatisticallysignificantdifferencebetweentreatment groupsontheprimaryendpointtherewasalsonostatisticallysignificantdifferencebetweenthetreatmentgroup foreachofthecomponentsoftheprimaryendpointincludingthecommoncarotidarterykeysecondaryimage endpoint show statistical difference treatment group overall incidence rate treatment relatedadverseeventsseriousadverseeventsoradverseeventsleadingtodiscontinuationweregenerallysimilar betweentreatmentgroupsbothmedicinesweregenerallywelltoleratedoverallthesafetyprofilesofezetimibe simvastatinandsimvastatinaloneweresimilarandgenerallyconsistentwiththeirproductlabelsinthetrialthere wasasignificant difference inlowdensitylipoprotein ldl cholesterol loweringseenbetween thetreatment groupsldlcholesterolloweringatmonthsonezetimibesimvastatinascomparedtoatmonth onsimvastatinalonethissurrogateendpointstudywasnotpowerednordesignedtoassesscardiovascularclinical event outcome msppartnershipiscurrently conduct improveit trial large clinical cardiovas cular outcomes trial compare vytorin ezetimibesimvastatin simvastatin include patient vytorin contain medicine ezetimibe simvastatin vytorin show reduce heart attack stroke simvastatin december february company jointventure partner scheringploughreceivedseveraljointlettersfromthehousecommitteeonenergyandcommerceandthehouse subcommittee oversight investigation letter senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer januarythecompaniesandthemsppartnershipeachreceivedtwosubpoenasfromthenewyorkstate attorneygeneralsofficeseekingsimilarinformationanddocumentsmerckandscheringploughhavealsoeach receivedaletterfromtheofficeoftheconnecticutattorneygeneraldatedfebruaryrequestingdocuments relatedtothemarketingandsaleofvytorinandzetiaandthetimingofdisclosuresoftheresultsofenhancethe companyiscooperatingwiththeseinvestigationsandworkingwithscheringploughtorespondtotheinquiriesin additionsincemidjanuarythecompanyhasbecomeawareoforbeenservedwithapproximatelycivil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia company enter agreement astra ab astra develop market astra productsintheunitedstatesinthecompanyandastraformedanequallyownedjointventurethatdevelope andmarketedmostofastrasnewprescriptionmedicinesintheunitedstatesincludingprilosecthefirstinaclassof medicationsknownasprotonpumpinhibitorswhichslowstheproductionofacidfromthecellsofthestomachlining inthecompanyandastrarestructure jointventurewherebythe companyacquire astra interestinthejointventurerenamedkbiinckbiandcontributedkbisoperatingassetstoanewuslimite partnership name astra pharmaceutical lp partnership company maintain limited partner interest partnership rename astrazeneca lp exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnershipagreementvariablereturnsbasedinpartuponsalesofcertainformerastrausaincproductsanda preferentialreturnrepresentingthecompanysshareofundistributedpartnershipgaapearningsinconjunction restructure payment million astra purchase option buy company interest kbi product exclude company interest gastrointestinal medicine nexium prilosecthecompanyalsograntedastraanoptionthesharesoptiontobuythecompanyscommonstock interestinkbiatanexercisepricebasedonthepresentvalueofestimatedfuturenetsalesofnexiumandprilosec april astra merged zeneca group plc form astrazeneca ab astrazeneca result merger exchange company relinquishment right future astra product existingorpendinguspatentsatthetimeofthemergerastrapaidmillionwhichissubjecttoatrueup calculationinthatmayrequirerepaymentofalloraportionofthisamountthemergeralsotriggersapartial redemptionofthecompanyslimitedpartnerinterestinfurthermoreasaresultofthemergerastrazenecas option asset option buy company interest kbi product exercisable companyhastherighttorequireastrazenecatopurchasesuchinterestininfebruarythecompany advisedazlpthatitwillnotexercisetheassetoptioninadditionthesharesoptionisexercisabletwoyearsafter astraspurchaseofthecompanysinterestinthekbiproductstheexerciseofthisoptionbyastraisalsoprovide forintheyearorifcombinedannualsalesofthetwoproductsfallbelowaminimumamountprovidedineach caseonlysolongasastrazenecasoptioninhasbeenexercisedtheexercisepriceisbasedonthepresent valueofestimatedfuturenetsalesofnexiumandprilosecasdeterminedatthetimeofexercisesubjecttocertain trueup mechanism company form joint venturewith johnson johnsonto develop market broad range nonprescription medicine consumer own joint venture include canada significant joint venture product pepcid ac famotidine overthecounter form companysulcer medication pepcid famotidine pepcid complete overthecounter product combine company ulcer medication antacid calcium carbonate magnesium hydroxide vaccine inthecompanyandpasteurmrieuxconnaughtnowsanofipasteursaformedajointventure tomarkethumanvaccinesineuropeandtocollaborateinthedevelopmentofcombinationvaccinesfordistribution inthethenexistingeuandtheeuropeanfreetradeassociationthecompanyandsanofipasteurcontribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly throughaffiliatesorbranche inbelgium italygermanyspainfranceaustriaireland swedenportugal netherlands switzerland united kingdom distributor rest territory company rhnepoulenc sa sanofiaventis sa combine respective animalhealthandpoultrygeneticsbusinessestoformmeriallimitedmerialafullyintegratedanimalhealth companywhichisastandalonejointventureequallyownedbyeachpartymerialprovidesacomprehensiverange pharmaceutical vaccine enhance health wellbeing performance wide range animal specie competitionthe market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access competition involve intensive search technological innovation ability market theseinnovationseffectivelywithitslongstandingemphasisonresearchanddevelopmentthecompanyiswell preparedtocompeteinthesearchfortechnologicalinnovationsadditionalresourcestomeetcompetitioninclude qualitycontrolflexibilitytomeetcustomerspecificationsanefficientdistributionsystemandastrongtechnical informationservicethecompanyisactiveinacquiringandmarketingproductsthroughjointventuresandlicense andhasbeenrefiningitssalesandmarketingeffortstofurtheraddresschangingindustryconditionstoenhanceit product portfolio company continue pursue external alliance earlystage latestage product opportunity include joint venture target acquisition introduction newproduct processesbycompetitorsmayresultinpricereductionsandproductreplacementsevenforproductsprotectedby patent example number ofcompound available totreat diseasestypically increase time result slow growth sale certain company product legislation enact states united states particularly area human pharmaceutical product allow encourage instance absence specific instruction prescribe physician mandate use generic product contain active chemical innovator productratherthanbrandname productsgovernmental andotherpressurestowardthedispensingofgeneric productshavesignificantlyreducedthesalesofcertainofthecompanysproductsnolongerprotectedbypatent suchaszocorwhichlostmarketexclusivityintheusinandthecompanyexperiencedasignificantdecline inzocorsalesthereafterfosamaxlostmarketexclusivityintheunitedstatesinfebruaryfosamaxplusd willlosemarketingexclusivityintheunitedstatesinaprilasaresultoftheseeventsthecompanyexpect significant decline fosamax fosamax plus sale distributionthecompanysellsitshumanhealthpharmaceutical productsprimarily todrugwhole salersandretailershospitalsgovernmentagenciesandmanagedhealthcareproviderssuchashealthmaintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional represen tativescommunicatetheeffectivenesssafetyandvalueofthecompanyspharmaceuticalandvaccineproductsto health care professional private practice group practice manage care organization rawmaterialsrawmaterialsandsupplieswhicharegenerallyavailablefrommultiplesourcesare purchase worldwide normally available quantity adequate meet need company pharmaceutical vaccine segment governmentregulationandinvestigationthepharmaceuticalindustryissubjecttoglobalregulation regional country state local agency particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling mar kete ofprescriptionpharmaceutical inmanycasesthefdarequirement haveincrease theamountoftime andmoneynecessarytodevelopnewproductsandbringthemtomarketintheunitedstatesinthefoodand drugadministrationmodernizationactthefdamodernizationactwaspassedandwastheculminationofa comprehensive legislative reform effort design streamline regulatory procedure fda improvetheregulationofdrugsmedicaldevicesandfoodthelegislationwasprincipallydesignedtoensurethe timely availability ofsafe effective drugsand biologic expedite premarket reviewprocess fornew productsakeyprovisionofthelegislationisthereauthorizationoftheprescriptiondruguserfeeactof permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug intheunitedstatesthegovernmentexpandedhealthcareaccessbyenactingthemedicareprescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentivesfor pharmaceutical inno vationatthesametimethelegislationwillensurethatprescriptiondrugcostswillbecontrolledbycompetitive pressure encourage appropriate use medicine congress consider consider proposal increase government role pharmaceutical pricing medicare program formanyyearsthepharmaceuticalindustryhasbeenunderfederalandstateoversightwiththeapproval processfornewdrugsdrugsafetyadvertisingandpromotiondrugpurchasingandreimbursementprogramsand formulariesvariouslyunderreviewthecompanybelievesthatitwillcontinuetobeabletoconductitsoperation includingtheintroductionofnewdrugstothemarketinthisregulatoryenvironmentonetypeoffederalinitiative contain federal health care spending prospective capitate payment system implement reducetherateofgrowthinmedicarereimbursementtohospitalssuchasystemestablishesinadvanceaflatrate forreimbursementforhealthcareforthosepatientsforwhomthepayorisfiscallyresponsiblethistypeofpayment system cost containment system widely public private payor cause hospitalshealthmaintenanceorganizationsandothercustomersofthecompanytobemorecostconsciousintheir treatment decision include decision medicine available patient companycontinuestoworkwithprivateandfederalemployerstoslowincreasesinhealthcarecostsfurtherthe companyseffortstodemonstratethatitsmedicinescanhelpsavecostsinotherareashaveencouragedtheuseof company medicine helped offset effect increase cost pressure federal state government pursue method directly reduce cost drug vaccinesforwhichtheypayforexamplefederallawsrequirethecompanytopayspecifiedrebatesformedicine reimbursedbymedicaidtoprovidediscountsforoutpatientmedicinespurchasedbycertainpublichealthservice entity disproportionate share hospital hospital meet certain criterion provide minimum discountsofoffofadefinednonfederalaveragemanufacturerpriceforpurchasesbycertaincomponentsof federal government department veterans affairs department defense initiativesin state seek rebate minimum require medicaid legislation casesforpatientsbeyondthosewhoareeligibleformedicaidunderthefederalvaccinesforchildrenentitlement program center disease control prevention cdc fund purchase recommend pediatricvaccinesatapublicsectorpricefortheimmunizationofmedicaideligibleuninsurednativeamerican andcertainunderinsuredchildrenthecompanywasawardedacdccontractinaprilwhichisineffectuntil march supply pediatric vaccine vaccine children program january patientspreviouslyeligibleformedicaidwhoarealsomedicarebeneficiariesyearsandolderordisabledleft stateadministere medicaid system cover new medicare prescription drug benefit outsidetheunitedstatesthecompanyencounterssimilarregulatoryandlegislativeissuesinmostofthe country business primary thrust governmental inquiry action determiningdrugsafetyandeffectivenessoftenwithmechanismsforcontrollingthepricesoforreimbursementfor prescription drugsandtheprofitsofprescription drugcompanie theeuhasadopte directivesconcerne classification label advertise wholesale distribution approval marketing medicinal product humanusethecompanyspoliciesandproceduresarealreadyconsistentwiththesubstanceofthesedirective consequently believe material effect company business inadditioncertaincountrieswithintheeurecognizingtheeconomicimportanceoftheresearchbase pharmaceuticalindustryandthevalueofinnovativemedicinestosocietyareworkingwithindustryrepresentative improve competitive climate variety mean include market deregulation european commission conduct pharmaceutical sector inquiry involve number company concern competition introduction innovative generic medicine inquirythecompanysofficesingermanywereinspectedbytheauthoritiesbeginningonjanuarythe commissionhasnotallegedthatthecompanyoranyofitssubsidiarieshaveengagedinanyunlawfulpracticesthe company cooperate commission sector inquiry aspreviouslydisclosedinmaythegovernmentofbrazilissuedacompulsorylicenseforstocrin make possible stocrin produce generic manufacturer despite company patent protectiononstocrininnovemberthegovernmentofthailandstatedthatithadissuedacompulsorylicense forstocrindespitethecompanyspatentprotectiononstocrinwhichthegovernmentofthailandcontendsmake possibleforstocrin tobeproduce byageneric manufacturerthecompanyremain commit toexplore mutually acceptable agreement government brazil thailand company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanctionsundercertaincircumstancesthecompanyonitsownmaydeemitadvisabletoinitiateproductrecall company believe able compete effectively environment thecompanyissubjecttoanumberofprivacyanddata protection lawsandregulationsgloballythe legislative regulatory landscape privacy datum protection continue evolve increasingamountoffocusonprivacyanddataprotectionissueswiththepotentialtoaffectdirectlythecompany business patentstrademarksandlicensespatentprotectionisconsideredintheaggregatetobeofmaterial importanceinthecompanysmarketingofhumanhealthproductsintheunitedstatesandinmostmajorforeign marketspatentsmaycoverproductspersepharmaceuticalformulationsprocessesfororintermediatesusefulin themanufactureofproductsortheusesofproductsprotectionforindividualproductsextendsforvaryingperiod inaccordancewiththelegallifeofpatentsinthevariouscountriestheprotectionaffordedwhichmayalsovary country country depend type patent scope coverage patent portfolio develop product introduce company normally provide market exclu sivity company follow key patent protection pediatric exclusivity major market product product year expiration cancida compound formulation comvax cosopt cozaar crixivan compound formulation emend compound patent term restoration gardasil hyzaar invanz compound pediatric exclusivity composition isentress januviajanumet maxalt compound primaxin propecia recombivax rotateq product patent term restoration singulair trusopt zetiavytorin ezetimibecomponent product patent term restoration zolinza compound patent term restoration zostavax abasicpatentisalsoineffectforsustivastocrinefavirenzbristolmyerssquibbbmsunderan exclusivelicensefromthecompanysellssustivaintheunitedstatescanadaandcertaineuropeancountriesthe company market stocrin country world basic patent aggrastat tirofiban hydrochlorideintheunitedstateswasdivestedwiththeproductinthecompanyretainsbasicpatentsfor aggrastat outside united states thefdamodernizationactincludesapediatricexclusivityprovisionthatmayprovideanadditionalsix month market exclusivity united states indication new currently market drug certain agreeduponpediatricstudiesarecompletedbytheapplicanttheseexclusivityprovisionswerereauthorizedby theprescriptiondruguserfeeactpassedinseptembercurrentuspatentlawprovidesadditionalpatent termunderpatenttermrestorationforperiodswhenthepatentedproductwasunderregulatoryreviewbeforethe fda information respect company patent patent litigation whiletheexpirationofaproductpatentnormallyresultsinalossofmarketexclusivityforthecovere pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulationsandivintheunitedstatesmarketexclusivitythatmaybeavailableunderfederallawtheeffectof productpatentexpirationonpharmaceutical productsalsodependsuponmanyotherfactorssuchasthenatureof themarket andthepositionoftheproductinitthegrowthofthemarketthecomplexitiesandeconomicsofthe processformanufactureoftheactiveingredientoftheproductandtherequirementsofnewdrugprovisionsofthe federal food drug cosmetic act similar law regulation country additionstomarketexclusivityaresoughtintheunitedstatesandothercountriesthroughallrelevant lawsincludinglawsincreasingpatentlifesomeofthebenefitsofincreasesinpatentlifehavebeenpartiallyoffset byageneralincreaseinthenumberofincentivesforanduseofgenericproductsadditionallyimprovementsin intellectual property lawsare soughtinthe unitedstate country reform ofpatent relevant law implementation international treaty fosamax lose market exclusivity united states february fosamax plus lose marketing exclusivity united states april result event company expect significant decline fosamax fosamax plus sale worldwideallofthecompanysimportantproductsaresoldundertrademarksthatareconsideredinthe aggregatetobeofmaterialimportancetrademarkprotectioncontinuesinsomecountriesaslongasusedinother country long register registration fix term renew indefinitely royalty receive patent knowhow license right amount million company pay royalty amount billion patent know license hold research development companysbusinessischaracterize introduction newproduct newusesforexiste productsthroughastrongresearchanddevelopmentprogramapproximatelypeopleareemployedinthe company research activity expenditure company research development program billioninbillioninandbillioninthecompanymaintainsitsongoingcommitment research broad range therapeutic area clinical development support new product company maintain number longterm exploratory fundamental research program biologyandchemistry aswellasresearch programsdirecte towardproductdevelopment mercksresearch developmentmodelisdesignedtoincreaseproductivityandimprovetheprobabilityofsuccessbyprioritizingthe company research development resource disease area atherosclerosis hypertension diabetes obesity novel vaccine neurodegenerative psychiatric disease target oncology therapy therapeutic area carefully choose base set criterion include unmet medical need scientific opportunityandcommercialopportunitywithinthesetherapeuticareasmerckwillcommitresourcestoachieve researchbreadthanddepthandtodevelopbestinclasstargetedanddifferentiatedproductsthatarevaluedhighly patient payer physician company focused investment area important unmet medical need addition company continue pursue appropriate external licensing opportunity inthedevelopmentofhumanhealthproductsindustrypracticeandgovernmentregulationsintheunite state foreign country provide determination effectiveness safety new chemical compoundsthroughpreclinicaltestsandcontrolledclinicalevaluationbeforeanewdrugmaybemarketedinthe unitedstatesrecordeddataonpreclinicalandclinicalexperienceareincludedinthendaorthebiologicslicense application fda require approval development certain product subject government regulation cover safety efficacy united states foreign country oncethecompanysscientistsdiscoveranewcompoundthattheybelievehaspromisetotreatamedical conditionthecompanycommencespreclinicaltestingwiththatcompoundpreclinicaltestingincludeslaboratory testing animal safety study gather data chemistrypharmacology toxicology pende acceptable preclinicaldatathecompanywillinitiateclinicaltestinginaccordancewithestablishedregulatoryrequirement theclinicaltestingbeginswithphaseistudieswhicharedesignedtoassesssafetytolerabilitypharmacokinetic preliminary pharmacodynamic activity compound human iffavorable additional large phase ii studiesareinitiatedtodeterminetheefficacyofthecompoundintheaffectedpopulationdefineappropriatedose forthecompoundaswellasidentifyanyadverseeffectsthatcouldlimitthecompoundsusefulnessifdatafrom thephaseiitrialsaresatisfactorythecompanycommenceslargescalephaseiiitrialstoconfirmthecompound efficacyandsafetyuponcompletionofthosetrialsifsatisfactorythecompanysubmitsregulatoryfilingswiththe appropriateregulatoryagenciesaroundtheworldtohavetheproductcandidateapprovedformarketingtherecan benoassurancethatacompoundthatistheresultofanyparticular programwillobtaintheregulatoryapproval necessary market intheunitedstatesthefdareviewprocessbeginsonceacompletendaissubmittedandreceivedby thefdapursuanttotheprescriptiondruguserfeeactthefdareviewperiodtargetsforndasorsupplemental ndasiseithersixmonthsforpriorityreviewortenmonthsforastandardreviewwithindaysafterreceiptof anndathefdadeterminesiftheapplication issufficientlycompletetopermitasubstantivereviewthefda alsoassessesatthattime whethertheapplication willbegrantedapriorityrevieworstandardreviewoncethe review timeline define fda act application timeline major amendment submit company initiative fda request pende applicationifthisoccursthefdamayextendthereviewperiodtoallowforreviewofthenewinformationbutby nomorethandaysextensionstothereviewperiodarecommunicatedtothecompanythefdacanactonan application issue approval letter nonapprovable letter approvable letter company drug candidate currently fda review august fda accept standard review nda cordaptive company investigational compoundcontainingmercksownerniacinandlaropiprantanovelflushingpathwayinhibitor designedtoreduceflushingoftenassociate withniacin treatment merckanticipate fdaaction inapril company move forward plan filing country outside united states company anticipate file nda fda company anticipate file nda mkb drug candidate combine novel approachtoraisinghdlcholesterolandloweringtriglyceridesfromerniacincombinedwithlaropiprantwiththe provenbenefitsofsimvastatininonecombinationproductinnovemberthecompanypresentedresultsofa study american heart association scientific session demonstrate er niacinlaropiprant cordaptive coadministere simvastatin significant additive effect reduce ldlc increase hdlc reduce triglyceride level phase iii study patient primary hypercholesterolemia mixeddyslipidemiainthestudygtwogramtabletsofcordaptivecoadministeredwithsimvastatinpoole acrossmgormgdosesreducedldlcbyincreasedhdlcbyandreducedtriglyceridelevelsby follow week treatment primary study endpoint ldlc reduction secondary endpoint include increase hdlc triglyceride reduction effect lipoprotein g tablet cordaptive contain g merckdevelope er niacin mg laropiprant thecompanyalsoanticipatesfilinganndaformktaranabantahighlyselectivecannabinoid receptorinverseagonistthatinearlyclinicalstudieshasdemonstratedweightlossversusplacebotaranabantwas generally welltolerate report cannabinoid receptor inverse agonist dose dependent psychiatric adverse event observe company previously announce initiation target phase iii program merck currently seven product phase iii development include mkb mk discuss mk investigational oral calcitonin generelate peptide receptor antagonist utilize new mechanism forthe treatment ofmigraine hasdemonstrate efficacyat comparable totriptans inearly clinicalstudiesinjuneclinicalresultsfromaphaseiistudywerepresentedforthefirsttimeattheamerican headache society annual meeting show mk significantly improve migraine pain relief hoursafterdosingcomparedtoplaceboandthereliefwassustainedthroughhoursmkwasgenerallywell toleratedinthestudyinadditiontothemeasureofmigrainepainmkprovidedreliefofmigraineassociate symptomsincludingnauseaandsensitivitytolightandsoundandimprovedfunctionaldisabilitytwohourspost doseaswellasreducedpatientsneedforrescuemedication thedrugcandidateenteredphaseiiidevelopment company anticipate file nda mkrolofyllineisaphaseiiiinvestigationaldrugbeingevaluatedforthetreatmentofacuteheart failure phase iii pilot study preliminary result indicate rolofylline generally tolerate treatmentresultedinagreaterproportionofpatientswithimproveddyspneafewerpatientswithworseningheart failureandgreaterweightlosscomparedtoplacebothesebenefitswereachievedwhilepreservingrenalfunction compare progressive worsen renal function patient treat placebo merck acquire drug candidate acquisition novacardia anticipate file ndawith fda mkdeforolimusisanovelmtormammaliantargetofrapamycininhibitorbeingevaluatedfor treatment cancer drug candidate jointly develop commercialize ariad pharmaceuticals inc agreement reach mid company anticipate file nda metastatic sarcoma indication anovelinvestigationalhepatitisbvaccinevcurrentlyisbeingevaluatedinaphaseiiiclinicaltrial adult patient undergo dialysis treatment merck jointly develop v dynavax tech nologiescorporationdynavaxunderanagreement reachedinlatemerckanticipate filinganndain adult mk odanacatib investigational highly selective inhibitor cathepsin kenzyme evaluate treatment osteoporosis cathepsin k enzyme believe play role osteoclastic bone resorption degrade protein component bone inhibition cathepsin k enzyme investigational compound odanacatib mechanism action different currently approvedtreatmentssuchasbisphosphonatesinseptembertwelvemonthresultsfromaphaseiibstudywith odanacatib demonstrate dosedependent increase bone mineral density bmd key fracture site reducedboneturnovercomparedtoplaceboinpostmenopausalwomenwithlowbmdwhengivenatdosesof mg finding present th annual meeting american society bone mineralresearchbmdreflectstheamountofmineralizedbonetissueinacertainvolumeofboneandcorrelate withthestrengthofbonesandwiththeirresistancetofractureabmdtestisusedtomeasurebonedensityandto helpdeterminefractureriskthephaseiiiprogrambeganinmidmerckanticipatesfilinganndawiththe fda additionally december company announce plan initiate sequence phase iii programinformkanacetrapibitsinvestigationalselectivecholesterylestertransferproteincetp inhibitortoobtainadditionalclinicalexperienceinpatientsbeforeinitiatinganoutcomesstudyinoctober thecompanypresentedresultsfromaphaseiibstudydemonstratingthatmksignificantlyreducedldlc andapolipoproteinbandincreasedhdlcandapolipoproteinabothasmonotherapyandincombinationwith atorvastatinmgcomparedtoplaceboinpatientswithdyslipidemiaanacetrapibproducedthesepositiveeffect onlipidswithnoobservedbloodpressurechangescetpinhibitorsworkbyinhibitingcetpaplasmaproteinthat facilitate transport cholesteryl ester triglyceride lipoprotein thecompanysclinicalpipelineincludescandidatesinmultiplediseaseareasincludingatherosclerosis cancerheartfailurehypertensioninfectiousdiseasesmigraineneurodegenerativediseasespsychiatricdisease ophthalmic disease pain respiratory disease company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early researchtolatestagecompoundsaswellasnewtechnologiesthecompanycompletedtransactionsin include target acquisition research collaboration preclinical clinical compound technology transaction broad range therapeutic category injulymerckandariadannouncedthattheyhadenteredintoaglobalcollaboration tojointly develop commercialize deforolimus mk ariad novel mtor inhibitor use cancer november dynavax merck announce global license development collaboration agreement jointly develop v currently evaluate multicenter phase iii clinical trial involve adult patient dialysis alsoinnovembergtxincgtxandmerckannouncedanagreementprovidingforaresearch anddevelopmentandglobalstrategiccollaborationforselectiveandrogenreceptormodulatorssarmsanew class drug potential treat agerelate muscle loss sarcopenia musculoskeletal conditionsthiscollaborationincludesgtxsleadsarmcandidateostarinemkwhichiscurrentlybeing evaluatedinaphaseiiclinicaltrialforthetreatmentofmusclelossinpatientswithcancerandestablishesabroad sarmcollaborationunderwhichgtxandmerckwillpooltheirprogramsandpartnertodiscoverdevelopand commercialize current future sarm molecules chart belowreflect companyscurrent research pipeline february candidate show phase iii include specific product candidate show phase ii include advanced compound withaspecific mechanism inagiven therapeutic area small molecule andbiologics aregivenmk numberdesignationsandvaccinecandidatesaregivenvnumberdesignationsbackupcompoundsregardlessof phase development additional indication therapeutic area additional claim line extension formulation inline product show phasei phasei phaseii phaseiii underfdareview alzheimersdisease infectiousdisease alzheimersdisease atherosclerosis atherosclerosis v mk mk mkb cordaptive atherosclerosis mk atherosclerosis cancer pendingtrademark mk mk mk mk mka mk mk mk deforolimus cancer v cancer ap usapproval mk neurologic mk heartfailure diabete mk mk mk mk janumet mk mk cardiovascular rolofylline hiv mk ophthalmic mk kw isentress v mk diabete hepatitisbvaccine mk cardiovascular parkinsonsdisease mk v mk mk hpv migraine usapproval mk psychiatricdisease v mk cinv diabete mk infectiousdisease obesity emendforinjection mk v mk mk mk v taranabant mk neurologic osteoporosis mk mk ophthalmic odanacatib sirna pain mk psychiatric disease mk respiratorydisease mk sarcopenia mk stroke mk proofofconceptmolecule clinicalprogramconductedbyallerganinc product service mark appear type form different surround text trademark service mark own license merck subsidiary affiliate include zetia vytorin trademark own entity merckscheringplough partnership note cozaar hyzaar register trademark ei du pont de nemours company wilmington de prilosec nexium trademark astrazeneca group trademark vasotec vaseretic own biovail laboratory incorporate ustrademark foraggrastatisownedbyguilfordpharmaceutical inc employee attheendofthecompanyhadapproximatelyemployeesworldwidewithapproximately employedintheunitedstatesincludingpuertoricoapproximatelyofworldwideemployeesofthe company represent collective bargaining group aspartofacostreductioninitiativeannouncedinoctoberandcompletedattheendofthe companyeliminatedpositionsthecompanycompletedasimilarprograminwithpositionsbeing eliminate december innovemberthecompanyannouncedthefirstphaseofaglobalrestructuringprogramdesignedto reducethecompanyscoststructureincreaseefficiencyandenhancecompetitivenesstheinitialstepsinclude theimplementation ofanewsupplystrategybythemerckmanufacturingdivisionwhichisintendedtocreatea lean costeffective customerfocused manufacturing model threeyear period globalrestructuringprogramthecompanyannouncedthatitexpectedtoeliminateapproximatelyposition manufacture division worldwide end half position reduction expectedtooccurintheunitedstateswiththeremainderinothercountriesasofdecembertherehave beenapproximatelypositionseliminate throughoutthecompanysinceinceptionoftheprogramapprox imatelyofwhichwereeliminatedduringcomprisedofactualheadcountreductionsandtheelimination contractor vacant position company continue hire new employee business requiresmerckpreviouslyannounceditsintentiontosellorclosefiveofitsmanufacturingfacilitiesworldwide andtwopreclinicalsitesandtoreduceoperationsatanumberofothersitesthroughtheendoffourofthe manufacturingfacilitieshadbeenclosedsoldorhadceasedoperationsandthetwopreclinicalsiteswereclose remain facility sell january company sell certain facility relate asset connection restructure program environmental matter thecompanybelievesthatitisincomplianceinallmaterialrespectswithapplicableenvironmentallaw regulation company incur capital expenditure approximately million environ mental protection facility company remediate environmental contamination result past industrialactivityatcertainofitssitesexpendituresforremediationandenvironmentalliabilitiesweremil lion million estimated million year amount consider potential recovery party company take active role identifyingandprovidingforthesecostsandinmanagementsopiniontheliabilitiesforallenvironmentalmatter whichareprobableandreasonablyestimablehavebeenaccruedandtotaledmillionatdecember possible predict certainty outcome environmental matter ultimate costsofremediationmanagementdoesnotbelievethatanyreasonablypossibleexpendituresthatmaybeincurre inexcessoftheliabilitiesaccruedshouldexceedmillionintheaggregatemanagementalsodoesnotbelieve expenditure material adverse effect company financial position result operation liquidity capital resource year geographic area information thecompanysoperationsoutsidetheunitedstatesareconductedprimarilythroughsubsidiariessale worldwidebysubsidiariesoutsidetheunitedstateswereofsalesinofsalesinandof sale thecompanysworldwidebusinessissubjecttorisksofcurrencyfluctuationsgovernmentalactionsand governmental proceeding abroad company regard risk deterrent expansionofitsoperationsabroadhoweverthecompanyclosely reviewsitsmethodsofoperation andadopt strategy responsive change economic political condition inrecentyearsthecompanyhasbeenexpandingitsoperationsincountrieslocatedinlatinamericathe middle east africa eastern europe asia pacific change government policy economic conditionsaremakingitpossibleforthecompanytoearnfairreturnsbusinessinthesedevelopingareaswhile stable offer important opportunity growth time financial information geographic area company business discuss item financial statement supplementary datum available information thecompanysinternetwebsiteaddressiswwwmerckcomthecompanywillmakeavailablefreeof chargeattheinvestorinformationportionofitswebsiteitsannualreportonformkquarterlyreportson form q current report form k amendment report file furnish pursuant sectionaordofthesecuritiesexchangeactofasamendedassoonasreasonablypracticableafter report electronically file furnish securities exchange commission sec thecompanyscorporategovernanceguidelinesandthechartersoftheboardofdirectorssixstande committee available company website wwwmerckcomaboutcorporategovernance information available print stockholder request company item risk factor youshouldcarefullyconsideralloftheinformationsetforthinthisformkincludingthefollowe riskfactorsbeforedecidingtoinvestinanyofthecompanyssecuritiestherisksbelowarenottheonlyonesthe company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operationsorprospectscouldbemateriallyadverselyaffectedbyanyoftheserisksthisformkalsocontain forwardlookingstatementsthatinvolverisksanduncertaintiesthecompanysresultscouldmateriallydifferfrom thoseanticipate intheseforwardlooking statement asaresult ofcertain factorsinclude risksit face describe cautionary factor affect future result company face significant litigation relate vioxx onseptemberthecompanyvoluntarilywithdrewvioxxitsarthritisandacutepainmedication fromthemarketworldwideasofdecemberapproximatelyproductliabilitylawsuitsinvolve approximately plaintiffgroupsallegingpersonalinjuriesresultingfromtheuseofvioxxhavebeenfile company state federal court united states company defendant approximatelypurportedclassactionsrelatedtotheuseofvioxxallofthesesuitsarereferredtoasthevioxx product liability lawsuit discuss november company announce enteredintoanagreementthesettlementagreementwiththelawfirmsthatcomprisetheexecutivecommittee plaintiff steering committee federal multidistrict vioxx litigation representative plaintiffscounselinthetexasnewjerseyandcaliforniastatecoordinatedproceedingstoresolvestateandfederal myocardial infarction mi ischemic stroke claim file date united states settlement agreement whichalsoapplie totolle claim wassignedbythepartiesafterseveralmeeting judge oversee coordination percent current claim vioxx productliabilitylitigationthesettlementagreementappliesonlytouslegalresidentsandthosewhoallegethat mi occur united states settlement agreement march subject extension plaintiff enroll resolutionprocessthesettlementprogramatleastpercentofeachofallcurrentlypendingandtolledimi claimsiiisclaimsiiieligiblemiandisclaimstogetherwhichinvolvedeathandiveligiblemiandisclaim whichtogetherallegemorethanmonthsofusemerckwillpayanaggregateofbillionintotwofundsfor qualifyingclaimsconsistingofbillionforqualifyingmiclaimsandmillionforqualifyingisclaimsthe companyexpectsthattheparticipationconditionswillbemethoweveriftheyarenotthecompanywillhavethe right waive condition terminate settlement agreement claim certain individual thirdparty payor remain pende new jersey court counsel purportingtorepresentalargenumberofthirdpartypayorshasthreatenedtofilenumerousadditionalsuchaction activity pende case currently stay pende court putative class action purportedly bring behalf individual purchaser user vioxx claim reimbursement allege economic loss entitlement medical monitoring case early procedural stage class certifiedinnewjerseythetrialcourtdismissedthecomplaintinthecaseofsinclairapurportedstatewidemedical monitoringclasstheappellatedivisionreversedthedismissalandtheissueisnowonappealtothenewjersey supreme court court hear argument october addition vioxx product liability lawsuit purport class action individual lawsuit bring company current officer director company allege company false misleading statement vioxx violation federalandstatesecuritieslawsallofthesesuitsarereferredtoasthevioxxsecuritieslawsuitsinaddition variousputativeclassactionshavebeenbroughtagainstthecompanyandseveralcurrentandformeremployee officer director company allege violation employee retirement income security act erisaallofthesesuitsarereferredtoasthevioxxerisalawsuitsinadditionshareholderderivative suitsthatwerepreviouslyfiledanddismissedarenowonappealandseveralshareholdershavefileddemandswith thecompanyassertingclaimsagainsttheboardmembersandcompanyofficersallofthesesuitsanddemand arereferredtoasthevioxxderivativelawsuitsandtogetherwiththevioxxsecuritieslawsuitsandthevioxx erisalawsuitsthevioxxshareholderlawsuitsthecompanyhasalsobeennamedasadefendantinaction invariouscountriesoutsidetheunitedstatesallofthesesuitsarereferredtoasthevioxxforeignlawsuits company sue seven state county respect marketing vioxx companyanticipatesthatadditionallawsuitsrelatingtovioxxwillbefiledagainstitandorcertainofitscurrentand officer director future thesecisconductingaformalinvestigationofthecompanyconcerningvioxxtheusdepartmentof justice issue subpoena request information relate company research marketing selling activitieswithrespecttovioxxinafederalhealthcareinvestigationundercriminalstatutestherearealsoongoe investigationsbylocalauthoritiesineuropeagroupofattorneysgeneralfromthirtyonestatesandthedistrictof columbia conduct investigation company sale marketing vioxx company cooperatingwithauthoritiesinalloftheseinvestigationsalloftheseinvestigationsarereferredtoasthevioxx investigation company predict outcome investigation result potential civil andor criminal liability date vioxx product liability litigation jury decide merck favor time plaintiffsfavorfivetimesonemerckverdictwassetasidebythecourtandhasnotbeenretriedanothermerck verdict set aside retry lead plaintiff verdict unresolved mistrialswithrespecttothefiveplaintiffsverdictsmerckalreadyhasfiledanappealorsoughtjudicialreviewin eachofthosecasesandinoneofthosefourafederaljudgeoverturnedthedamageawardshortlyaftertrialthe vioxx product liability litigation discuss fully item legal proceeding outcome vioxx product liability trial interpret indicate trend outcome likely future vioxx trial company currently anticipate number vioxx product liability lawsuit try atrialintheoregonsecuritiescaseisscheduledforbutthecompanycannotpredictwhetherthistrial willproceedonscheduleorthetimingofanyoftheothervioxxshareholderlawsuittrialsthecompanybelieve meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend company insurancecoveragewithrespecttothevioxxlawsuitswillnotbeadequatetocoveritsdefensecostsandanylosse company spend million include million fourth quarter aggregate legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholderlawsuitsiiithevioxxforeignlawsuitsandivthevioxx investigation collectivelythevioxx litigationinthesecondquarterofthecompanyrecordedachargeofmillionandinthethirdquarter itrecordedanotherchargeofmilliontoincreasethereservesolelyforitsfuturelegaldefensecostsrelatedto thevioxxlitigationfrommillionatdecembertomillionatdecemberinadditionas notedabovethecompanyrecordedapretaxchargeofbillionequaltotheaggregateamounttobepaidtothe qualifying claimants settlement program company total reserve vioxx litigation decemberwasbillionthevioxxreservethevioxxreserveisbasedoncertainassumption describedbelowunderlegalproceedingsandisthebestestimateoftheamountthatthecompanybelievesat time spend thecompanyisnotcurrentlyabletoestimateanyadditionalamountofdamagesthatitmayberequire pay connection vioxx lawsuit vioxx investigation proceeding expect continueforyearsandthecompanyhasverylittleinformationastothecoursetheproceedingswilltakeinviewof theinherentdifficultyofpredictingtheoutcomeoflitigationparticularlywheretherearemanyclaimantsandthe claimantsseekunspecifieddamagesthecompanyisunabletopredicttheoutcomeofthesemattersandatthistime cannotreasonablyestimatethepossiblelossorrangeoflosswithrespecttothevioxxlawsuitsnotincludedinthe settlementprogramthecompanyhasnotestablishedanyreservesforanypotentialliabilityrelatingtothevioxx lawsuit include settlement program vioxx investigation series unfavorable outcome vioxx lawsuit vioxx investigation result payment substantial damage finesorresulte criminal penalty inexcessof vioxx reservecould haveamaterialadverseeffectonthecompanysbusinesscashflowresultsofoperationsfinancialpositionand prospect certainofthecompanysmajorproductsaregoingtolosepatentprotectioninthenearfutureand occur company expect significant decline sale product thecompanydependsuponpatentstoprovideitwithexclusivemarketingrightsforitsproductsforsome period time product patent company product recently expire expireintheunitedstatesandinothercountriesthecompanyfacesstrongcompetitionfromlowerpricegeneric drugslossofpatentprotectionforoneofthecompanysproductstypicallyleadstoarapidlossofsalesforthat product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company result operation fosamax lose market exclusivity united states february fosamax plus lose marketing exclusivity united states april result event company expect significantdeclinesinusfosamaxandfosamaxplusdsalesussalesoffosamaxandfosamaxplusdwere billion aggregate sale fosamax outside united states adversely affect availability generic alendronate sodium product market include united kingdom canada germany companys research development effort succeed develop commercially successfulproductsandthecompanymaynotbeabletoacquirecommerciallysuccessfulproductsinother way consequence companymay able replace sale successful product lose patent protection likeothermajorpharmaceuticalcompaniesinordertoremaincompetitivethecompanymustcontinue launch new product year decline sale product zocor fosamax mean companysfuturesuccessisdependentonitspipelineofnewproductsincludingnewproductswhichitdevelops throughjointventuresandproductswhichitisabletoobtainthroughlicenseoracquisitiontoaccomplishthisthe companycommitssubstantialeffortfundsandotherresourcestoresearchanddevelopmentboththroughitsown dedicatedresourcesandthroughvariouscollaborationswiththirdpartiestosupportitsresearchanddevelopment effort company ongoing substantial expenditure assurance effort fundingwillresultinacommerciallysuccessfulproductthecompanymustalsocommitsubstantialeffortsfund resource recruit retain high quality scientist personnel pharmaceutical research development expertise foradescriptionoftheresearchanddevelopmentprocessseeresearchanddevelopmentaboveeach phase test highly regulate phase substantial risk company encounterseriousobstaclesorwillnotachieveitsgoalsandaccordinglythecompanymayabandonaproductin hasinvestedsubstantial amount oftime andmoneysome risksencountere inthe research developmentprocessincludethefollowingpreclinicaltestingofanewcompoundmayyielddisappointingresult clinicaltrialsofanewdrugmaynotbesuccessfulanewdrugmaynotbeeffectiveormayhaveharmfulsideeffect anewdrugmaynotbeapprovedbythefdaforitsintendeduseitmaynotbepossibletoobtainapatentforanew drug sale new product disappoint thecompanycannotstatewithcertainty whenorwhetheranyofitsproductsnowunderdevelopment willbelaunchedwhetheritwillbeabletodeveloplicenseorotherwiseacquirecompoundsproductcandidatesor productsorwhetheranyproductsoncelaunchedwillbecommerciallysuccessfulthecompanymustmaintaina continuous flow successful new product successful new indication brand extension exist productssufficientbothtocoveritssubstantialresearchanddevelopmentcostsandtoreplacesalesthatarelosta profitableproductssuchaszocorandfosamaxlosepatentprotectionoraredisplacedbycompetingproductsor therapy failuretodosointheshorttermorlongtermwouldhaveamaterial adverseeffectonthecompanys business result operation cash flow financial position prospect issuesconcerningvytorinandtheenhanceclinicaltrialcouldhaveamaterialadverseeffecton sale vytorin zetia thecompanyandscheringploughsellvytorinandzetiathroughtheirjointventurecompanymerck scheringploughpharmaceuticalsthemsppartnershiponjanuarythemsppartnershipannounce primary endpoint result enhance effect combination ezetimibe highdose simvastatinvssimvastatinaloneontheatherosclerotic processinpatientswithheterozygousfamilial hyper cholesterolemia trial enhance surrogate endpoint trial conduct patient heterozygous familial hypercholesterolemia rare condition affect approximately population primary endpointwasthemeanchangeintheintimamediathicknessmeasuredatthreesitesinthecarotidarteriestheright leave common carotid internal carotid carotid bulb patient treat ezetimibesimvastatin mgversuspatientstreate withsimvastatin mgaloneoveratwoyearperiodtherewasnostatistically significantdifferencebetweentreatmentgroupsontheprimaryendpointtherewasalsonostatisticallysignificant differencebetweenthetreatmentgroupsforeachofthecomponentsoftheprimaryendpointincludingthecommon carotid artery december february company jointventure partner scheringploughreceivedseveraljointlettersfromthehousecommitteeonenergyandcommerceandthehouse subcommittee oversight investigation letter senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer januarythecompaniesandthemsppartnershipeachreceivedtwosubpoenasfromthenewyorkstate attorneygeneralsofficeseekingsimilarinformationanddocumentsmerckandscheringploughhavealsoeach receivedaletterfromtheofficeoftheconnecticutattorneygeneraldatedfebruaryrequestingdocuments relatedtothemarketingandsaleofvytorinandzetiaandthetimingofdisclosuresoftheresultsofenhancethe companyiscooperatingwiththeseinvestigationsandworkingwithscheringploughtorespondtotheinquiriesin additionsincemidjanuarythecompanyhasbecomeawareoforbeenservedwithapproximatelycivil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia company closely monitor sale vytorin zetia follow release enhanceclinicaltrialresultsinapressreleaseonjanuarytodatesalesofbothproductsintheus company prior expectation addition wholesaler moderate purchase product reduce inventory level theseissuesconcerne theenhanceclinical trial haveamaterial adverseeffect onthemsp partnershipssalesofvytorinandzetiaifsalesofsuchproductsaremateriallyadverselyaffectedthecompany business cash flow result operation financial position prospect materially adversely affect addition unfavorable outcome result government investigation consumer fraud litigation concern sale promotion product material adverse effect company financial position liquidity result operation company product include product development market companyobtain maintain regulatory approval companysactivitie include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authoritiesintheunitedstatesincludingthefdaandbyforeignregulatoryauthoritiesincludingtheeuropean commission united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time moneynecessarytodevelopnewproductsandbringthem tomarket intheunitedstatesregulation outsidethe united states primarily focus drug safety effectiveness case cost reduction fdaandforeignregulatoryauthoritieshavesubstantialdiscretiontorequireadditionaltestingtodelayorwithhold registration marketing approval mandate product withdrawal evenifthecompanyissuccessfulindevelopingnewproductsitwillnotbeabletomarketanyofthose productsunlessanduntilithasobtainedallrequiredregulatoryapprovalsineachjurisdictionwhereitproposesto marketthenewproductsonceobtainedthecompanymustmaintainapprovalaslongasitplanstomarketitsnew products jurisdiction approval require company failure obtain approval significant delaysintheapprovalprocessoritsfailuretomaintainapprovalinanyjurisdictionwillpreventitfromsellingthe new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover productsthatithasintroducednormallyprovidemarketexclusivitywhichisimportantforthesuccessfulmarkete andsaleofitsproductsthecompanyseekspatentscoveringeachofitsproductsineachofthemarketswhereit intend sell product meaningful patent protection available company succeed obtain patent cover product party government authoritiesmaychallengeorseektoinvalidateorcircumventitspatentsandpatentapplicationsitisimportantfor thecompanysbusinesstodefendsuccessfullythepatentrightsthatprovidemarketexclusivityforitsproductsthe companyisofteninvolvedinpatentdisputesrelatingtochallengestoitspatentsorinfringementandsimilarclaims againstthecompanythecompanyaggressivelydefendsitsimportantpatentsbothwithinandoutsidetheunite statesincludingbyfilingclaimsofinfringementagainstotherpartiesseeitemlegalproceedingspatent litigation belowinparticularmanufacturer ofgeneric pharmaceutical productsfromtime totime fileabbre viated new drug application anda fda seek market generic form company productspriortotheexpiration ofrelevant patent ownedbythe companythecompanynormally respondsby vigorouslydefendingitspatentincludingbyfilinglawsuitsallegingpatentinfringementpatentlitigationandother challenge company patent costly unpredictable deprive company market exclusivityforapatentedproductorinsomecasesthirdpartypatentsmaypreventthecompanyfrommarkete sell product particular geographic area ifoneormoreimportantproductslosepatentprotectioninprofitablemarketssalesofthoseproductsare likelytodeclinesignificantlyasaresultofgenericversionsofthoseproductsbecomingavailablethecompany result operation adversely affect lost sale company successfully launch commercially successful replacement product company face intense competition lowercost generic product ingeneralthecompanyfacesincreasingcompetitionfromlowercostgenericproductsthepatentright thatprotectitsproductsareofvaryingstrengthsanddurationsinadditioninsomecountriespatentprotectioni significantlyweakerthanintheunitedstatesortheeuintheunitedstatespoliticalpressuretoreducespende prescription drug lead legislation encourages use generic product companyspolicytoactivelyprotectitspatentrightsgenericchallengestothecompanysproductscanariseatany time able prevent emergence generic competition product lossofpatentprotectionforaproducttypicallyisfollowedpromptlybygenericsubstitutesreducingthe companyssalesofthatproductavailabilityofgenericsubstitutesforthecompanysdrugsmayadverselyaffect itsresultsofoperationsandcashflowinadditionproposalsemergefromtimetotimeintheunitedstatesandother countriesforlegislationtofurtherencouragetheearlyandrapidapprovalofgenericdrugsanysuchproposalthatis enactedintolawcouldworsenthissubstantialnegativeeffectonthecompanyssalesandpotentiallyitsresultsof operation cash flow company face intense competition new product company product face intense competition competitor product competition increase new product enter market event competitor product safer effectiveormoreeffectivelymarketedandsoldthanthecompanysproductsalternativelyinthecaseofgeneric competitiontheymaybeequallysafeandeffectiveproductswhicharesoldatasubstantiallylowerpricethanthe company product result company fail maintain competitive position material adverse effect business result operation company face pricing pressure respect product company product subject increase price pressure restriction worldwide include united state include practice manage care group institutional govern mental purchaser ii federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act act theactincludedaprescriptiondrugbenefitforindividualswhichfirstwentintoeffectonjanuary theincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicarebeneficiariescouldresultin pricing pressure company expect pricing pressure increase future company experience difficulty delay manufacture product thecompanymayexperiencedifficultiesanddelaysinherentinmanufacturingitsproductsparticularly vaccine failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturingshutdownsproductshortagesanddelaysinproductmanufacturingiiconstructiondelaysrelated totheconstructionofnewfacilitiesortheexpansionofexistingfacilitiesincludingthoseintendedtosupportfuture demandforthecompanysproductsandiiiothermanufacture ordistributionproblemsincludingchangesin manufacturing production site limit manufacturing capacity regulatory requirement change typesofproductsproducedorphysicallimitationsthatcouldimpactcontinuoussupplymanufacturingdifficultie result product shortage lead lose sale pharmaceutical product develop unexpected safetyor efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim company product liability insurance product sell august asaresultofanumberoffactorsproductliabilityinsurancehasbecomelessavailablewhilethecosthas increasedsignificantlythecompanyhasevaluateditsrisksandhasdeterminedthatthecostofobtainingproduct liabilityinsuranceoutweighsthelikelybenefitsofthecoveragethatisavailableandassuchhasnoinsurancefor certain product liability effective august include liability product sell date change law regulation adversely affect company business allaspectsofthecompanysbusinessincludingresearchanddevelopmentmanufacturingmarketing pricingsaleslitigationandintellectualpropertyrightsaresubjecttoextensivelegislationandregulationchange inapplicablefederalandstatelawsandagencyregulationscouldhaveamaterialadverseeffectonthecompany business cautionary factor affect future result cautionary statement private security litigation reform act thisreportandotherwrittenreportsandoralstatementsmadefromtimetotimebythecompanymay containsocalledforwardlookingstatementsallofwhicharebasedonmanagementscurrentexpectationsand subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan willestimatesforecastsprojectsandotherwordsofsimilarmeaningonecanalsoidentifythembythe factthattheydonotrelatestrictlytohistoricalorcurrentfactsthesestatementsarelikelytoaddressthecompany growth strategy financial result product development product approval product potential development program onemustcarefully consider anysuchstatement shouldunderstand manyfactor cause actualresultstodiffermateriallyfromthecompanysforwardlookingstatementsthesefactorsincludeinaccurate assumptionsandabroadvarietyofotherrisksanduncertaintiesincludingsomethatareknownandsomethatare notnoforwardlookingstatementcanbeguaranteedandactualfutureresultsmayvarymateriallythecompany doesnotassumetheobligationtoupdateanyforwardlookingstatementthecompanycautionsyounottoplace undue reliance forwardlooke statement possible predict identify factor include follow cid significant litigation relate vioxx include settlement agreement consummate cid competition generic product company product lose patent protection cid increase brand competition therapeutic area important company longterm business performance cid difficulty uncertaintie inherent new product development outcome lengthy complexprocessofnewproductdevelopmentisinherentlyuncertainadrugcandidatecanfailatanystageof theprocessandoneormorelatestageproductcandidatescouldfailtoreceiveregulatoryapprovalnewproduct candidate appear promise development fail reach market efficacy safety concernstheinabilitytoobtainnecessaryregulatoryapprovalsthedifficultyorexcessivecosttomanufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level cid pricingpressuresbothintheunitedstatesandabroadincludingrulesandpracticesofmanagedcaregroups judicialdecisionsandgovernmentallawsandregulationsrelatedtomedicaremedicaidandhealthcarereform pharmaceutical reimbursement pricing general cid change government law regulation enforcement thereof affect company business cid efficacyorsafetyconcernswithrespecttomarketedproductswhetherornotscientificallyjustifiedleadingto product recall withdrawal decline sale cid legalfactorsincludingproductliabilityclaimsantitrustlitigationandgovernmentalinvestigationsinclude taxdisputesenvironmentalconcernsandpatentdisputeswithbrandedandgenericcompetitorsanyofwhich preclude commercialization product negatively affect profitability exist product cid lostmarketopportunityresultingfromdelaysanduncertaintiesintheapprovalprocessofthefdaandforeign regulatory authority cid increase focusonprivacyissuesincountriesaroundtheworldincludingtheunitedstatesandtheeuthe legislativeandregulatorylandscapeforprivacyanddataprotectioncontinuestoevolveandtherehasbeenan increase focus privacy datum protection issue potential affect directly company business cid change tax law include change relate taxation foreign earning cid change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company cid economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item b unresolved staff comment item property companys corporate headquarters locate whitehouse station new jersey companys uspharmaceutical businessisconducte throughdivisional headquarters locate inuppergwyneddand west point pennsylvania company vaccine business conduct divisional headquarters locate west point principal research facility human health product locate rahway newjerseyand west pointthecompanyalsohasproductionfacilitiesforhumanhealthproductsatsevenlocationsintheunitedstate andpuertoricobranchwarehousesprovideservicesthroughoutthecountryoutsidetheunitedstatesthrough subsidiariesthecompanyownsorhasaninterestinmanufacturingplantsorotherpropertiesinaustraliacanada japan singapore south africa countries western europe central south america asia capital expenditure billion compare million united state amount million million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title whichtheyconsidertobesatisfactorythecompanyconsidersthatitspropertiesareingoodoperatingcondition machinery equipment maintain plant manufacture product suitablefortheirintendedpurposesandhavecapacitiesandprojectedcapacitiesadequateforcurrentandprojecte need exist company product capacity plant convert need modi fication requirement newly introduce future product item legal proceeding companyis involve invariousclaim legal proceeding anature consider normal businessincludingproductliabilityintellectualpropertyandcommerciallitigationaswellasadditionalmatter antitrust action vioxx litigation product liability lawsuit previously disclose individual putative class action file company stateandfederalcourtsallegingpersonalinjuryandoreconomiclosswithrespecttothepurchaseoruseofvioxx allsuchactionsfiledinfederalcourtarecoordinatedinamultidistrictlitigationintheusdistrictcourtforthe easterndistrictoflouisianathemdlbeforedistrictjudgeeldonefallonanumberofsuchactionsfiledin statecourtarecoordinatedinseparatecoordinatedproceedingsinstatecourtsinnewjerseycaliforniaandtexas andthecountiesofphiladelphiapennsylvaniaandwashoeandclarkcountiesnevadaasofdecember thecompanyhadbeenservedorwasawarethatithadbeennamedasadefendantinapproximatelylawsuit whichincludeapproximatelyplaintiffgroupsallegingpersonalinjuriesresultingfromtheuseofvioxxand approximately putative class action allege personal injury andor economic loss action discussedinthisparagrapharecollectivelyreferredtoasthevioxxproductliabilitylawsuitsoftheselawsuit approximately lawsuit represent approximately plaintiff group slate federalmdlandapproximatelylawsuitsrepresentingapproximatelyplaintiffgroupsareincludedin coordinate proceed new jersey superior court judge carol e higbee inadditiontothevioxxproductliability lawsuitsdiscussedabovetheclaim ofoverplaintiff hadbeendismissedasofdecember ofthesetherehavebeenoverplaintiffswhoseclaimswere dismissedwithprejudiceietheycannotbebroughtagaineitherbyplaintiffsthemselvesorbythecourtsover additionalplaintiffshavehadtheirclaimsdismissedwithoutprejudiceiesubjecttotheapplicablestatuteof limitation bring merck enter tolling agreement tolling agreement mdl plaintiff steer committeepscthatestablishedaproceduretohalttherunningofthestatuteoflimitationstollingastocertain category ofclaim allegedly arisingfromthe useofvioxx bynonnewjerseycitizens tolling agreement appliedtoindividualswhohavenotfiledlawsuitsandmay ormaynoteventually filelawsuitsandonlytothose claimantswhoseektotollclaimsalleginginjuriesresultingfromathromboticcardiovasculareventthatresultsina myocardialinfarctionmiorischemicstrokeisthetollingagreementprovidedcounseladditionaltimeto evaluate potential claim tolling agreement require toll claim file federal court decemberapproximatelyclaimantshadenteredintotollingagreementsthepartiesagreedthat april deadline filing tolling agreement additional tolling agreement accept november merck announce enter agreement settlement agreement law firm comprise executive committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceedingstoresolvestateandfederalmiandisclaimsfiledasofthatdateintheunitedstatesthesettlement agreementwhichalsoappliestotolledclaimswassignedbythepartiesafterseveralmeetingswiththreeofthe fourjudgesoverseeingthecoordinationofmorethanpercentofthecurrentclaimsinthevioxxlitigationthe settlementagreementappliesonlytouslegalresidentsandthosewhoallegethattheirmiorisoccurredinthe united states theentire settlement agreement include accompanyingexhibitsmaybefoundat wwwmerckcom thecompanyhasincludedthiswebsiteaddressonlyasaninactivetextualreferenceanddoesnotintendittobean active link website incorporate reference information contain certain participation condition settlement agreement meet condition waive merck merckwillpayafixedaggregateamountofbillionintotwofundsforqualifyingclaimsthatenterintothe resolution process settlement program individual claimant examine administrators settlement program determine qualification base objective document fact provide claimant includingrecordssufficientforascientificevaluationofindependentriskfactorstheconditionsinthesettlement agreementalsorequireclaimantstopassthreegatesaninjurygaterequiringobjectivemedicalproofofanmior iseachasdefinedinthesettlementagreementadurationgatebasedondocumentedreceiptofatleastvioxx pill proximity gate require receipt pill sufficient number proximity event tosupport presumption ingestion vioxx day claim injury settlement agreement provide merck admit causation fault merck payment obligationsunderthesettlementagreementwillbetriggeredonlyifamongotherconditionslawfirmsonthe federalandstatepscsandfirmsthathavetriedcasesinthecoordinatedproceedingselecttorecommendenrollment program percent client allege mi march subject extensionplaintiffsenrollinthesettlementprogramatleastpercentofeachofallcurrentlypendingandtolle imiclaimsiiisclaimsiiieligiblemiandisclaimstogetherwhichinvolvedeathandiveligiblemiandis claimstogetherwhichallegemorethanmonthsofusethecompanyhastherighttowaivetheseparticipation condition underthesettlementagreementmerckwillcreateseparatefundsintheamountofbillionformi claimsandmillionforisclaimsoncetriggeredmerckstotalpaymentforbothfundsofbillionisa fixedamounttobeallocatedamongqualifyingclaimantsbasedontheirindividualevaluationwhileatthistimethe exact number claimant cover settlement agreement unknown total dollar fix paymentstoindividualqualifyingclaimantscouldbeginasearlyasaugustandthenwillbepaidoveraperiod oftimemerckretainsitsrighttoterminatethisprocesswithoutanypaymenttoanyclaimantandtodefendeach claimindividuallyattrialifanyoftheaforementionedparticipationconditionsinthesettlementagreementarenot meet settlement agreement announce november judges federal mdl california texasandnewjerseystate coordinate proceedingsentered aseriesoforderstheorderstem porarily stay respective litigation require plaintiff register claim january requireplaintiffswithcasespendingasofnovembertopreserveandproducerecordsandserveexpert reportsandrequireplaintiffswhofilethereaftertomakesimilarproductionsonanaccelerate schedulethe clark county nevada coordinate proceeding generally stay asoffebruarymorethanplaintiffshadsubmittedregistrationmaterialsincludingmore thanplaintiffswhoallegeanmiorisinadditionasoffebruarymorethanclaimantshave startedsubmittingenrollmentmaterialstheregistrationandenrollmentmaterialscurrentlyarebeingevaluatedfor eligibilityaccuracyandcompletenesstheclaimsadministratorcontinuestoreceivenewmaterialsfromplaintiffs vioxx product liability lawsuit currently schedule trial company providedalistofsuchtrialsatitswebsiteatwwwmerckcomwhichitwillperiodicallyupdateasappropriatethe companyhasincludeditswebsiteaddressonlyasaninactivetextualreferenceanddoesnotintendittobeanactive link website incorporate reference information contain company previously disclose outcome vioxx product liability lawsuit try prior september chart followingset forth result trial certain significant ruling occur fourth quarter respect vioxx product liability lawsuit october jury kozic v merck case try state court tampa florida found unanimously favor merck count reject claim company wasliable plaintiff heart attackindecemberplaintifffiledanappealbutagreedtoanorderstayingallotherposttrialactivitypende entry settlement program january judge victoria chaney declare mistrial consolidated trial case appellvmerckandarrigalevmerckwhichhadcommencedonoctoberincaliforniastatecourtinlos angelesafterthejuryindicatedthatitcouldnotreachaverdictjudgechaneyhadrescheduledtheretrialofthe combine trial appell arrigale january case stay inaprilinatrialinvolvingtwoplaintiffsthomasconaandjohnmcdarbyinsuperiorcourtof newjerseylawdivisionatlanticcountythejuryreturnedasplitverdictthejurydeterminedthatvioxxdidnot substantially contribute heart attack mr cona substantially contribute heart attack mr mcdarby jury conclude case merck violate new jerseys consumer fraud statute whichallowsplaintiffstoreceivetheirexpensesforpurchasingthedrugtrebledaswellasreasonableattorney fee jury award million compensatory damage mr mcdarby wife plaintiffinthat case punitivedamage million onjune judge higbee deny merck motion new trial june judge higbee award approximately million aggregate attorneysfeesandcoststhecompanyhasappealedthejudgmentsinbothcasesandtheappellatedivisionheld oral argument case january onmarchajuryfoundformerckonallcountsinschwallervmerckwhichwastriedinstate court madison county illinois plaintiff move new trial plaintiff file supplementalmotionforanewtrialonseptemberondecemberjudgestacksignedaconsent order stay posttrial activity case march ondecemberthejuryinalbrightvmerckacasetriedinstatecourtinbirminghamalabama returnedaverdictformerckonallcountsplaintiffappeale injulytothealabamasupremecourtbutin december plaintiff agree stay appeal pende entry settlement program april judge randy wilson presides texas vioxx coordinate proceeding dismissedthefailuretowarnclaimofplaintiffrubyledbetterwhosecasewasscheduledtobetriedonmay judge wilson rely texas statute enact provide failure warn regardingaprescriptionmedicineifthemedicineisdistributedwithfdaapprovedlabelingthereisanexception inthestatuteifrequiredmaterial andrelevantinformationwaswithheldfromthefdathatwouldhaveledtoa different decision approve labeling judge wilson find exception preempt federal law fda find information withhold judge wilson currently preside approximatelyvioxxsuitsintexasinwhichaprincipalallegationisfailuretowarnjudgewilsoncertifie thedecisionforanexpeditedappealtothetexascourtofcivilappealsplaintiffshaveappealedthedecisionon october merck file motion abate hearing appeal supreme courts decision warner lambert v kent decide october texas court appealsdeniedmercksmotiontoabatethepartiesarecurrentlybriefingtheappealthecompanyexpectsoral argument set spring injulyindohertyvmerckinsuperiorcourtofnewjerseylawdivisionatlanticcountyajury returnedaverdictinfavorofthecompanyonallcountsthejuryrejectedaclaimbytheplaintiffthathernearly threeyearsofvioxxusecausedherheartattackthejuryalsofoundinmercksfavorontheplaintiffsconsumer fraudclaimplaintifffiledamotionforanewtrialinaugustondecemberjudgehigbeedenie plaintiff motion new trial prejudice light plaintiff express intention participate settlement program aconsolidatedtrialhermansvmerckandtheretrialofhumestonvmerckbeganonjanuary inthecoordinatedproceedinginnewjerseysuperiorcourtbeforejudgehigbeehumestonvmerckwasfirsttrie inresultinginajuryverdictinfavorofmerckonnovemberhoweveronaugustjudge higbee set aside november jury verdict order new trial ground newly discover evidence thehermanshumestontrialwasseparatedintotwophasesageneralphaseregardingmercksconduct aplaintiffspecific phaseonmarchthe juryfoundformerckinthegeneral phaseonthe hermans failuretowarnclaimandtheconsumerfraudclaimwassubsequentlysubmittedtojudgehigbeefordecisionon march jury find plaintiff humeston case award compensatory damage mr humeston million mrs humeston million jury awardedmillioninpunitivedamagesmerckhasmovedforajudgmentnotwithstandingtheverdictanew trialorreductionoftheawardtheseandotherposttrialmotionsarecurrentlypendingondecember court dismiss motion new trial prejudice herman onjulythenewjerseyappellate divisionunanimouslyupheldjudgehigbeesdismissalof vioxxproductliabilitylawsuitsbroughtbyresidentsoftheunitedkingdomplaintiffshadaskedthenewjersey supremecourttoreviewthedecisiononnovemberthenewjerseysupremecourtdeclinedtoreview decision merckvoluntarilywithdrewvioxxfromthemarketonseptembermoststateshavestatutesof limitationsforproductliabilityclaimsofnomorethanthreeyearswhichrequirethatclaimsmustbefiledwithinno morethanthreeyearsaftertheplaintiffslearnedorcouldhavelearnedoftheirpotentialcauseofactionasaresult somemayviewseptemberasasignificantdeadlineforfilingvioxxcasesitisimportanttonotehowever thatthelawregardingstatutesoflimitation canbecomplexandvariable dependingonthefactsandapplicable lawsomestateshavelongerstatutesoflimitationstherearealsoargumentsthatthestatutesoflimitationsbegan run september new jersey superior court judge higbee federal district court judge fallonhaveissuedordersincasesfromnewjerseyandeightotherjurisdictionsrulingthatthestatutoryperiodfor makingvioxxpersonalinjuryclaimshaspassedjudgehigbeesorderwasissuedonoctoberandjudge fallon issue november thefollowingchartsetsforththeresultsofallusvioxxproductliabilitytrialstodatejurieshavenow decidedinfavorofthecompanytimesandinplaintiffsfavorfivetimesonemerckverdictwassetasidebythe courtandhasnotbeenretriedanothermerckverdictwassetasideandretriedleadingtooneofthefiveplaintiff verdictstherehavebeentwounresolvedmistrialswithrespecttothefiveplaintiffsverdictsmerckhasfiledan appealorsoughtjudicialreviewineachofthosecasesandinoneofthosefiveafederaljudgereducedthedamage award trial certain plaintiff trial list eligible settlement program stateor federal verdictdate plaintiff court result comment aug ernst texas verdict forplaintiff juryawardedplaintiffmillion thecourtreducedamountto approximately million plus interestthejudgmentisnowon appeal novand humeston newjersey verdict formerck inthetrial thejuryfoundfor march thenjudgesetaside merck inaugustthecourtset theverdictorderinga asidetheverdict andorderedanew newtrialwhich trialforjanuary resultedinaverdict attheconclusion ofthetrial forplaintiff thejuryawardedplaintiffatotalof million indamagesthejury alsoawardedplaintiffthenominal sumofontheir consumer fraudactclaim merckhasmove forajudgmentnotwithstande verdict areducedverdictamount foranewtrialthesemotionsarestill pende decand plunkett federal verdict formerck merckprevailedinthefebruary feb judgethensetaside retrial thecourtsetasidethe theverdict februaryverdict inmay nodatehasbeensetforanewtrial april mcdarby nj verdict forplaintiff plaintiffwasawardedmillion damagesinjunethecourt awardedplaintiffsinthisandthe conaclaim triedwithit approximately million inattorney feesandcost merckhasappeale thejudgmentinclude theawardof attorneysfeesandcost april cona nj verdict formerckon thejuryfoundformerckonthe failuretowarnclaim failuretowarnclaim thejury awardedplaintiffthenominalsumof forhisconsumerfraudact claim injunethecourt awardedplaintiffsinthisandthe mcdarbyclaim try withit approximately million inattorney feesandcost merckhasappeale thejudgmentinclude theawardof attorneysfeesandcost april garza texas verdict forplaintiff judgereducedmillion juryaward tomillion plusinterestmerck filedanappealonmarch stateor federal verdictdate plaintiff court result comment july doherty nj verdict formerck thecourtdeniedthemotion fornew trialwithoutprejudice pende plaintiffsentryintothesettlement program aug grossberg california verdict formerck plaintiffsmotionforanewtrial deniedandhissubsequentappealwas dismiss aug barnett federal verdict forplaintiff juryawardedplaintiffmillion damagesthejudgeruledtheaward wasgrosslyexcessiveandreduce theawardtomillion merckha appeal thejudgmenttothecourtof appeals sept smith federal verdict formerck nov mason federal verdict formerck dec dedrick federal verdict formerck plaintiffsmotionforanewtrial deniedinmay dec albright alabama verdict formerck plaintiffappealed injulytothe alabamasupremecourtbutin decemberplaintiffagreedto stayhisappealpendinghisentryinto thesettlement program jan arrigaleappell california mistrialdeclare juryfaile toreturnverdictsincase thejurydeadlocke filedbytwoplaintiffswhoallege vioxxcontributedtotheirheart attacksthesecasesarenowstaye march hermans newjersey verdict formerckon thejuryfoundformerckonthe thefailuretowarn failuretowarnclaim thepartie claim submittedtheconsumerfraudact claim tothecourtforresolutionthis remainspendingbutsubjecttothe stay march schwaller illinois verdict formerck plaintiffmovedforanewtrial decemberjudgestack signedaconsentorderstayingall posttrialactivityinthecaseuntil march oct kozic florida verdict formerck indecemberplaintifffiledan appealbutagreedtoanorderstaye allotherposttrialactivitypendinghis entryintothesettlement program lawsuit aspreviouslydisclosedonjulyanewjerseystatetrialcourtcertifiedanationwideclassof thirdpartypayorssuchasunionsandhealthinsuranceplansthatpaidinwholeorinpartforthevioxxusedbytheir planmembersorinsuredsthenamedplaintiffinthatcasesoughtrecoveryofcertain vioxxpurchasecostsplus penaltiesbasedonallegationsthatthepurportedclassmemberspaidmoreforvioxxthantheywouldhavehadthey know product allege risk march new jersey superior court appellate division affirm class certification order september new jersey supreme court reverse certificationofanationwideclassactionofthirdpartypayorsfindingthatthesuitdoesnotmeettherequirement class action claim certain individual thirdparty payor remain pende new jersey court counselpurportingtorepresentalargenumberofthirdpartypayorshasthreatenedtofilenumerousadditionalsuch action activity pende case currently stay pende court putative class action purportedly bring behalf individual purchaser user vioxx claim reimbursement allege economic loss entitlement medical monitoring case early procedural stage class certifiedinnewjerseythetrialcourtdismissedthecomplaintinthecaseofsinclairapurportedstatewidemedical monitoringclasstheappellatedivisionreversedthedismissalandtheissueisnowonappealtothenewjersey supreme court court hear argument october aspreviouslyreportedthecompanyhasalsobeennamedasadefendantinseparatelawsuitsbroughtby theattorneysgeneralofsevenstatesandthecityofnewyorkacoloradotaxpayerhasalsofiledaderivativesuit onbehalfofthestateofcoloradonamingthecompanytheseactionsallegethatthecompanymisrepresentedthe safety vioxx seek recovery cost vioxx purchase reimburse state agency iireimbursementofallsumspaidbythestateanditsagenciesformedicalservicesforthetreatmentofperson injure vioxx iii damage common law theory andor iv remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty addition company name lawsuit contain similar allegationsfiledbygovernmentalentitiesseekingthereimbursementofallegedmedicaidexpendituresforvioxx lawsuit class action file santa clara county california behalf similarly situate californiacountiesandanactionfiledbyeriecountynewyorkwiththeexceptionofthecasefiledbytexas remain texas state court currently schedule trial september new york attorney general erie county case pende transfer rest action describe paragraph transfer federal mdl experience significant activity date shareholder lawsuit aspreviouslydisclosedinaddition tothevioxx productliability lawsuitsthecompanyandvarious current officer director defendant invarious putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx securitieslawsuitspendinginfederalcourthavebeentransferredbythejudicialpanelonmultidistrictlitigation jpml united states district court district new jersey district judge stanley r chesler forinclusion inanationwide mdlthe shareholder mdljudgechesler hasconsolidate vioxx securitieslawsuitsforallpurposestheputativeclassactionwhichrequesteddamagesonbehalfofpurchasersof companystockbetweenmayandoctoberallegedthatthedefendantsmadefalseandmisleade statement vioxx inviolation section band ofthe securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assertedclaimsundersectionaofthesecuritiesandexchangeactagainstcertaindefendantsrelatingtotheir salesofmerckstockandundersectionsandofthesecuritiesactofagainstcertaindefendantsbase statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan onapril judge chesler grant defendant motion dismissthecomplaintwithprejudiceplaintiffshaveappealedjudgecheslersdecisiontotheunitedstatescourt appeals circuit inoctoberadutchpensionfundfiledacomplaintinthedistrictofnewjerseyallegingviolation offederalsecuritieslawsaswellasviolationsofstatelawagainstthecompanyandcertainofficerspursuanttothe casemanagementordergoverningtheshareholdermdlthecasewhichisbasedonthesameallegationsasthe vioxxsecuritieslawsuitswasconsolidatedwiththevioxxsecuritieslawsuitsdefendantsmotiontodismissthe pensionfundscomplaintwasfiledonaugustinseptemberthedutchpensionfundfiledanamende complaintratherthanrespondingtodefendantsmotiontodismissinadditioninsixnewcomplaintswere file district new jersey behalf foreign institutional investor allege violation federalsecuritieslawsaswellasviolationsofstatelawagainstthecompanyandcertainofficersdefendantsare notrequiredtorespondtothesecomplaintsuntilafterthethirdcircuitissuesadecisiononthesecuritieslawsuit currently appeal aspreviouslydisclosedonaugustacomplaintwasfiledinoregonstatecourtbythestateof oregonthroughtheoregonstatetreasureronbehalfoftheoregonpublicemployeeretirementfundagainstthe companyandcertaincurrentandformerofficersanddirectorsunderoregonsecuritieslawatrialdatehasbeenset october aspreviouslydisclosedvariousshareholderderivativeactionsfiledinfederalcourtweretransferredto shareholder mdlandconsolidate forall purposesbyjudgechesler thevioxx derivativelawsuit mayjudgecheslergranteddefendantsmotiontodismissanddeniedplaintiffsrequestforleavetoamend complaint plaintiff appeal argue judge chesler err deny plaintiff leave amend complaintwithmaterialsacquiredduringdiscoveryonjulytheunitedstatescourtofappealsforthe thirdcircuitreversedthedistrictcourtsdecisiononthegroundsthatjudgecheslershouldhaveallowedplaintiff use discovery material try establish demand futility remand case district courtsconsideration ofwhetherevenwiththeadditional material plaintiffsrequesttoamendtheircomplaint futile plaintiff file brief support request leave amend complaint november motion pende addition previously disclose putative class action file federal court employeeretirementincomesecurityacterisaagainstthecompanyandcertaincurrentandformerofficer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim behalf certain company current employee participant certain company retirement plan breach fiduciarydutythelawsuitsmakesimilarallegationstotheallegationscontainedinthevioxxsecuritieslawsuit july judge chesler grant deny defendant motion dismiss erisa complaintinoctoberplaintiffsmovedforcertificationofaclassofindividualswhowereparticipantsinand beneficiariesofthecompanysretirementsavingsplansatanytimebetweenoctoberandseptember plan account include investment merck common stock fund andor merck common stock motion pende previously disclose october individual shareholder demand company board legal action mr raymond gilmartin chairman president chief executiveofficerandotherindividualsforallegedlycausingdamagetothecompanywithrespecttotheallegedly improper marketing vioxx december special committee board director retain honorable johnsmartin jrof debevoiseplimpton llp toconduct anindependent investigationofamong thing allegation set forth inthe demand judgemartinsreport wasmade public inseptember basedonthespecialcommitteesrecommendationmadeaftercarefulconsiderationofthemartinreportandthe impactthatderivativelitigationwouldhaveonthecompanytheboardrejectedthedemandonoctober shareholder file lawsuit state court atlantic county nj current executive directorsofthecompanyallegingthattheboardsrejectionoftheirdemandwasunreasonableandimproperand defendant breach duty company allow vioxx market international lawsuit aspreviouslydisclosedinadditiontothelawsuitsdiscussedabovethecompanyhasbeennamedasa defendantinlitigationrelatingtovioxxinvariouscountriescollectivelythevioxxforeignlawsuitsineurope canada brazil argentina australia turkey israel additional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future insurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible co insurancethisinsuranceprovidescoverageforlegaldefensecostsandpotential damageamountsinconnection withthevioxxproductliabilitylawsuitsthecompanysinsurancecoveragewithrespecttothevioxxlawsuit adequate cover defense cost loss previously disclose company upper level excess insurer provide excess insurance potentiallyapplicabletoallofthevioxxlawsuitshadcommencedanarbitrationseekingamongotherthingsto cancel policy tovoid oftheir obligation policy toraise coverage issueswith respecttothevioxxlawsuitsaspreviouslydisclosedinnovemberthetribunalinthearbitrationruledinthe companysfavororderingtheupperlevelexcessinsurerstocomplywiththeirobligationsunderthepoliciesthe companyrecordedamilliongaininthefourthquarterasaresultofcertainothersettlementsandthetribunal decisioninadditionpriortorecordingthegaininthefourthquarterofasaresultofsettlementswithand payment certain insurer company previously receive insurance proceed approx imately million company claim resolve low level excess insurerstoobtainreimbursementforamountspaidinconnectionwithvioxxproductliabilitylawsuitsasaresult ofsettlementsthathavealreadybeenmadethecompanywillnotrecoverthefullamountofthelimitsdiscussedin paragraph section resolution claim low level insurer affect total insurance recover claim remain coverage approximately million fromthelowerlevelexcessinsurersthecompanyhasnoadditional insuranceforthevioxxproduct liability lawsuit thecompanyhasdirectorsandofficersinsurancecoverageapplicabletothevioxxsecuritieslawsuit andvioxxderivativelawsuitswithstatedupperlimitsofapproximatelymillionthecompanyhasfiduciary insurance vioxx erisalawsuit state upper limit approximately million asa resultofthearbitration additional insurancecoveragefortheseclaimsshouldalsobeavailable ifneededunder upperlevelexcesspoliciesthatprovidecoverageforavarietyofriskstherearedisputeswiththeinsurersaboutthe availabilityofsomeorallofthecompanysinsurancecoveragefortheseclaimsandtherearelikelytobeadditional disputestheamountsactuallyrecoveredunderthepoliciesdiscussedinthisparagraphmaybelessthanthestated upper limit investigation aspreviouslydisclosedinnovemberthecompanywasadvisedbythestaffofthesecthatitwas commencinganinformalinquiryconcerningvioxxonjanuarythecompanyannouncedthatitreceive notice thesecissuedaformalnotice ofinvestigationalsothecompanyhasreceivedsubpoenasfromthe usdepartmentofjusticethedojrequestinginformationrelatedtothecompanysresearchmarketingand sellingactivitieswithrespecttovioxxinafederalhealthcareinvestigationundercriminalstatutesinadditionas previouslydisclosedinvestigationsarebeingconductedbylocalauthoritiesincertaincitiesineuropeinorderto determine anycriminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company receive number civil investigative demand cid fromagroupofattorneysgeneralfromstatesandthedistrictofcolumbiawhoareinvestigatingwhetherthe company violate state consumer protection law market vioxxthe company cooperate attorney general respond cid inadditionthecompanyreceivedasubpoenainseptemberfromthestateofcaliforniaattorney generalseekingdocumentsandinformationrelatedtotheplacementofvioxxoncaliforniasmedicalformulary company cooperate attorney general respond subpoena reserve asdiscussedaboveonnovembermerckenteredintothesettlement agreementwiththelaw firm comprise executive committee psc federal vioxx mdl representative plaintiffscounselinthetexasnewjerseyandcaliforniastatecoordinatedproceedingstoresolvestateandfederal miandisclaimsfiledasofthatdateintheunitedstatesthesettlementagreementwhichalsoappliestotolle claimswassignedbythepartiesafterseveralmeetingswiththreeofthefourjudgesoverseeingthecoordinationof percent current claim vioxx litigation settlement agreement apply uslegalresidentsandthosewhoallegethattheirmiorisoccurredintheunitedstatesasaresultofenteringinto settlement agreement company record pretax charge billion represent fix aggregate pay plaintiff qualify payment settlement program company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict whetherthistrialwillproceedonscheduleorthetimingofanyoftheothervioxxshareholderlawsuittrialsthe companybelievesthatithasmeritoriousdefensestothevioxxlawsuitsandwillvigorouslydefendagainstthemin viewoftheinherentdifficultyofpredictingtheoutcomeoflitigationparticularlywheretherearemanyclaimant andtheclaimantsseekindeterminatedamagesthecompanyisunabletopredicttheoutcomeofthesemattersand time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation include case verdict judgment enter companyand nowin postverdict proceedingsoronappealineachofthosecasesthecompanybelievesithasstrongpointstoraiseonappealand thereforethatunfavorableoutcomesinsuchcasesarenotprobableunfavorableoutcomesinthevioxxlitigation material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probableandreasonablyestimableasofdecemberthecompanyhadareserveofmillionsolelyfor itsfuturelegaldefensecostsrelatedtothevioxxlitigationduringthecompanyspentmillioninthe aggregate legal defense cost relate vioxx litigation record additional charge million thusasofdecemberthecompanyhadareserveofmillionsolelyforitsfuturelegaldefensecost relate vioxx litigation company spend approximately million aggregate legal defense cost worldwiderelate toithevioxx productliability lawsuitsiithevioxx shareholderlawsuitsiiithevioxx foreignlawsuitsandivthevioxxinvestigationscollectivelythevioxxlitigationinthesecondquarterand thirdquarterofthecompanyrecordedchargesofmillionandmillionrespectivelytoincreasethe reserve solely future legal defense cost relate vioxx litigation increase reserve company consider factor consider previously establish reserve vioxx litigationinthefourthquarterthecompanyspentapproximatelymillioninvioxxlegaldefensecostswhich result ina reserveof million december itsfuture legal defense costsrelate vioxx litigation enter settlement agreement company review reserve vioxx legal defense cost allocate approximately million reserve merck anticipate future cost administerthesettlementprogramsomeofthesignificantfactorsconsideredinthereviewofthereservewereas followstheactualcostsincurredbythecompanythedevelopmentofthecompanyslegaldefensestrategyand structureinlightofthescopeofthevioxxlitigationincludingthesettlementagreementandtheexpectationthat thesettlementagreementwillbeconsummatedbutthatcertainlawsuitswillcontinuetobependingthenumberof case bring company cost outcome complete trial current informationregardinganticipatedtimingprogressionandrelatedcostsofpretrialactivitiesandtrialsinthevioxx productliabilitylawsuitseventssuchasscheduledtrialsthatareexpectedtooccurthroughoutand inherent inability predict ultimate outcome trial disposition vioxx product liability lawsuitsnot participate noteligible settlement program limit companysability reasonably estimate legal cost billion reserve settlement program aggregate reserve establish vioxx litigation december approximately billion vioxx reserve company anticipate need increase reserve quarter continuetomonitoritslegaldefensecostsandreviewtheadequacyoftheassociatedreservesandmaydetermineto increaseitsreservesforlegaldefensecostsatanytimeinthefutureifbaseduponthefactorssetforthitbelievesit appropriate product liability litigation previously disclose company defendant product liability lawsuit united states involvingfosamaxthefosamaxlitigationasofdecemberapproximatelycaseswhichinclude approximatelyplaintiffgroupshadbeenfiledandwerependingagainstmerckineitherfederalorstatecourt includingcaseswhichseekclassactioncertificationaswellasdamagesandmedicalmonitoringintheseaction plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasivedentalproceduressuchastoothextractionordentalimplantsandordelayedhealinginassociationwith use fosamaxonaugust jpmlordere fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdlforcoordinatedpretrialproceedingsthefosamaxmdlhasbeentransferredtojudgejohnkeenaninthe unitedstatesdistrictcourtforthesoutherndistrictofnewyorkasaresultofthejpmlorderapproximately case judge keenan judge keenan issue case management order set forth schedulegoverningtheproceedingswhichfocusesprimarilyuponresolvingtheclassactioncertificationmotionsin andcomplete factdiscoveryinaninitial groupofcasesbyaugustbriefingandargumenton plaintiffsmotionsforcertificationofmedicalmonitoringclasseswerecompletedinandjudgekeenanissue order deny motion january january judge keenan issue order dismiss prejudice class claim assert class action lawsuitsfile merck soughtpersonalinjurydamagesandormedicalmonitoringreliefonaclasswidebasisdiscoveryisongoinginboth thefosamaxmdllitigationaswellasinvariousstatecourtcasesthecompanyintendstodefendagainstthese lawsuit asofdecemberthecompanyhadaremainingreserveofapproximatelymillionsolelyfor future legal defense cost fosamax litigation significant factor consider establishmentofthereserveforthefosamaxlitigationlegaldefensecostswereasfollowstheactualcostsincurred company far development company legal defense strategy structure light creationofthefosamaxmdlthenumberofcasesbeingbroughtagainstthecompanyandtheanticipatedtime progression relate cost pretrial activity fosamax litigation company continue monitoritslegaldefensecostsandreviewtheadequacyoftheassociatedreservesduetotheuncertainnatureof litigationthecompanyisunabletoestimateitscostsbeyondthecompanyhasnotestablishedanyreserve foranypotentialliabilityrelatingtothefosamaxlitigationunfavorableoutcomesinthefosamaxlitigationcould material adverse effect company financial position liquidity result operation commercial litigation previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidatedclassactioncomplaintwhichaggregatedtheclaimspreviouslyfiledinvariousfederaldistrictcourt action alsoexpande number ofmanufacturer toinclude somewhich like companyhadnotbeen defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissaltheplaintiffsfiledanamendedconsolidatedclassactioncomplaintwhichdidnotnamethecompanyas defendant company pharmaceutical manufacturer defendant similar complaint pendinginfederalandstatecourtbroughtindividuallybyanumberofcountiesinthestateofnewyorkfortyof thecountycaseshavebeenconsolidatedthecompanywasdismissedfromthesuffolkcountycasewhichwasthe firstofthenewyorkcountycasestobefiledinadditionasofdecemberthecompanywasadefendant state case bring attorney general state defend aspreviouslydisclosedinjanuarythedojnotifiedthefederalcourtinneworleanslouisiana thatitwasnotgoingtointerveneatthattimeinapendingfederalfalseclaimsactcasethatwasfiledundersealin december company court issue order unseal complaint file physicianinlouisianaandorderedthatthecomplaintbeservedthecomplaintwhichallegedthatthecompany discount pepcid certain louisiana hospital lead increase cost medicaid dismiss amendedcomplaintwasfiledundersealandthecasehasbeenadministrativelyclosedbythecourtuntilthesealis liftedthestateoflouisianahasfileditsownamendedcomplaintincorporatingtheallegationscontainedinthe sealedamendedcomplaintaspartoftheresolutionofthegovernmentinvestigationsdiscussedbelowthesealin case lift case dismiss inaprilthecompanywasnamedinaquitamlawsuitunderthenevadafalseclaimsactthesuit inwhichthenevadaattorneygeneralhasintervenedallegesthatthecompanyinappropriately offerednominal pricing marketing pricing inducement certain customer fail comply obligation medicaid good price scheme relate arrangement company motion todismissthis action wasdenie bythe district court thismatter hasalsobeen dismissedaspart ofthe resolution government investigation december february company jointventure partner scheringploughreceivedseveraljointlettersfromthehousecommitteeonenergyandcommerceandthehouse subcommittee oversight investigation letter senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer januarythecompaniesandthemsppartnershipeachreceivedtwosubpoenasfromthenewyorkstate attorneygeneralsofficeseekingsimilarinformationanddocumentsmerckandscheringploughhavealsoeach receivedaletterfromtheofficeoftheconnecticutattorneygeneraldatedfebruaryrequestingdocuments relatedtothemarketingandsaleofvytorinandzetiaandthetimingofdisclosuresoftheresultsofenhancethe companyiscooperatingwiththeseinvestigationsandworkingwithscheringploughtorespondtotheinquiriesin additionsincemidjanuarythecompanyhasbecomeawareoforbeenservedwithapproximatelycivil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia unfavorable outcome result government investigation consumer fraud litigation material adverse effect company financial position liquidity result operation governmental proceeding previously disclose company receive subpoena doj connection investigationofthecompanysmarketingandsellingactivitiesincludingnominalpricingprogramsandsample company report receive cid attorney general texas company marketing selling activity relate texas previously disclose company receive cid attorney general texas ask additional information company marketingandsellingactivitiesrelatedtotexasincludingwithrespecttocertainofitsnominalpricingprogram sample april company receive subpoena office inspector general district columbia connection investigation company interaction physicians districtofcolumbiamarylandandvirginiainnovemberthecompanyreceivedaletterrequestfromthe doj connection investigation company pricing pepcid february company announce enter agreement government settle federal andstatecivilcasesallegingviolationsofthemedicaidrebate statuteaswellasfederal andstate falseclaimsactsinconnectionwithcertainnominalpricingprogramsandsalesandmarketingactivitiesbetween andtoresolvethesemattersthecompanyagreedtopayapproximatelymillionplusinterestand reasonable feesandexpensestothefederal governmentstatesparticipating inthemedicaidprogram andthe district columbia fourth quarter company record pretax charge million connection anticipate resolution investigation investigation describe precede paragraph resolve settlement agreement settlement describe arise civil action file seal district court locatedinphiladelphiaandneworleansbothactionscontainedallegationsinvolvingpastpricingprogramsthe philadelphiasettlementrelatestopastprogramsinwhichthecompanyofferedhospitalssignificantlydiscounte price certain medication include mevacor vioxx zocor philadelphia matter government allegedthatthecompanyimproperlyexcludedcertaindiscountsthosewhichwerenominalinamountfrom itsbestpricereportedtomedicaidunderthemedicaidrebateagreementthephiladelphiaactionalsorelatedto certainmarketingandsalesprogramsconductedbetweenandthephiladelphiasettlementaccountsfor million plus interest total settlement new orleans settlement resolve civil action contain allegation involve pricing discount offeredtohospitalsforpepcidtheoriginalpricingprogramknownastheflexprogramwaslaunchedinand continue operate flexnp program termination april new orleans settlement account million plus interest total settlement inconnectionwiththesesettlementsthecompanyenteredintoacorporateintegrityagreementwiththe department ofhealth andhumanservice whichincorporate companysexiste comprehensivecompli ance program govern pharmaceutical sale marketing activity united states aspreviouslydisclosedthecompanyhadreceivedaletterfromdojadvisingitoftheexistenceofacivil complaintbroughtunderthequitamprovisionsofthefalseclaimsactallegingthatthecompanyviolatedcertain rulesrelatedtoitscalculationsofbestpriceandotherfederalpricingbenchmarkcalculationscertainofwhichmay affect company medicaid rebate obligation doj inform company intend intervene action close investigation lawsuit dismiss company cooperate investigation addition investigation time time federal state foreign regulator authority seek information practice pharmaceuticalindustryorthecompanysbusinesspracticesininquiriesotherthantheinvestigationsdiscussedin section feasible predict outcome inquiry vaccine litigation aspreviouslydisclosedthecompanywasapartyinclaimsbroughtundertheconsumerprotectionact ofintheunitedkingdomwhichallegethatcertainchildrensufferfromavarietyofconditionsasaresultof vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mump rubella include companysmmrii condition include autism orwithout inflam matoryboweldiseaseepilepsyencephalitisencephalopathyguillainbarresyndromeandtransversemyelitisall oftheremainingcaseshavebeendiscontinuedorstruckoutbythecourtandthegrouplitigationhasconclude therearenoclaimsoutstandingagainstmerckaspreviouslydisclosedthecompanyisalsoapartytoindividual class action product liability lawsuit claim united states involve pediatric vaccine eg hepatitis b vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december therewere approximately activethimerosal relate lawsuitswith approximately plaintiff defen dant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case currently schedule trial company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation thecompanyhasbeensuccessfulinhavingcasesofthistypeeitherdismissedorstayedontheground thattheactionisprohibitedunderthenationalchildhoodvaccineinjuryactthevaccineactthevaccineact prohibitsanypersonfromfilingormaintainingacivilactioninstateorfederalcourtseekingdamagesagainsta vaccinemanufacturerforvaccinerelatedinjuriesunlessapetitionisfirstfiledintheunitedstatescourtoffederal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturerthepetitionermusteitherapursuehisorherpetitiontoconclusioninvaccinecourtandthentimely fileanelectiontoproceedwithacivilactioninlieuofacceptingthevaccinecourtsadjudicationofthepetitionor btimelyexercisearighttowithdrawthepetitionpriortovaccinecourtadjudicationinaccordancewithcertain statutorilyprescribedtimeperiodsthecompanyisnotapartytovaccinecourtproceedingsbecausethepetition bring united states department health human service companyisawarethat approximately casespende inthevaccine courtinvolve allegationsthatthimerosalcontainingvaccinesandorthemmriivaccinecauseautismspectrumdisordersnot thimerosalcontaine vaccine involve vaccine court proceeding company vaccine companyisthesolesourceofthemmriivaccinedomesticallyinjunethespecialmasterspresidingover thevaccine courtproceedingsheldatwoandahalfweekhearinginwhichbothpetitioner andthegovernment present evidence ontheissueofwhetherthecombination ofmmriivaccine andthimerosal invaccine causeautismspectrumdisordersandwhetheritdidcauseautismspectrumdisorderinthepetitioner inthatcase twoshorteradditionalevidentiaryhearingsofthattypeaddressingthatissuewereheldinthefallofruling inthesethreecasesareexpectedinaccordingtothevaccinecourtitexpectstoholdevidentiaryhearingsin sixadditionalsocalledtestcasesbyseptemberaddressingtheissueofwhetherthimerosalinvaccinesor mmr ii vaccine cause autism spectrum disorder cause disorder petitionersthevaccinecourthasindicatedthatitintendstousetheevidencepresentedatthesetestcasehearing guide adjudication remain autism spectrum disorder case patent litigation fromtimetotimegenericmanufacturersofpharmaceuticalproductsfileandaswiththefdaseeke market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax propecia prilosec nexium singulair trusopt cosopt primaxin priortotheexpirationofthecompanysandastrazenecasinthecaseofprilosecandnexiumpatentsconcerning product addition anda submit fda seek market united states generic form zetia prior expiration scheringplough patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patentsgenericmanufacturershavereceivedfdaapprovaltomarketagenericformofprilosecthecompany file patent infringement suit federal court company file andas generic alendronate fosamaxfinasteridepropeciadorzolamidetrusoptmontelukastsingulairdorzolamidetimololcosopt imipenemcilastatin primaxinandastrazenecaandthecompanyhavefiledpatentinfringementsuitsinfederal courtagainstcompaniesfilingandasforgenericomeprazole prilosecandesomeprazole nexiumalsothe company scheringplough file patent infringement suit federal court company file andasforgenericezetimibezetiasimilarpatentchallengesexistincertainforeignjurisdictionsthecompany intends vigorously defend patent believe valid infringement generic company attemptingtomarketproductspriortotheexpirationdatesofsuchpatentsaswithanylitigationtherecanbeno assuranceoftheoutcomeswhichifadversecouldresultinsignificantlyshortenedperiodsofexclusivityforthese product infebruaryscheringploughreceivedanoticefromagenericcompanyindicatingthatithadfile anandaforzetiaandthatitischallengingtheuspatentsthatarelistedforzetiamerckandscheringplough market zetia ajoint venture mspsingapore companyllc onmarch scheringplough mspsingaporecompanyllcfiledapatentinfringementsuitagainstglenmarkpharmaceuticalsincusaandits parent corporation glenmark lawsuit automatically stay fda approval glenmark anda month adverse court decision whichever occur early aspreviouslydisclosedinjanuarythecompanyreceivedaletterfromranbaxylaboratoriesltd ranbaxystatingthatithadfiledanandaseekingapprovalofagenericversionofmercksprimaxininapril company file patent infringement suit ranbaxy aspreviouslydisclose infebruarythe companyreceivedanotice fromtevapharmaceutical tevaageneric companyindicating hadfiledanandaformontelukast andthat ischallenge uspatent islistedforsingulaironaprilthe companyfiledapatent infringement action teva lawsuit automatically stay fda approval tevas anda month adverse court decision whichever occur early previously disclose january court appeal federal circuit washingtondcfoundthecompanyspatentclaimsforonceweeklyadministrationoffosamaxtobeinvalidthe companyexhaustedalloptionstoappealthisdecisioninbasedonthecourtofappealsdecisionfosamax lostmarketexclusivityintheunitedstatesinfebruaryfosamaxplusdwilllosemarketingexclusivityinthe unitedstatesinaprilasaresultoftheseeventsthecompanyexpectssignificantdeclinesinusfosamax fosamax plus sale inmaythefederalcourtofcanadatrialdivisionissuedadecisionrefusingtobartheapprovalof generic alendronate groundsthat merck patent weekly alendronate likely invalid decision cannotbeappealedandgenericalendronatewaslaunchedincanadainjuneinjulymerckwassuedin federal court canada apotex corp apotex seek damage lose sale generic weekly alendronate patent proceeding aspreviouslydisclosedinseptemberthecompanyappealedadecisionoftheoppositiondivision oftheeuropeanpatentofficeepothatrevokedthecompanyspatentineuropethatcoverstheonceweekly administration alendronate march board appeal epo uphold decision opposition division revoke patent march epo issue patent europe companythatcoverstheonceweeklyadministrationofalendronateunderitstermsthisnewpatentiseffective untiljulyoppositionshavebeenfiledintheepoagainstthispatentadditionallymerckhasbroughtpatent infringementsuitsinvariouseuropeanjurisdictionsbaseduponthispatentmercksbasicpatentcoveringtheuseof alendronate hasbeen challenge european country company receive adverse decision germany holland united kingdom decision united kingdom upheld appeal company appeal decision germany holland inadditionaspreviouslydisclosedinjapanafteraproceedingwasfiledchallengingthevalidityofthe company japanese patent onceweekly administration alendronate patent office invalidate patent decision appeal onjanuarythecompanysuedhitechpharmacalcoinchitechofamityville new yorkforpatentinfringementinresponsetohitechsapplicationtothefdaseekingapprovalofagenericversion ofmercksophthalmicdrugstrusoptandcosoptwhichareusedtotreatelevatedintraocularpressureinpatient withopenangleglaucomaorocularhypertensioninthelawsuitmercksuedtoenforceapatentcoveringanactive ingredient dorzolamide whichispresentinbothtrusoptandcosoptandthedistrictcourtenteredjudgment mercksfavorwhichwasupheldonappealthepatentcoveringdorzolamideprovidesexclusivityfortrusoptand cosoptuntiloctoberincludingsixmonthsofpediatricexclusivityaftersuchtimethecompanyexpect significantdeclinesinussalesoftheseproductsmerckhaselectednottoenforcetwootheruspatentsliste fdawhich cover combination dorzolamide timolol active ingredient cosopt inthecaseofomeprazoleonmaythetrialcourtissuedadecisionwithrespecttofourgeneric company sell generic omeprazole court find impax laboratories inc apotex product infringedastrazenecasformulationpatentswhileproductsmadebymylanlaboratoriesandlekpharmaceutical andchemicalcodddidnotinfringethecompaniesfoundtohaveinfringedwereorderedoffthemarketuntil october expiration pediatric exclusivity period companyand astrazeneca receivednotice inoctober ranbaxy file andafor esomeprazolemagnesiumtheandacontainsparagraphivchallengestopatentsonnexiumonnovember thecompanyandastrazenecasuedranbaxyintheunitedstatesdistrictcourtinnewjerseyaccordingly fdaapprovalofranbaxysandaisstayedformonthsuntilapriloruntilanadversecourtdecisionif whichever occur early company astrazeneca receive notice january ivax pharmaceuticals inc subsequently acquire teva file anda esomeprazole magnesium andacontainsparagraphivchallengestopatentsonnexiumonmarchthecompanyandastrazeneca suedtevaintheunitedstatesdistrictcourtinnewjerseyaccordinglyfdaapprovaloftevasandaisstaye month september adverse court decision whichever occur early january company astrazeneca sue dr reddys district court new jersey base drreddysfilingofanandaforesomeprazolemagnesiumaccordinglyfdaapprovalofdrreddysandais stay month july adverse court decision whichever occur early europe company aware company seek registration generic losartan activeingredientforcozaarthecompanyhaspatentrightstolosartanvialicensefromeidupontdenemour andcompanydupontthecompanyandduponthavefiledpatentinfringementproceedingsagainstvarious company portugal spain norway austria aspreviouslydisclosedinthethirdquarterofthecompanyresolvedcertainpatentdisputeswhich result net gain company litigation innovemberanindividualshareholderdeliveredalettertothecompanysboardallegingthatthe companyhadsustaineddamagesthroughthecompanysadoptionofitschangeincontrolseparationbenefitsplan thecicplaninnovembertheshareholdermadeademandontheboardtotakelegalactionagainstthe boardscurrentorformermembersforallegedlycausingdamagetothecompanywithrespecttotheadoptionofthe cicplaninresponsetothatdemandlettertheindependentmembersoftheboarddeterminedatthenovember board meeting board shareholder request consideration careful consideration board shareholder advise board determine legal action february individual shareholder deliver letter company board director demandingthattheboardtakelegalactionagainsttheresponsibleindividualstorecovertheamountspaidbythe company resolve governmental investigation referred previously disclose august united states district court district new jerseygrantedamotionbythecompanymedcohealthsolutionsincmedcohealthandcertainofficersand directorstodismissashareholderderivativeactioninvolvingclaimsrelatedtothecompanysrevenuerecognition practiceforretailcopaymentspaidbyindividualstowhommedcohealthprovidespharmaceuticalbenefitsaswell asotherallegationsthecomplaintwasdismissedwithprejudiceplaintiffsappealedthedecisionondecember theuscourtofappealsforthethirdcircuitupheldmostofthedistrictcourtsdecisiondismissingthe suit send issue company board director properly refuse shareholder demand relate company treatment retail copayment district court reconsideration differentlegalstandardplaintiffsmovedtoremandtheiractiontostatecourtonaugustandthedistrict courtgrante motion onfebruary theshareholder derivativesuitwaspendingbefore superior court new jersey chancery division hunterdon county remain issue dismiss prejudice favor medco health merck individual defendant july aspreviouslydisclosedpriortothespinoffofmedcohealththecompanyandmedcohealthagreedto settleonaclassactionbasisaseriesoflawsuitsassertingviolationsoferisathegruercasesthecompany medcohealthandcertainplaintiffscounselfiledthesettlementagreementwiththefederaldistrictcourtinnew york case commence number plaintiff include participant number pharmaceutical benefitplansforwhichmedcohealthisthepharmacybenefitmanageraswellastrusteesofsuchplanshavebeen consolidatedmedcohealthandthecompanyagreedtotheproposedsettlementinordertoavoidthesignificant costanddistractionofprolongedlitigationtheproposedclasssettlementhasbeenagreedtobyplaintiffsinfiveof thecasesfiledagainstmedcohealthandthecompanyundertheproposedsettlementthecompanyandmedco health agree pay total million medco health agree modify certain business practicesortocontinuecertainspecifiedbusinesspracticesforaperiodoffiveyearsthefinancialcompensationi intend benefit member settlement class include erisa plan medco health administer pharmacy benefit anytime december district court hold hearing hear objectionstothefairnessoftheproposedsettlementandapprovedthesettlementinbuthasnotyetdetermined number class member plan haveproperly elect toparticipate inthe settlement settlement becomesfinalonlyifandwhenallappealshavebeenresolvedcertainclassmemberplanshaveindicatedthatthey willnotparticipateinthesettlementcasesinitiatedbythreesuchplansandtwoindividualsremainpendinginthe southern district new york plaintiff case assert claim base erisa federalandstatelawsthatarethesameasorsimilartotheclaimsthathadbeenassertedbysettlingclassmembersin gruer case company medco health name defendant case notice appeal file appellate court hear oral argument decembertheappellatecourtissuedadecisionvacatingthedistrictcourtsjudgmentandremandingthe casestothedistrictcourttoallowthedistrictcourttoresolvecertainjurisdictionalissuesahearingwasheldto address suchissuesonfebruary district court issue rule onaugust resolve jurisdictional issuesinfavorofthe settle plaintiffstheclass member theother party hadpreviously appeal district court judgment renew appeals october renew appeal affirmedinpartandvacatedinpartbythefederalcourtofappealstheappealscourtremandedtheclasssettlement proceeding district court afterthespinoffofmedcohealthmedcohealthassumedsubstantiallyalloftheliabilityexposurefor matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involvingthecompanywhicharependingwhileitisnotfeasibletopredicttheoutcomeofsuchproceedingsor theproceedingsdiscussedinthisitemintheopinionofthecompanyallsuchproceedingsareeitheradequately coveredbyinsuranceorifnotsocoveredshouldnotultimatelyresultinanyliabilitythatwouldhaveamaterial adverseeffectonthefinancialpositionliquidityorresultsofoperationsofthecompanyotherthanproceedingsfor separate assessment provide item environmental matter companyis aparty toa number proceeding bring comprehensiveenvironmental response compensation liability act commonly know superfund federal state equiv alentstheseproceedingsseektorequiretheoperatorsofhazardouswastedisposalfacilitiestransportersofwaste site generator hazardous waste dispose site clean site reimburse governmentforcleanupcoststhecompanyhasbeenmadeapartytotheseproceedingsasanallegedgeneratorof waste dispose site case government allege defendant jointly severally liableforthecleanupcostsalthoughjointandseveralliabilityisallegedtheseproceedingsarefrequentlyresolve sothattheallocationofcleanupcostsamongthepartiesmorenearlyreflectstherelativecontributionsofthepartie tothesitesituationthecompanyspotentialliabilityvariesgreatlyfromsitetositeforsomesitesthepotential liabilityisdeminimisandforothersthecostsofcleanuphavenotyetbeendeterminedwhileitisnotfeasibleto predict theoutcome ofmanyoftheseproceedingsbroughtbyfederal orstate agency orprivate litigant inthe opinionofthecompanysuchproceedingsshouldnotultimatelyresultinanyliabilitywhichwouldhaveamaterial adverseeffect onthe financial position result operation liquidity capital resource companythe companyhastakenanactiveroleinidentifyingandprovidingforthesecostsandsuchamountsdonotincludeany reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party merck enter consent decree decree united states america pennsylvaniadepartmentofenvironmentalprotectionandthepennsylvaniafishandboatcommissionresolve government claim assert enforcement action united states america commonwealth pennsylvania v merck co inc response previously disclose accidental release gallon potassiumthiocyanatefromthesiteinjunethatresultedinafishkillinthewissahickoncreekaswellasthe dischargeofmaterialsonaugustandthatcausedfoaminginthecreekpursuanttothetermsofthe decreemerckwillpaycivilpenaltiesintheamountofmillionfundsupplementalenvironmentalproject intheamountofmillionandimplementonsiteremedialmeasuresintheamountofmillionamotionto enter decree pende court previously disclose september approximately plaintiff file amend complaint merck defendant united states district court eastern district california assertingclaimsunderthecleanwateracttheresourceconservationandrecoveryactaswellasnegligence andnuisancethesuitseeksdamagesfordiminutionofpropertyvaluemedicalmonitoringandotherallegedreal personal property damage associate groundwater soil contamination find site merck subsidiary merce california company intend defend claim item submission matter vote security holder applicable executive officer registrant age february richard clarkage april chairman president chief executive officer chief executive officer president junepresidentmerckmanufacturingdivisionresponsibleforthecompanysmanufactur ing information service operational excellence organization worldwide january chairman president chief executive officer medco health solutions inc whollyowne subsidiary company adele ambroseage december vice president chief communication officerresponsible global communication organization april sabbatical priortoaprilmsambrosewasexecutivevicepresidentpublicrelationsinvestorcommu nications att wireless wireless service provider september april davidw ansticeage septemberexecutivevicepresidentstrategyinitiativesresponsiblefortheendtoendand globalsupportfunctioninitiativesandforprovidingstrategicdirectioninkeypharmaceuticalemerge market china india august president human healthasia pacificresponsible company prescription drug business asia pacific region japan australia new zealand company joint venture relationship scheringplough januarypresidenthumanhealthresponsibleforthecompanysprescriptiondrugbusiness injapanlatinamericacanadaaustralianewzealandandthecompanysjointventurerelationship scheringplough john cananage january senior vice president controllerresponsible corporate controller group september vice president controllerresponsible corporate controller group june vice president corporate audit assurance service septembervicepresidentandcontrollerasiaandjointventuresresponsibleforfinancial operational oversight asia human health company joint ventures celia colbertage january senior vice president secretary september assistant general counsel november responsible corporate secretary function corporate staff group willie deeseage januaryexecutivevicepresidentandpresidentmerckmanufacturingdivisionmmd responsible company global manufacturing procurement operational excellence function president mmdresponsible company global manufacturing procurement operational excellence function january senior vice president global procurement priortojanuarymrdeesewasseniorvicepresidentglobalprocurementandlogisticsto glaxosmithkline plc kenneth c frazierage august executive vice president president global human healthresponsible company market sale organization worldwide include global pharmaceutical vaccine franchise november executive vice president general counselresponsible legal public affair function merck company foundation notforprofit charitable organization affiliate company decemberseniorvicepresidentandgeneralcounselresponsibleforlegalandpublicaffair functionsandthemerckcompanyfoundationanotforprofitcharitableorganizationaffiliatedwith company mirian graddickweirage january executive vice president human resourcesresponsible global human resource organization september senior vice president human resource prior september dr graddickweir executive vice president human resource employeecommunicationsatattcommunicationsservicesproviderandhasheldseveralother senior human resource leadership position att year peter n kelloggage augustexecutivevicepresidentandchieffinancialofficerresponsibleforthecompany worldwide financial organization investor relation corporate development licensing company joint venture relationship priortoaugustmrkelloggwasexecutivevicepresidentfinanceandchieffinancialofficerof biogen idec biotechnology company november merger biogen inc idecpharmaceuticalscorporationmrkelloggwasformerlyexecutivevicepresidentfinanceand chief financial officer biogen inc serve vice president finance chief financial officer july peter kimage january executive vice president president merck research laboratory mrl responsible company research development effort worldwide january president mrl bruce n kuhlikage january executive vice president general counselresponsible legal communica tion public policy function merck company foundation notforprofit charitable organization affiliate company vice president associate general counselprimary responsibility company vioxx litigation defense priortomaymrkuhlikwasseniorvice presidentandgeneralcounselforthepharmaceutical research manufacturers america october mark e mcdonoughage februaryvicepresidentandtreasurerresponsibleforthecompanystreasuryfunctionand provide financial support human resource january assistant treasurer global capital marketsresponsible managing company investment financing portfolio treasury share repurchase program september senior director human health financeresponsible provide global fran chisebase financial reporting analytic executive committee franchise divisional stakeholder margaret g mcglynnage august president merck vaccines infectious diseasesglobal responsibility vaccine business infectious disease franchise include company sanofipasteur joint venture augustpresidentmerckvaccinesglobalresponsibilitiesforthevaccinesbusinessinclude company sanofipasteur joint venture january president human healthresponsible prescription drug divisionshospitalandspecialty productfranchisescomprisingushumanhealthushhand manage care group ushh stefan oschmannage septemberpresidenteuropemiddleeastafricacanadaresponsibleforthecompany business operation europe middle east africa canada october senior vice president worldwide human health marketing january manage director msd germany subsidiary company j chris scaletage januaryexecutivevicepresidentglobalservicesandchiefinformationofficercio responsible global share service human resource finance site service information service function enterprise business process redesign initiative january senior vice president global services cioresponsible global share servicesacrossthehumanresourcesfinancesiteservicesandinformationservicesfunctionandthe enterprise business process redesign initiative march senior vice president information services cioresponsible area informationtechnologyandservicesincludingapplicationdevelopmenttechnicalsupportvoiceand data communication computer operation worldwide prior march mr scalet senior vice president information technology cio international paper company global forest product paper packaging company adam h schechterage august president global pharmaceuticalsglobal responsibility company ath erosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchise commercial responsibility united states company portfolio prescription medicine july president human healthcommercial responsibility united states company portfolio prescription medicine october general managerushuman healthdivisionresponsible neuropsychiatry osteoporosismigrainerespiratory andnewproductsfranchise februaryvicepresidentgeneralmanagermerckscheringploughpharmaceuticalsusjoint venture august vice president merck human health division arthritis analgesia franchise business group wendy l yarnoage august chief marketing officerresponsible global human health commercial operation support organization include company global human health business process andprogrammanagementglobalmarketingsupportglobalmedicalaffairsglobalproductaccess outcome research global alliance management new product license september chief marketing officerresponsible global marketing service global alliance management global pricing global human health business practice compliance franchise oncology specialty neuroscience respiratory bone arthritis analgesia infectious disease hospital product november general manager business unit human health january executive vice president worldwide human health marketing allofficerslistedaboveserveatthepleasureoftheboardofdirectorsnoneoftheseofficerswaselecte pursuant arrangement understand officer board ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price thefollowingtablealsosetsforthforthecalendarperiodsindicatedthedividendpershareinformation cash dividend pay common share year th q rd q nd q st q common stock market price th q rd q nd q st q high low high low january approximately stockholders record equity compensation plan information follow table summarize information option warrant right equity compensationunderthecompanysequityplansasofthecloseofbusinessondecemberthetabledoe notinclude information taxqualifiedplanssuchasthemerckcoincemployee savingsandsecurity plan numberof securities numberof remainingavailable securitiestobe forfutureissuance issuedupon weightedaverage underequity exerciseof exercisepriceof compensationplan outstanding outstanding exclude optionswarrant optionswarrant securities andrights andrights reflectedincolumna plancategory b c equity compensation plan approve security holder equity compensation plan approve security holder total includesoptionstopurchasesharesofcompanycommonstockandotherrightsunderthefollowingstockholderapprovedplansthe incentivestockplantheincentivestockplantheincentivestockplantheincentivestockplanthenonemployee directorsstockoptionplanthenonemployeedirectorsstockoptionplanandthenonemployeedirectorsstockoptionplan excludesapproximatelysharesofrestrictedstockunitsandperformanceshareunitsassumingmaximumpayout undertheandincentivestockplansalsoexcludessharesofphantomstockdeferredunderthemerckcoincdeferral programasofdecembernoadditionalshareswerereservedunderthedeferralprogrambeginningjanuaryonetenthof percentoftheoutstandingsharesofmerckcommonstockonthelastbusinessdayoftheprecedingcalendaryearplusanysharesauthorize underthedeferralprogrambutnotissuedarereservedforfutureissuanceasofdecembertheactualamountofshare tobeissuedprospectivelyequalstheamountparticipantselecttodeferfrompayoutsunderthecompanysvariousincentiveprogramssuch astheexecutiveincentiveplanintophantomstockincreasedbytheamountofdividendsthatwouldbepaidonanequivalentnumberof sharesofmerckcommonstockdividedbythemarketpriceofmerckcommonstock thetabledoesnotincludeinformationforequitycompensationplansandoptionsandotherwarrantsandrightsassumedbythecompanyin connectionwithmergersandacquisitionsandpursuanttowhichthereremainoutstandingoptionsorotherwarrantsorrightscollectively assumedplanswhichincludethefollowingmedcocontainmentservicesincclasscnonqualifiedstockoptionplansibia neurosciencesincequityandincentivestockoptionplanprovantagehealthservicesincstockincentiveplanrosetta inpharmaticsincandemployeestockoptionplansatotalofsharesofmerckcommonstockmaybepurchasedunder theassumedplansataweightedaverageexercisepriceofnofurthergrantsmaybemadeunderanyassumedplan performance graph follow graph compare cumulative total stockholder return stock price appreciation plus reinveste dividend companys common stock cumulative total return include reinveste dividend dow jones pharmaceutical index djuspr refer dow jones pharmaceutical indexunite states own company standard poor index sp indexforthe fiveyearsende december amountsbelowhave roundedtothe near dollar percent comparison fiveyear cumulative total return merck co inc dow jones pharmaceutical index sp index end period value cagr merck djuspr sp srallod merck djuspr sp merck djuspr sp assumesthatthevalueoftheinvestmentincompanycommonstockandeachindexwasondecemberand thatalldividendswerereinveste compoundannualgrowthrate issuerpurchasesofequitysecuritiesforthethreemonthperiodendeddecemberareasfollow issuer purchase equity security total number million total share purchase approx dollar value number average share share price pay publicly announce purchase period purchase share plan program plan programs october october na november november december december total thesesharerepurchasesweremadeaspartofaplanannouncedinjulytopurchasebillioninmerckshare item select financial datum follow select financial datum read conjunction item management discussionandanalysisoffinancialconditionandresultsofoperationsandconsolidatedfinancialstatement note thereto contain item financial statement supplementary datum report merck co inc subsidiarie million share amount resultsforyear sale materialsandproductioncost marketingandadministrativeexpense researchanddevelopmentexpense restructuringcost equityincomefromaffiliate usvioxxsettlementagreementcharge otherincomeexpensenet incomefromcontinuingoperationsbeforetaxe taxesonincome incomefromcontinuingoperation incomefromdiscontinuedoperationsnetoftaxe netincome basicearningspercommonshare continuingoperation discontinuedoperation netincome earningspercommonshareassumingdilution continuingoperation discontinuedoperation netincome cashdividendsdeclare cashdividendspaidpercommonshare capitalexpenditure depreciation yearendposition workingcapital propertyplantandequipmentnet totalasset longtermdebt stockholdersequity financialratio incomefromcontinuingoperationsasaofsale netincomeasaofaveragetotalasset yearendstatistic averagecommonsharesoutstandingmillion averagecommonsharesoutstandingassumingdilutionmillion numberofstockholdersofrecord numberofemployee amountsforincludetheimpactoftheusvioxxsettlementagreementchargerestructuringactionsacivilgovernmentalinvestigationschargean insurancearbitrationsettlementgainacquiredresearchexpenseresultingfromanacquisitionadditionalvioxxlegaldefensecostsgainsonsalesofassetsand productdivestituresaswellasanetgainonthesettlementsofcertainpatentdispute amountsforincludetheimpactofrestructuringactionsacquiredresearchexpensesresultingfromacquisitionsadditionalvioxxlegaldefensecostsandthe adoptionofanewaccountingstandardrequiringtheexpensingofstockoption amountsforincludetheimpactofthenettaxchargeprimarilyassociatedwiththeamericanjobscreationactrepatriationrestructuringactionsand additionalvioxxlegaldefensecost amountsforincludetheimpactofthewithdrawalofvioxxvioxxlegaldefensecostsandrestructuringaction amountsforincludetheimpactoftheimplementationofanewdistributionprogramforuswholesalersandrestructuringaction amountdoesnotaddasaresultofrounde item management discussion analysis financial condition result operation description merck business merckisaglobal researchdrivenpharmaceutical companythatdiscoversdevelopsmanufacture marketsabroadrangeofinnovativeproductstoimprovehumanandanimalhealththecompanysoperationsare principallymanagedonaproductsbasisandarecomprisedoftworeportablesegmentsthepharmaceuticalsegment andthevaccinessegmentthepharmaceuticalsegmentincludeshumanhealthpharmaceuticalproductsmarkete directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarilytodrugwholesalersandretailershospitalsgovernmentagenciesandmanagedhealthcareproviderssuch health maintenance organization pharmacy benefit manager institution vaccine segment includeshumanhealthvaccineproductsmarketedeitherdirectlyorthroughajointventuretheseproductsconsist preventative pediatric adolescent adult vaccine primarily administer physician officesmerck sell thesehumanhealthvaccinesprimarilytophysicianswholesalersphysiciandistributorsandgovernmententitie thecompanysprofessionalrepresentativescommunicatetheeffectivenesssafetyandvalueofitspharmaceutical vaccine product health care professional private practice group practice manage care organization overview duringmerckbeganrealizingbenefitsfromitsmultiyearstrategicplandesignedtoreengineerthe waythecompanydevelopsanddistributesmedicinesandvaccinesworldwidethecompanyisbenefitingfromthe evolution new commercial model design align company product research development marketingeffortsutilizingthelatesttechnologiesandbroadeningitsengagementwithcustomersphysiciansand scientific leaderstogetneededmedicine andvaccinesthroughthedevelopmentpipeline andtopatientssooner thecompanyisalsoworkingtobuildasustainable research anddevelopment advantage byleveraging technol ogiestofacilitatedrugdiscoveryanddevelopmentandhassuccessfullyreducedclinicaldevelopmentcycletime theprogressoftheseeffortsisdemonstratedinpartbythecompanysrevenuegrowthinwhich reflectedthecontinuedmarketpenetrationandglobalrolloutofgardasilavaccinetohelppreventcervicalcancer precancerous lowgrade lesion vulvar vaginal precancer genital wart cause human papillomavirus hpv type januvia medicine enhance natural body system improve blood sugar control patient type diabetes rotateq pediatric vaccine help prevent rotavirusgastroenteritis ininfant andchildren couple withthe strongperformance ofseveral inline product thisgrowthhasmorethanoffsetrevenuedeclinesassociatedwiththelossofusmarketexclusivityfor zocor proscar additionallythecompanycontinue theadvancement ofdrugcandidate throughitspipeline theusfoodanddrugadministrationthefdaapprovedbothjanumetanoralantihyperglycemicagent combine sitagliptin januvia metformin single tablet address key defect type diabete isentress firstinclass integrase inhibitor treatment hiv infection treatment experience patient addition january fda approve emend injection intravenous therapy prevention chemotherapyinduce nausea vomit cinv company antic ipate fdawill action new drug application nda cordaptive propose trademarkformkaanextendedreleaseerniacincombinedwithlaropiprantanovelflushingpathway inhibitorforcholesterolmanagementfurtherthecompanymadeasupplementalfilingwiththefdainjanuary forgardasilforanexpandedindicationforwomenthroughageandanticipatesmakingasupplemental filing isentress later expand indication use treatmentnave patient company currentlyhassevencandidatesinphaseiiidevelopmentandanticipatesmakingndafilingswithrespecttotwoof candidate mkb simvastatin combine laropiprant er niacin mk taranabant investigational medication treatment obesity aspartofimplementingthenewcommercialmodelthecompanyisreengineeringitscorebusinesstobe efficient goal reduce aspect cost base realize gross margin improvement reengineering include implementation manufacturing marketing cost saving initiative initial phaseoftheglobalrestructuringprogramannouncedinwasdesignedtoreducethecompanyscoststructure increaseefficiencyandenhancecompetitivenessthescopeofthisinitialphaseincludedtheimplementationofa newsupplystrategybythemerckmanufacturingdivisionoverathreeyearperiodfocusingonestablishinglean supplychainsleveraginglowcostexternalmanufacturingandconsolidatingourmanufacturingplantnetworkas partofthisprogramthroughjanuarymerckhadclosedsoldorceasedoperationsatfivemanufacturingsite preclinical site eliminate approximately position companywide comprise actual headcountreductionsandtheeliminationofcontractorsandvacantpositionsthecompanyhowevercontinuesto hirenewemployeesasthebusinessrequiresthepretaxcostsofthisrestructuringprogramsinceinceptionthrough end billion approximately noncash relate primarily accelerate depreciation facility schedule closure approximately represent separation restructuring relate cost cost million expect approximately million tomillion inatwhichtimetheinitial phaseoftherestructuring programrelate tothe manufacturingstrategyisexpectedtobesubstantiallycompletemerckcontinuestoexpecttheinitialphaseofit cost reduction program combine cost saving company expect achieve marketing administrativeandresearchanddevelopmentexpenseswillyieldcumulativepretaxsavingsoftobillion onnovembermerckenteredintoanagreementthesettlementagreementwiththelawfirm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representative plaintiff counsel state coordinate proceeding resolve state federal myocardial infarction miandischemic strokeisclaim alreadyfiledagainstthecompanyinthe unitedstatesifcertainparticipationconditionsunderthesettlementagreementaremetorwaivedthecompany willpayanaggregatefixedamountofbillionintotwofundsforqualifyingclaimsconsistingofbillion qualify mi claim million qualifying claim enter resolution process settlementprogramasaconsequenceofthesettlementagreementthecompanyrecordedapretaxchargeof billioninthefourthquarterofinadditionthecompanyrecordedapretaxgainofmillionrelating toinsuranceproceedswhichthecompanywasawardedoragreedtoreceivepursuanttonegotiatedsettlementsin previously disclose arbitration company upper level excess product liability insurance carrier relate coverage cost incur vioxx product liability litigation note consolidated financial statement information alsointhefourthquarterofthecompanyrecordedapretaxchargeofmillioninconnection withtheanticipate resolution ofinvestigationsofcivilclaim byfederal andstate authority relate tocertain pastmarketingandsellingactivitiesincludingnominalpricingprogramsandsamplesonfebruarythe companyenteredintodefinitiveagreementsresolvingtheinvestigationsseenotetotheconsolidatedfinancial statement information earning common share ep assume dilution share include impactoftheusvioxxsettlementagreementchargecostsassociatedwiththeglobalrestructuringprogramthe charge relate resolution certain civil governmental investigation gain insurance arbitrationawardrelatedtovioxxproductliabilitylitigationcoveragewhichcollectivelyreducedepsbyper shareinadditionepsinreflectsanacquiredresearchchargerelatedtotheacquisitionofnovacardiainc novacardia additional reserve establish solely future legal defense cost vioxx litigation favorable impact gain sale asset product divestiture net gain settlement certain patent dispute item discuss fully note consolidated financial statement competition health care environment market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access intheunitedstatesthegovernmentexpandedhealthcareaccessbyenactingthemedicareprescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentivesfor pharmaceutical inno vationatthesametimethelegislationwillensurethatprescriptiondrugcostswillbecontrolledbycompetitive pressure encourage appropriate use medicine congress consider consider proposal increase government role pharmaceutical pricing medicare program inaddressingcostcontainmentpressurethecompanyhasmadeacontinuingefforttodemonstratethat itsmedicinescanhelpsavecostsinoverallpatienthealthcareinadditionpricingflexibilityacrossthecompany productportfoliohasencouragedgrowinguseofitsmedicinesandmitigatedtheeffectsofincreasingcostpressure outside united states difficult environment encumber government costcontainment action company work partnership payer encourage allocate scarce resource optimizehealthcareoutcomeslimitingthepotentiallydetrimentaleffectsofgovernmentpoliciesonsalesgrowth access innovative medicine vaccine support discovery development innovative productstobenefitpatientsthecompanyalsoisworkingwithgovernmentsinmanyemergingmarketsineastern europelatinamericaandasiatoencouragethemtoincreasetheirinvestmentsinhealthandtherebyimprovetheir citizensaccesstomedicineswithineuropeeuropeaninstitutionssuchastheeuropeancommissionechave recognize economic importance researchbase pharmaceutical industry value innovative medicinestosocietyasaresulttheyareworkingwithindustryrepresentativestoimprovethecompetitiveclimate variety mean include market deregulation order advance relate policy debate ec launch high level pharmaceutical forum hlpfattheendofthisinitiativeaimsatimprovingtheprospectsoftheresearchbasedpharmaceutical industryineuropeandthusthehealthprospectsofallpatientswhowillbenefitfrominnovativetherapiesthrough anactivedialogue amongallstakeholdersinthehealthcaresystemfrompayerstopatient thisinitiativeisan attempttotacklekeypolicyissuesineuropeipromotinggreaterpricingflexibilityformedicinesiiensure health authority apply good practice evaluation relative effectiveness medicine iiiimprovinggreateraccesstoinformationonmedicinesforpatientsineuropethecompanyhasbeenactively engagedwiththeecandotherstakeholdersinordertoachieveasuccessfuloutcomeforthehlpfthatwouldhelp european patient gain great quick access medicine thecompanyiscommittedtoimprovingaccesstomedicinesandenhancingthequalityoflifeforpeople world african comprehensive hivaids partnership botswana partnership government botswana bill melinda gates foundation merck company foundationmerck coincissupportingbotswanasresponsetohivaidsthroughacomprehensiveandsustainableapproachto hivpreventioncaretreatmentandsupportinmaythecompanyinitiatedapartnershipwiththepeople republicofchinafocusedinitiallyinsichuanprovincetohelpstrengthenchinasresponsetothehivepidemic catalyze access hiv medicine develop country price reduction guideline thatthecompanyannouncedinmerckmakesnoprofitonthesaleofitscurrenthivaidsmedicinesinthe worldspoorestcountriesandthosehardesthitbythepandemicandoffersitshivaidsmedicinesatsignificantly reducedpricestomediumincomecountriesinfebruarymerckannouncedthatithadagainreducedtheprice ofstocrinintheleastdevelopedcountriesoftheworldandthosehardesthitbythepandemicbytheendof morethanpeoplelivingwithhivandaidsindevelopingcountriesandterritorieswereestimatedtobe ontreatmentwithantiretroviralregimenscontainingcrixivanstocrinoratriplathroughtheseandotheraction merckisworkingindependentlyandwithpartnersinthepublicandprivatesectorsaliketofocusonthemostcritical barrierstoaccesstomedicinesinthedevelopingworldtheneedforsustainablefinancingincreasedinternational assistance additional investment education training health infrastructure capacity develop country aspreviouslydisclosedinmaythegovernmentofbrazilissuedacompulsorylicenseforstocrin make possible stocrin produce generic manufacturer despite company patent protectiononstocrininnovemberthegovernmentofthailandstatedthatithadissuedacompulsorylicense forstocrindespitethecompanyspatentprotectiononstocrinwhichthegovernmentofthailandcontendsmake possibleforstocrin tobeproduce byageneric manufacturerthecompanyremain commit toexplore mutually acceptable agreement government brazil thailand thecompanyissubjecttoanumberofprivacyanddata protection lawsandregulationsgloballythe legislative regulatory landscape privacy datum protection continue evolve increasingamountoffocusonprivacyanddataprotectionissueswiththepotentialtoaffectdirectlythecompany business include recently enact law majority state require security breach notification predict outcome legislative regulatory advocacy initiativesthecompanyiswellpositionedtorespondtotheevolvinghealthcareenvironmentandmarketforce patent certain company product expire merck enter continue enter authorized generic agreement reduce shortterm limit basis impact postpatent expiry sale erosion medicine available generic form companyanticipate theworldwidetrend towardcostcontainment willcontinue result ongoing pressure health care budget company continues successfully launch new product contributetohealthcaredebatesandmonitorreformsitsnewproductspoliciesandstrategiesshouldenableitto maintain strong position change economic environment acquisition inseptembermerckcompletedtheacquisitionofnovacardiaformillionwhichwaspaid throughtheissuanceofmerckcommonstocknovacardiaisaclinicalstagepharmaceuticalcompanyfocusedon cardiovascular disease acquisition add rolofylline mk novacardias investigational phase iii compoundforacuteheartfailuretomerckspipelineinconnectionwiththeacquisitionthecompanyrecordeda chargeofmillionforacquiredresearchassociatedwithrolofyllineasattheacquisitiondatetechnological feasibility establish alternative future use exist chargewa deductible tax purposestheongoingactivitywithrespecttothefuturedevelopmentofrolofyllineisnotexpectedtobematerialto company research development expense december merck complete acquisition sirna therapeutics inc sirna approx imatelybillionsirnaisabiotechnologycompanythatisaleaderindevelopinganewclassofmedicinesbased onrnainterferencernaitechnologywhichcouldsignificantlyalterthetreatmentofdiseaseinconnection withtheacquisitionthecompanyrecordedachargeofmillionforacquiredresearchassociatedwithsirnas compoundscurrentlyunderdevelopmentwhichrelatedtothedevelopmentoftreatmentsforboththehepatitisb andhepatitiscviruseswhichareinpreclinical developmentaswellaslicensingagreementsheldbysirnathe chargewasnotdeductible fortaxpurposestheongoingactivitywithrespecttoeachofthesecompoundsunder developmentisnotexpectedtobematerialtothecompanysresearchanddevelopmentexpensestheacquisition ofsirnaisexpectedtoincreasemercksabilitytousernaitechnologytoturnoffatargetedgeneinahumancell potentially render inoperative gene responsible trigger specific disease injunemerckacquiredglycofiincglycofiaprivatelyheldbiotechnologycompanythatis aleaderinthefieldofyeastglycoengineeringwhichistheadditionofspecificcarbohydratemodificationstothe protein yeast optimization biologic drug molecule million cash million purchase pricenetofmillionofsharesalreadyownedandnettransactioncoststhecompanyrecordedamillion chargeforacquiredresearchinconnectionwiththeacquisitionwhichwasnotdeductiblefortaxpurposesinmay merckacquire abmaxisincabmaxis aprivatelyheld biopharmaceutical companydedicate tothe discovery optimization monoclonal antibody product human therapeutic diagnostic million cash substantially purchase price allocate intangible asset relate abmaxistechnologyplatformwhileeachoftheacquisitionshasindependentscientificmeritsthecombinationof theglycofiandabmaxisplatformsispotentiallysynergisticgivingmercktheabilitytooperateacrosstheentire spectrum therapeutic antibody discovery development commercialization note consolidated financial statement discussion acquisition operating result sale worldwidesalestotaledbillionforanincreaseofprimarilyattributabletoavolume increaseafavorableeffectfromforeignexchangeandalessthanfavorableeffectfrompricechangessale performance reflect strong growth company vaccine include gardasil vaccine help prevent cervical cancer precancerous lowgrade lesion vulvar vaginal precancer genital wart causedbyhpvtypesandvarivaxavaccinetohelppreventchickenpoxrotateqavaccinetohelp protect rotavirus gastroenteritis infant child zostavax vaccine help prevent shingles herpeszosteralsocontributingtosalesgrowthwasstrongperformanceofsingulairamedicineindicatedforthe chronic treatment asthma relief symptom allergic rhinitis high sale januvia sales janumetforthetreatmentoftypediabetesaswellasincreasedsalesofcozaarhyzaarforhypertensionandor heart failure sale growth partially offset low sale zocor company statin modifying cholesterolandproscaraurologyproductforthetreatmentofsymptomaticbenignprostateenlargementmerck usmarketexclusivityforzocorandproscarbothexpiredinjunealsooffsettingsalesgrowthinwere lowerrevenuesfromthecompanysrelationshipwithastrazenecalpazlpandlowersalesoffosamaxand fosamax plus treatment case fosamax prevention osteoporosis domesticsalesincreasedoverwhileforeignsalesalsogrewforeignsalesrepresente oftotalsalesindomesticandforeignsalesgrowthreflectsthestrongperformanceofthecompanysvaccine growth singulair addition domestic sale particular benefit high sale januvia increase partially offset loss zocor proscar market exclusivity foreign sale negatively affect continued generic erosion relate fosamax product worldwidesalesforincreasedintotaloverprimarilydrivenbystronggrowthofsingulair vaccine high revenue company relationship azlp increase sale cozaarhyzaarinadditionsalesinreflectedcertainsupplysalesincludingthecompanysarrangementwith drreddyslaboratoriesdrreddysforthesaleofgenericsimvastatintheseincreaseswerepartiallyoffset bylowersalesofzocorandproscarforeignexchangeandpricechangeshadvirtuallynoimpactonsalesgrowthin foreign sale represent total sale sale company product follow million singulair cozaarhyzaar fosamax zocor cosopttrusopt primaxin januvia cancidas vasotecvaseretic maxalt proscar propecia arcoxia crixivanstocrin emend invanz janumet pharmaceutical vaccine gardasil rotateq zostavax proquadmmr iivarivax hepatitis vaccine vaccine presentednetofdiscountsandreturn otherpharmaceuticalprimarilyincludessalesofotherhumanpharmaceuticalproductsandrevenuefromthecompanysrelationshipwith azlpprimarilyrelatingtosalesofnexiumaswellasprilosecrevenuefromazlpwasbillionbillionandbillionin andrespectivelyinotherpharmaceuticalalsoreflectedcertainsupplysalesincludingsupplysalesassociatedwiththe companysarrangementwithdrreddysforthesaleofgenericsimvastatin theseamountsdonotreflectsalesofvaccinessoldinmostmajoreuropeanmarketsthroughthecompanysjointventuresanofipasteur msdtheresultsofwhicharereflectedinequityincomefromaffiliate otherprimarilyincludesotherhumanandanimalhealthjointventuresupplysalesandothermiscellaneousrevenue company pharmaceutical product include therapeutic preventive agent generally sell prescriptionforthetreatmentofhumandisordersamongthesearesingulairaleukotrienereceptorantagonistfor chronic treatment asthma relief symptom allergic rhinitis cozaar hyzaar vasotec vasereticthecompanysmostsignificanthypertensionandorheartfailureproductsfosamaxandfosamaxplusd marketedasfosavancethroughouttheeuropeanunioneuandasfosamacinjapanforthetreatmentandin case fosamax prevention osteoporosis zocor mercks atherosclerosis product cosopt trusopt merck largestselle ophthalmological product primaxin cancidas antibacterialantifungal product januviaandjanumetforthetreatmentoftypediabetesmaxaltanacutemigraineproductproscaraurology product treatment symptomatic benign prostate enlargement propecia product treatment malepatternhairlossarcoxiaforthetreatmentofarthritisandpaincrixivanandstocrinforthetreatmentofhiv infectionemendforthepreventionofchemotherapyinducedandpostoperativenauseaandvomitingandinvanz treatment infection company vaccine product include gardasil vaccine help prevent cervical cancer pre cancerousandlowgradelesionsvulvarandvaginalprecancersandgenitalwartscausedbyhpvtypes rotateq vaccine help protect rotavirus gastroenteritis infant child zostavax vaccine help prevent shingles herpe zoster varivax vaccine help prevent chickenpox proquad pediatric combination vaccine measle mump rubella varicella mmr ii vaccine measle mump rubella segment revenue million pharmaceutical segment revenue vaccine segment revenue segment revenues revenues total revenue inaccordancewithsegmentreportingrequirementsvaccinessegmentrevenuesexcludemillionmillionandmillionin andrespectivelyofvaccine salesbycertain nonussubsidiariesmanagedbyandincluded inthepharmaceutical segment includesothernonreportablehumanandanimalhealthsegment otherrevenuesareprimarilycomprisedofmiscellaneouscorporaterevenuessalesrelatedtodivestedproductsorbusinessesandother supplysalesnotincludedinsegmentresult pharmaceutical segment revenue sale pharmaceutical segment decline primarily decline zocorandproscarpostpatentexpirationpartially offsetbyincreasesinsingulaircozaarhyzaarandfor high sale januvia sale janumet worldwidesalesofsingulairamedicineindicatedforthechronictreatmentofasthmaandthereliefof symptom allergic rhinitis grew reach billion rise billion reflect continued demand asthma seasonal perennial allergic rhinitis medication singulair continuestobethenumberoneprescribedproductintheusrespiratorymarketinaprilthefdaapprove anewindicationforsingulairforthepreventionofexerciseinducedbronchoconstrictioninpatientsyearsofage old singulair oral tablet approve united states use january singulair approve japan treatment allergic rhinitis globalsalesofcozaaranditscompanionagenthyzaaracombinationofcozaarandhydrochlorothi azideforthetreatmentofhypertensionincreasedtobillioninandgrewtobillionin cozaarandhyzaarareamongtheleadingmembersofthegrowingangiotensinreceptorblockerclassofmedicine worldwide sale fosamax fosamax plus treatment case fosamax preventionofosteoporosisdeclinedintobillionanddecreasedintobillionussale offosamaxandfosamaxplusdwerebillioninessentiallyflatcomparedwithsalesoutsideofthe united states affect availability generic alendronate sodium product key market fosamax lose market exclusivity united states february fosamax plus lose marketing exclusivityintheunitedstatesinaprilasaresultoftheseeventsthecompanyexpectssignificantdecline fosamax fosamax plus sale worldwidesalesofzocormercksstatinformodifyingcholesteroldeclinedinanddecrease insalesofzocorinbothperiodsweresignificantlynegativelyaffectedbythecontinuingimpactofthe loss market exclusivity june infebruarythecompanyenteredintoanagreement withdrreddysthatauthorizedthesaleof generic simvastatin term agreement company reimburse costplus basis drreddysforsupplyingfinishedgoodsandreceivedashareofthenetprofitsrecordedbydrreddysin merck record million revenue associate dr reddys arrangement simvastatin merck continue manufacture simvastatin brand zocor vytorin company investigational compound mkb globalsalesofjanuviathefirstdipeptidylpeptidasedppinhibitorapprovedintheunitedstate use treatment type diabete million compare million januviawasapprovedbythefdainoctoberandbytheecinmarchdppinhibitorsrepresentanew classofprescriptionmedicationsthatimprovebloodsugarcontrolinpatientswithtypediabetesbyenhancinga natural body system call incretin system end januvia approve country territorieshadbeenlaunchedinmorethanofthoseandwasunderreviewinmorethanadozenotherssincethe october approval manage care formulary januvia widely available october merck announce fda approve expand labeling januvia new regimenswithjanuviadescribedintheupdatedlabelingincludeasanadjuncttodietandexerciseinitialtherapyin combinationwithmetforminaddontherapytoasulfonylureaglimepiridewhenthesingleagentalonedoesnot provide adequate glycemic control addon therapy combination sulfonylurea glimepiride metformin dual therapy provide adequate glycemic control inmarchthefdaapprovedjanumetmercksoralantihyperglycemicagentthatcombinesjanuvia withmetformininasingletablettoaddressallthreekeydefectsoftypediabetesjanumethasbeenapprovedas anadjuncttodietandexercisetoimprovebloodsugarcontrolinadultpatientswithtypediabeteswhoarenot adequatelycontrolledonmetforminorsitagliptinaloneorinpatientsalreadybeingtreatedwiththecombinationof sitagliptinandmetforminbytheendofjanumetwasapprovedinsevencountriesthecompanyisseeke thenecessaryapprovalstomakethemedicineavailableforuseinmanyothercountriesaroundtheworldglobal sale janumet million october fda grant isentress raltegravir previously know mk accelerate approvalforuseincombinationwithotherantiretroviralagentsforthetreatmentofhivinfectionintreatment experience adult patient evidence viral replication hiv strain resistant multiple antiretroviral agent isentress medicine approve new class antiretroviral drug call integrase inhibitors isentress work inhibit insertion hiv dna human dna integrase enzymeinhibitingintegrasefromperformingthisessentialfunctionlimitstheabilityofthevirustoreplicateand infect new cell fda decision base week analysis clinical trial isentress combinationwithoptimizedbackgroundtherapyintreatmentexperiencedpatientsprovidedsignificantreduction inhivrnaviralloadandincreasesincdcellcountsinfebruarythecompanyannouncedweekdata thatdemonstratedisentressincombinationwithotherantihivmedicinesmaintainedsignificanthivviralload suppressionandincreasedcdcellcountsthroughweeksoftherapycomparedtoplaceboincombinationwith antihiv medicine phase iii study treatmentexperience patient fail antiretroviral therapy patientsinthestudieshadhivresistanttoatleastonedrugineachofthreeclassesoforalantiretroviralmedicine bytheendofthemedicinewasapprovedforuseintheeucanadaandmexicomerckisalsoconducting phase iii clinical trial isentress treatmentnave previously untreate hiv population potent antiretroviralactivityhasbeendemonstratedwithnosignificantchangesinserumlipidsatweekandisentress wasgenerallywelltoleratedinpatientsthecompanyanticipatesmakingasupplementalfilingwithfdaforthe treatmentnave indication sale isentress million product experience growth include cosopt treat elevated intraocular pressure patientswithopenangleglaucomaorocularhypertensionemendforpreventionofacuteanddelayednauseaand vomitingassociatedwithmoderatelyandhighlyemetogeniccancerchemotherapyaswellasforthetreatmentof postoperativenauseaandvomitingarcoxiaforthetreatmentofarthritisandpainmaxalttotreatmigrainepain primaxin antibiotic propecia male pattern hair lossand invanzfor treatment ofselecte moderate severe infection adult thepatentthatprovidesusmarketexclusivityfortrusoptandcosoptexpiresinoctoberafter time company expect significant decline sale product proscar merck urology product treatment symptomatic benign prostate enlargement lost marketexclusivityintheunitedstatesinjunemercksussalesofproscardeclinedinand inthebasicpatentforproscaralsocoverspropeciahoweverpropeciaisprotecte byadditional patent expire october inaprilthefdaissuedanonapprovable letter inresponsetothecompanysndaforarcoxia etoricoxib symptomatic treatment osteoarthritis arcoxia review fda investigationalselectivecoxinhibitorsincethendawassubmittedindecemberforamgoncedaily dosealongwithreviewofaseparaterelatedndaforamgoncedailydosesubmittedinaprilinthenon approvable letter fda indicate merck need provide additional datum support benefittorisk profile propose dose arcoxia order gain approval merck continue evaluate theoptionsavailablewithregardtoapotentialpathforwardintheunitedstatesarcoxiaiscurrentlyavailablein countriesineuropelatinamericatheasiapacificregionandmiddleeastnorthernafricamerckwillcontinue tomarketarcoxiaoutsidetheunitedstateswhereithasbeenapprovedforabroadrangeofindicationsinclude osteoarthritis november merck glaxosmithkline gsk announce enter agreementforoverthecountermarketingrightsformevacorlovastatinmevacorispartofaclassofcholesterol reduce medicine know statin patent mevacor expire january merck receive nonapprovable letter fda nda seek approval overthecounter mevacor fda indicate letter require revise label additional datum merck order gain marketingapprovalasaconsequenceofthefdasnonapprovableletterthecompanyterminatedtheagreement gsk vaccine segment revenue salesofthevaccinessegmentwerebillioninbillioninandmillionin theincreasesinandaretheresultofnewproductlaunchesinthelatterpartofandthecontinue success ofinlinevaccine followingdiscussionofvaccine include total vaccine sale whichthevast majority include vaccine segment remainder represent certain sale vaccine nonussubsidiariesaremanagedbyandincludedinthepharmaceuticalsegmenttheseamountsdonotreflect salesofvaccinessoldinmostmajoreuropeanmarketsthroughsanofipasteurmsdspmsdthecompany joint venture sanofi pasteur result reflect equity income affiliate total vaccine sale record merck include billion reflect vaccine segment million reflect pharmaceutical segment billion compare billion billion growth invaccine lead gardasil strong performance varivax rotateq zostavax totalsalesasrecordedbymerckforgardasilwerebillioninwhichincludedinitialpurchase state center disease control prevention cdc vaccine child programcomparedwithmillioningardasilwasapprovedbythefdainjuneandistheonly approvedvaccineintheunitedstatestohelppreventcervicalcancerprecancerousandlowgradelesionsvulvar andvaginalprecancersandgenitalwartscausedbyhpvtypesandgardasilwasapprovedforusein theeuinseptembergardasilisathreedoseintramuscularvaccinegivenoversixmonthsapprovedforto yearoldgirlsandwomenbytheendofgardasilwasapprovedincountriesmanyunderfasttrackor expedite review launch way country vaccine remain review approximatelyothercountriesandterritoriesthecompanyisapartytocertainthirdpartylicenseagreement respect gardasil include crosslicense settlement agreement gsk result agreement company pay royalty worldwide gardasil sale approximately aggregate include material production cost march cdc adopt unanimous recommendation advisory committee immunizationpracticesacipfortheuseofgardasilinjunetheacipvotedunanimouslytorecommend thatgirlsandwomentoyearsoldbevaccinatedwithgardasiltheaciprecommendedthatandyear oldfemalesbevaccinatedwithgardasilatthediscretionoftheirphysiciansthevaccinationguidelinespublishe inthecdcsmorbidityandmortalityweeklyreportfinalizetheprovisionalrecommendationsissuedbytheacip fda accept standard review supplemental biologic license application sblaforgardasilwhichincludesdataonprotectionagainstvaginalandvulvarcancercausedbyhpvtype datum immune memory july fda accept standard review sbla preventionofcervicaldiseasecausedbynonvaccinetypescrossprotectionfdaactiononboththevaginaland vulvar cancer sbla cross protection sbla expect second quarter innovemberthecompanypresenteddataattheinternationalpapillomavirusconferenceaboutthe efficacyofgardasilinwomenthroughageinjanuarymercksubmittedansblawiththefdaseekingan expand indication use gardasil woman age clinical study evaluate efficacy gardasil male year age continue company expect submit fda indication male year age rotateq merck vaccine help protect rotavirus gastroenteritis infant child achieve worldwide sale record merck million compare million thefdaapprovedrotateqinfebruarybytheendofrotateqwasapprovedincountriesand launch indecemberthecompanyannouncedthattheprescribinginformationforrotateqnowinclude datum show rotateq reduce hospitalization emergency department visit cause gpa rotavirusserotypebyzerocaseswereseeninthosewhoreceivedrotateqcomparedwithcasesinplacebo recipientsthesedataarefromaposthocanalysisofhealthcareutilizationdatafrommorethaninfantsin rotavirus efficacy safety trial rest large prelicensure vaccine clinical trial conduct july company announce gardasil rotateq adopt usbasedimmunizationprojectsofthecdcvaccinesforchildrenprogramthevaccinesforchildrenprogram provide vaccine child medicaideligible uninsured underinsured see federally qualified health center rural health clinic native american previously disclose company work resolve issue relate bulk manufacturing process company varicella zoster virus vzvcontaine vaccine manufacturing ofbulkvaricellahasresumedhoweverproductwillnotbeavailableuntilthechangeshavebeenfullyvalidatedand approvedbytheapplicableregulatoryagenciesthissituationdoesnotaffectthequalityofanyofmercksvzv containingvaccinescurrentlyonthemarketanylotsofvaccineininventorythatarereadyforreleasetothemarket oranyvaccineswhichwillbefilledandfinishedfromexistingvzvbulkproquadthecompanyscombination vaccine protect measle mump rubella chickenpox vzvcontaining vaccine currently available order order transition appropriate mmr ii varivaxtotalsalesasrecordedbymerckforproquadweremillionforcomparedwithmillion merck sale varivax company vaccine prevention chickenpox varicella million incompare withmillion inastheacipsjuneseconddoserecomman dation continue implement varivax vaccine available united states help protect chickenpox sale zostavax company vaccine help prevent shingles herpe zoster record merck weremillionincomparedwithmillioninzostavaxwasapprovedbythefdaaswellasby regulatoryauthoritiesinaustraliaandtheeuinmaythevaccineisthefirstandonlymedicaloptionforthe prevention shingles indecembermerckannouncedthatithadinitiatedavoluntaryrecalloflotsofitshaemophilus influenzae type bvaccine pedvaxhib haemophilus bconjugate vaccine meningococcal protein conjugate lot combination haemophilus influenzae type b hepatitis b vaccine comvax haemophilus b conjugatemeningococcalproteinconjugateandhepatitisbrecombinantvaccinetherecallwasspecificto theselotsanddidnotaffectanyothervaccinesmanufacturedbymerckmerckconductedtherecallbecauseit assure sterility specific vaccine lot potential contamination specific lot identifiedaspartofthecompanysstandardevaluationofitsmanufacturingprocessessterilitytestsofthevaccine lotsthatarethesubjectofthisrecallhavenotfoundanycontaminationinthevaccinetheefficacyofthevaccine affect cost associate recall significant mercktemporarilystoppedacceptingordersforpediatricandadultvialformulationsofvaqtaavaccine hepatitis october united states merck continue accept order adult formulationofvaqtainprefilledsyringesuntilsuppliesaredepletedthissituationistheresultofmanufacturing change require regulatory review approval prior product distribution manufacturing change approve availability pediatric adult formulation vaqta affect unitedstatesthecompanyexpectsthepediatricformulationofvaqtawillbeavailableagainearlyinthirdquarter theadultformulationofvaqtainvialsisexpectedtobeavailableagaininfourthquarteroutsideofthe unitedstatestheimpactofthissituationwillvarydependingoninventorylevelsandtheregulatoryrequirementsin eachmarketthissituationdoesnotinanywayimpactthequalityorsafetyofvaqtaavailableonthemarketsale vaqta record merck million cost expense million change change material production marketing administrative cid research development restructuring cost cid equity income affiliate vioxx settlement agreement charge income expense net orgreater material production inmaterialsandproductioncostsincreasedprimarilyduetoanincreaseinsalesthisincreasewa partiallyoffsetbylowercostsrelatedtotheglobalrestructuringprograminmillionofrestructuring costscomprisedofmillionofaccelerateddepreciationassociatedwiththeplannedsaleorclosureofcertain ofthecompanysmanufacturingfacilitiesandmillionofassetimpairmentchargeswererecordedcompare million represent million accelerate depreciation million asset impairment note consolidated financial statement impact inflation material production cost significant inmaterialsandproductioncostsincreasedcomparedwithaincreaseinsalesprimarily reflect high global restructuring cost material production cost include stock option expenseofmillionasaresultoftheadoptionoffinancialaccountingstandardsboardfasbstatement norsharebasedpaymentfasrseenotetotheconsolidatedfinancialstatementsaddition ally material production cost include unfavorable impact inflation grossmarginwasincompare withinandintherestructuring chargesnotedabovehadanunfavorableimpactofpercentagepointsinpercentagepointsinand percentagepointsingrossmargininreflectsaslightunfavorableimpactfromchangesinproduct mixandthepositiveimpactofmanufacturingefficienciesgrossmargininreflectstheunfavorableimpactof changesinproductmixincludingthedeclineinzocorsalesasaresultofthelossofusmarketexclusivityinjune marketing administrative marketing administrative expense decline compare include unfavorableeffectfromforeignexchangeandaunfavorableeffectfrominflationmarketingandadministrative expense reflect necessary support newand anticipate product launch market admin istrative expensesinand include million million respectivelyofadditional reserve solelyforfuturevioxxlegaldefensecostsinadditionmarketingandadministrativeexpensesforincludeda million gain fromaninsurance arbitration awardrelate vioxx productliability litigation coveragesee note consolidated financial statement information vioxxrelate matter market administrative expense reflect million charge fosamax legal defense cost inmarketingandadministrativeexpensesincreasedincludingaunfavorableeffectfrom inflation marketing administrative expense reflect million additional reserve vioxx fosamax legal defense cost expense associate launch new vaccine januvia united states stock option expense million research development researchanddevelopmentexpensesincreasedinandinincludingunfavorableeffect frominflationofinbothandresearchanddevelopmentexpensesinalsoreflectedsignificant growthinthenumberofcompoundsenteringclinicaltrialsfrominternalprojectsaswellasintegrationoflatestage acquisition research development expense include million acquire research expense relatedtothenovacardiaacquisitionandamillioninitialmilestonepaymentassociatedwiththelicensingof deforolimus mk phase iii compound company develop ariad pharmaceuticals inc ariadinresearchanddevelopmentexpensesincludedmillionofacquiredresearchrelatedto theacquisitionofsirnaaswellasmillionofacquiredresearchassociatedwiththeglycofiacquisitionin addition research development expense reflect accelerate depreciation cost million relate closure research facility connection global restructuring program duringthecompanycontinuedtheadvancementofdrugcandidatesthroughthepipelineincluding fda approval janumet isentress company research pipeline chart include item businessresearch development inadditiononjanuarythefdaapprovedemendfosaprepitant dimeglumine forinjection mgforthepreventionofcinvemendforinjectionprovidesanewoptionfordayoneoralemendmgas partoftherecommendedthreedayregimenthatdeliversfivedaysofprotectionfromnauseaandvomitingpriorto fda decision eu january grant marketing approval emend injection know ivemend eu action apply eu member country norway iceland inaugustthefdaacceptedforstandardreviewthendaforcordaptivetheproposedtrademark mka er niacinlaropiprant cordaptive investigational compound contain merck er niacinandlaropiprantanovelflushingpathwayinhibitordesignedtoreduceflushingoftenassociatedwithniacin treatmentniaciniswidelyrecognizedasaneffectivelipidmodifyingtherapyhowevertreatmenthasbeenlimite asaresultoftheflushingsideeffectdataincludedintheapplicationsupporttheproposeduseofcordaptiveeither aloneorwithastatinasadjunctivetherapytodietforthetreatmentofelevatedlowdensitylipoproteincholesterol ldlc bad cholesterol low highdensity lipoprotein cholesterol hdlc good cholesterol elevate triglyceride level condition associate increase risk heart disease inseptemberthecompanyannouncedphaseiiiclinicalstudyresultsinwhichcordaptivereduce ldlclevelsincreasedhdlclevelsandreducedtriglyceridelevelscomparedtoplacebopatientstreatedwith cordaptive report significantly flush compare patient treat er niacin cordaptive administer gram dose add ongoing statin therapy patient dyslipidemiaacrossweekstoofthestudygramstwogramtabletsofcordaptiveproducedsignificant percentchangesfrombaselineinldlclevelshdlclevelsandtriglyceridelevelsrelative toplaceboinadditionpatientstreatedwithcordaptivereportedsignificantlylessflushingbothattheinitiationof therapyandduringmaintenancetherapycomparedtopatientsonerniacinalonemerckanticipatesfdaactionin april company move forward filing country outside united states thecompanycurrentlyhassevendrugcandidatesinphaseiiidevelopmentandanticipatesmakingnda filing respect candidate mkb drug candidate combine novel approach raise hdlc lower triglyceridesfromerniacincombinedwithlaropiprantwiththeprovenbenefitsofsimvastatininonecombination product november company present result study american heart association scientific session demonstrate er niacinlaropiprant cordaptive coadministere simvastatin significantadditiveeffectsonreducingldlcincreasinghdlcandreducingtriglyceride levelsinaphaseiii studywithpatientswithprimaryhypercholesterolemiaormixeddyslipidemiainthestudygtwogramtablet cordaptive coadministere simvastatin pool mg mg dose reduce ldlc increasedhdlcbyandreducedtriglyceridelevelsbyfollowingweeksoftreatmenttheprimary studyendpointwasldlcreductionsecondaryendpointsincludedincreasedhdlctriglyceridereductionand effectsonotherlipoproteinsagtabletofcordaptivecontainsgofmerckdevelopederniacinandmgof laropiprantanovelflushingpathwayinhibitorthatisdesignedtoreducetheflushingassociatedwithniacinthe company plan file mkb fda mktaranabantisaninvestigationalhighlyselectivecannabinoidreceptorinverseagonistthatin early clinical study demonstrate doserelate weight loss versus placebo taranabant generally tolerate report cannabinoid receptor inverse agonist dosedependent psychiatricadverseeventswereobservedthecompanypreviouslyannouncedtheinitiationofatargetedphaseiii program merck anticipate file nda mk investigational oral calcitonin generelate peptide receptor antagonist utilize new mechanism forthe treatment ofmigraine hasdemonstrate efficacyat comparable totriptans inearly clinicalstudiesinjuneclinicalresultsfromaphaseiistudywerepresentedforthefirsttimeattheamerican headache society annual meeting show mk significantly improve migraine pain relief hoursafterdosingcomparedtoplaceboandthereliefwassustainedthroughhoursmkwasgenerallywell toleratedinthestudyinadditiontothemeasureofmigrainepainmkprovidedreliefofmigraineassociate symptomsincludingnauseaandsensitivitytolightandsoundandimprovedfunctionaldisabilitytwohourspost doseaswellasreducedpatientsneedforrescuemedication thedrugcandidateenteredphaseiiidevelopment company anticipate file nda mk mkrolofyllineisaphaseiiiinvestigationaldrugbeingevaluatedforthetreatmentofacuteheart failure phase iii pilot study preliminary result indicate rolofylline generally tolerate treatmentresultedinagreaterproportionofpatientswithimproveddyspneafewerpatientswithworseningheart failureandgreaterweightlosscomparedtoplacebothesebenefitswereachievedwhilepreservingrenalfunction compare progressive worsen renal function patient treat placebo merck acquire drug candidate acquisition novacardia anticipate file ndawith fda mkdeforolimusisanovelmtormammaliantargetofrapamycininhibitorbeingevaluatedfor thetreatmentofcancerthedrugcandidateisbeingjointlydevelopedandcommercializedwithariadunderan agreement reach mid discuss company anticipate file nda metastatic sarcoma indication anovelinvestigationalhepatitisbvaccinevcurrentlyisbeingevaluatedinaphaseiiiclinicaltrial adult patient undergo dialysis treatment merck jointly develop v dynavax tech nologies corporation dynavax agreement reach late discuss merck anticipate file nda adult mkodanacatibisaninvestigationalhighlyselectiveinhibitorofthecathepsinkenzymewhichi evaluate treatment osteoporosis cathepsin k enzyme believe play role osteoclastic bone resorption degrade protein component bone inhibition cathepsin k enzyme investigational compound odanacatib mechanism action different currently approvedtreatmentssuchasbisphosphonatesinseptembertwelvemonthresultsfromaphaseiibstudywith odanacatib demonstrate dosedependent increase bone mineral density bmd key fracture site reducedboneturnovercomparedtoplaceboinpostmenopausalwomenwithlowbmdwhengivenatdosesof mg finding present th annual meeting american society bone mineralresearchbmdreflectstheamountofmineralizedbonetissueinacertainvolumeofboneandcorrelate withthestrengthofbonesandwiththeirresistancetofractureabmdtestisusedtomeasurebonedensityandto helpdeterminefractureriskthephaseiiiprogrambeganinmidmerckanticipatesfilinganndawiththe fda additionally december company announce plan initiate sequence phase iii programinformkanacetrapibitsinvestigationalselectivecholesterylestertransferproteincetp inhibitortoobtainadditionalclinicalexperienceinpatientsbeforeinitiatinganoutcomesstudyinoctober thecompanypresentedresultsfromaphaseiibstudydemonstratingthatmksignificantlyreducedldlc andapolipoproteinbandincreasedhdlcandapolipoproteinabothasmonotherapyandincombinationwith atorvastatinmgcomparedtoplaceboinpatientswithdyslipidemiaanacetrapibproducedthesepositiveeffect onlipidswithnoobservedbloodpressurechangescetpinhibitorsworkbyinhibitingcetpaplasmaproteinthat facilitate transport cholesteryl ester triglyceride lipoprotein inmarchmerckandhlundbeckaslundbeckannouncedthediscontinuationoftheirjoint development program gaboxadol investigational new medicine treatment insomnia phase iii development datum complete clinical study suggest overall clinical profile gaboxadolininsomniadoesnotsupportfurtherdevelopmentasaresultofthisinformationmerckandlundbeck file nda gaboxadol treatment insomnia fda regulatory agency worldwide terminate ongoing clinical study september merck announce vaccination phase ii clinical trial company investigationalhivvaccinevwasdiscontinuedbecausethevaccinewasnoteffectivethetrialcalledstep cosponsor merck national institutes healths national institute allergy infectious disease niaid hiv vaccine trial network independent datum safety monitoring board dsmbforsteprecommendeddiscontinuationbecausethesteptrialwouldnotmeetitsefficacyendpoint october niaid announce separate dsmb second clinical trial conduct southafricaofthesamevaccinecandidaterecommendedthatvaccinationandenrollmentinthesouthafricatrial permanently discontinue south africa dsmb recommend volunteer trial tell whethertheyreceivedthevaccineorplacebobestronglyencouragedtoreturntostudysitesforprotocolrelate test counsel possibility receive vaccine increase susceptibility hivinfection detail analyse available datum conduct include analysis well understand increase susceptibility hiv infection volunteer receive vaccine vaccine cause hivinfection inaugustmerckandgileadsciencesincgileadestablishedanagreementforthedistribution ofatriplaindevelopingcountriesaroundtheworldatriplacontainsmgofefavirenzanonnucleosidereverse transcriptase inhibitor mg emtricitabine mg tenofovir disoproxil fumarate nucleoside reverse transcriptase inhibitor efavirenz market merck tradename stocrin territory outsideoftheunitedstatescanadaandcertaineuropeancountrieswhereitiscommercializedbybristolmyer squibb tradename sustiva emtricitabine tenofovir disoproxil fumarate commercialize gilead tradename emtriva viread respectively atripla approve eu merck continue remain focused augment internal effort capitalize growth opportunity range target acquisition research collaboration preclinical clinical compound technology transaction drive near longterm growth company complete transaction broad range therapeutic category earlystage technology transaction merck currently evaluate opportunity actively monitor landscape range target acquisition meet companysstrategic criterion highlight activity year include injulymerckandariadannouncedthattheyhadenteredintoaglobalcollaboration tojointly developandcommercializedeforolimusmkariadsnovelmtorinhibitorforuseincancereachparty fund cost global development mk merck fund cost exusdevelopmentthatisspecifictothedevelopmentorcommercializationofmkoutsidetheusthatis notcurrentlypartoftheglobaldevelopmentplantheagreementprovidedforaninitialpaymentofmillionto ariadwhichthecompanyrecordedasresearchanddevelopmentexpenseuptomillionmoreinmilestone paymentstoariadbasedonthesuccessfuldevelopmentofmkinmultiple cancerindicationsinclude millionpaidfortheinitiationofthephaseiiiclinical trialinmetastatic sarcomasandmilliontobe pay initiation phase ii phase iii clinical trial additional million base achievement significant sale threshold million estimate contribution merck global developmentuptomillionininterestbearingrepayabledevelopmentcostadvancesfrommercktocovera portionofariadsshareofglobaldevelopmentcostsafterariadhaspaidmillioninglobaldevelopment costsandpotentialcommercialreturnsfromprofitsharingintheusorroyaltiespaidbymerckoutsidetheusin ariad distribute sell mk cancer indication ariad merck co promoteandwilleachreceiveoftheincomefromsuchsalesoutsidetheusmerckwilldistributeselland promote mk merck pay ariad tiere doubledigit royalty endmarket sale mk september merck complete acquisition novacardia privately hold clinicalstage pharmaceutical company focus cardiovascular disease acquisition add rolofylline mk novacardias investigational phase iii compound acute heart failure merck pipeline merck acquire alloftheoutstandingequityofnovacardiaforatotalpurchasepriceofmillionincludingmillionof cash investment hand closing pay issuance million share merck common stock tothe novacardia shareholder basedonmercksaverage closing stockprice forthe day prior closing acquisition connection acquisition company record charge millionforacquiredresearchassociatedwithrolofyllineasattheacquisitiondatetechnologicalfeasibility establish alternative future use exist acquisition november merck dynavax announce global license development collaboration agreementtojointlydevelopvanovelinvestigationalhepatitisbvaccinewhichiscurrentlybeingevaluatedin amulticenterphaseiiiclinicaltrialinvolvingadultsandinpatientsondialysisunderthetermsoftheagreement merckreceivesworldwideexclusiverightstovwillfundfuturevaccinedevelopmentandberesponsiblefor commercialization dynavax receive initial payment million company record research development expense eligible receive million development sale milestone payment doubledigit tiere royalty global sale v november merck gtx inc gtx announce enter agreement provide research development global strategic collaboration selective androgen receptor modulator sarm new class drug potential treat agerelate muscle loss sarcopeniaaswellasothermusculoskeletalconditionsthiscollaborationincludesgtxsleadsarmcandidate ostarinemkwhichiscurrentlybeingevaluatedinaphaseiiclinicaltrialforthetreatmentofmusclelossin patient cancer establish broad sarm collaboration gtx merck pool programsandpartnertodiscoverdevelopandcommercializecurrentaswellasfuturesarmmoleculesaspartof thisglobalagreementmerckwillberesponsibleforallfuturecostsassociatedwithongoingdevelopmentandif approvedcommercializationofostarineandotherinvestigationalsarmsresultingfromthecollaborationunder thetermsofthecollaborationagreementandrelatedstockpurchaseagreementgtxandmerckwillcombinetheir respective sarm research programs gtx receive upfront payment million record merckasresearchanddevelopmentexpenseandwillalsoreceivemillioninresearchreimbursementstobe paidovertheinitialthreeyearsofthecollaborationinadditionmerckmadeaninvestmentofmillioningtx commonstockgtxwillalsobeeligibletoreceiveuptomillioninfuturemilestonepaymentsassociatedwith thedevelopmentandapprovalofadrugcandidate ifmultiple indicationsreceiveregulatoryapprovaladditional milestone received development approval collaboration drug candidate gtx receive royalty result worldwide product revenue company maintain number longterm exploratory fundamental research program biologyandchemistry aswellasresearch programsdirecte towardproductdevelopment mercksresearch developmentmodelisdesignedtoincreaseproductivityandimprovetheprobabilityofsuccessbyprioritizingthe company research development resource disease area atherosclerosis hypertension diabetes obesity novel vaccine neurodegenerative psychiatric disease target oncology therapy company focused investment area important unmet medical need addition companyisfocusedonutilizingnewresearchtechnologiesbuildingallianceswithexternalpartnersandmake targetedacquisitionswhichwillcomplementthecompanysstronginternalresearchcapabilitiesachartreflecte company current research pipeline february set forth item business sharebase compensation january company adopt fas r note consolidated financial statement fas r require sharebase payment employee expense requisite service periodbasedonthegrantdatefairvalueoftheawardspriortoadoptingfasrthecompanyaccountedfor employeestockoptionsusingtheintrinsicvaluemethodwhichmeasuressharebasedcompensationexpenseasthe amountbywhichthemarketpriceofthestockatthedateofgrantexceedstheexercisepricethecompanyelecte themodifiedprospectivetransitionmethodforadoptingfasrandthereforepriorperiodswerenotrestate underthismethod theprovisionsoffasrapplie toall awardsgrante ormodifiedafter january total pretax sharebase compensation expense million million million addition unrecognized expense award vested date adoptionarerecognizedinnetincomeintheperiodsafterthedateofadoptionatdecembertherewa million total pretax unrecognized compensation expense relate nonveste stock option restrict stockunitandperformanceshareunitawardswhichwillberecognizedoveraweightedaverageperiodofyear segment report sharebased compensation cost unallocated expense restructure cost restructure cost million million million respectively merck incur million million million respectively separation cost associate actual headcount reduction headcount reduction wereprobable andcouldbereasonablyestimate related totheglobal restructure programthecompany eliminate position position position position eliminationsarecomprisedofactualheadcountreductionsandtheeliminationofcontractorsandvacantposition alsoincludedinrestructuringcostsarecurtailmentsettlementandterminationchargesonthecompanyspension postretirement benefit plan shutdown cost addition company record million forseparation costsassociate withotherrestructure program forsegment report restruc ture cost unallocated expense equity income affiliate equityincomefromaffiliatesreflectstheperformanceofthecompanysjointventuresandpartnership inandtheincreaseinequityincomefromaffiliatesprimarilyreflectsthesuccessfulperformance vytorin zetia merckscheringplough partnership select joint venture affiliate information vioxx settlement agreement charge onnovembermerckenteredintothesettlementagreementwiththelawfirmsthatcomprisethe executive committee plaintiff steering committee federal multidistrict vioxx litigation representativesofplaintiffscounselinstatecoordinatedproceedingstoresolvestateandfederalmiandisclaim file company united states certain participation condition settlement agreementaremetorwaivedthecompanywillpayanaggregatefixedamountofbillionintotwofundsfor qualifyingclaimsconsistingofbillionforqualifyingmiclaimsandmillionforqualifyingisclaimsthat enterintothesettlementprogramasaconsequenceofthesettlementagreementthecompanyrecordedapretax charge billion note consolidated financial statement income expense net thechangeinotherincomeexpensenetduringprimarilyreflectsamillionchargerelate totheresolutionofcertaincivilgovernmentalinvestigationsseenotetotheconsolidatedfinancialstatement partiallyoffsetbythefavorableimpactofgainsonsalesofassetsandproductdivestituresaswellasanetgainon thesettlementsofcertainpatentdisputesthechangeinotherincomeexpensenetinreflectsanincreasein interestincomegeneratedfromthecompanysinvestmentportfolioderivedfromhigherinterestratesandhigher average investment portfolio balance segment profit million pharmaceutical segment profit vaccine segment profit segment profit income income taxis segment profit comprise segment revenue certain element material production costsandoperatingexpensesinclude componentsofequity income lossfromaffiliatesanddepreciation amortization expense internal management reporting present chief operating decision maker companydoesnotallocatethevastmajorityofindirectproductioncostsresearchanddevelopmentexpensesand general andadministrativeexpensesaswellasthecostoffinancingtheseactivitiesseparatedivisionsmaintain responsibility formonitore andmanaging thesecostsincluding depreciation relate tofixedassetsutilize thesedivisionsandtherefore theyarenotinclude insegmentprofitsalsoexclude fromthedetermination segmentprofitsaretheusvioxxsettlementagreementchargetaxespaidatthejointventurelevelandaportion equity income additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit operate profit relate divested productsorbusinessesothersupplysalesandadjustmentstoeliminatetheeffectofdoublecountingcertainitemsof income expense pharmaceutical segmentprofitsincreasedinandinreflecte higherequityincome primarilydrivenbythestrongperformanceofthemerckscheringploughpartnershippartiallyoffsetbythelossof market exclusivity zocor proscar vaccinessegmentprofitsnearlytripledinandgrewindrivenbythelaunchofthreenew vaccinesinthelatterpartofandthesuccessfulperformanceofvarivaxvaccinessegmentprofitsalsoreflect equity income spmsd taxis income thecompanyseffectiveincometaxratewasininandinthe effective tax rate reflect reduction domestic pretax income primarily result vioxx settlement agreement charge relate change mix domestic foreign pretax income high effectivetaxrateinreflectsanunfavorableimpactofpercentagepointsprimarilyrelatedtothecompany decisiontorepatriatebillionofforeignearningsinaccordancewiththeamericanjobscreationactof ajca net income earning share million share amount change change net income cid cid sale average total asset earning common share assume dilution cid cid net income earning common share net income decrease decline earning common share assume dilutiondeclinedincomparedtoadeclineofinthedeclinesinreflecttheimpactofthe vioxx settlement agreement charge civil governmental investigation charge partially offset low reserve legal defense cost gain insurance arbitration award relate vioxx product liability litigationcoverageloweracquiredresearchcostsandthefavorableimpactofgainsonsalesofassetsandproduct divestituresaswellasanetgainonthesettlement ofcertain patentdisputesnetincomeandepsinalso reflect revenue growth vaccine singulair januvia high equity income affiliate net income eps decline primarily reflect acquire research charge high restructuring charge increasedreservesforlegaldefensecostsandtheincrementalimpactofexpensingstockoptionspartiallyoffsetby growthinequityincomefromaffiliatesnetincomeasapercentageofsaleswasininand inthedecreaseinthepercentageofsalesratioinascomparedtoreflectsthesamefactor discussedabovenetincomeasapercentageofaveragetotalassetswasininandin select joint venture affiliate information toexpanditsresearchbaseandrealizesynergiesfromcombiningcapabilitiesopportunitiesandasset previous year company form number joint venture note consolidated financial statement merckscheringplough partnership company scheringplough corporation scheringplough collectively ner enter agreement create separate equallyowne partnership develop market unitedstatesnewprescriptionmedicinesinthecholesterolmanagement andrespiratorytherapeuticareasthese agreementsgenerallyprovideforequalsharingofdevelopmentcostsandforcopromotionofapprovedproductsby company cholesterolmanagement partnership agreement expand include countriesoftheworldexcludingjapaninezetimibethefirstinanewclassofcholesterolloweringagent waslaunchedintheunitedstatesaszetiamarketedasezetroloutsidetheunitedstatesinacombination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states cholesterol agreement provide share operating income generate merck scheringplough cholesterol partnership msp partnership base percentage vary product saleslevelandcountryintheusmarketthepartnersshareprofitsonzetiaandvytorinsalesequallywiththe exception million annual zetia sale scheringplough receive great share profitsoperatingincomeincludesexpensesthatthepartnershavecontractuallyagreedtosharesuchasaportion ofmanufacturingcostsspecificallyidentifiedpromotioncostsincludingdirecttoconsumeradvertisinganddirect identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msppartnership share partner market administrative expense include certain sale force cost certain manufacturing costsare include inequity income affiliate howeverthese cost reflect inthe overall result company certain research development expense generally share equally partner adjust earn milestone sale joint venture product follow million vytorin zetia global sales vytorin grow vytorin combination tablet cholesteroltreatmenttoprovideldlcholesterolloweringthroughthedualinhibitionofcholesterolproductionand absorption global sales zetia increase january msp partnership announce primary endpoint result enhanceeffectofcombination ezetimibe andhighdosesimvastatinvssimvastatinaloneontheathero sclerotic process patient heterozygous familial hypercholesterolemia trial msp partnership submittedanabstractontheenhancetrialforpresentationattheamericancollegeofcardiologymeetingin marchandwasnotifiedofitsacceptancebythecollegeenhancewasasurrogateendpointtrialconducte inpatientswithheterozygousfamilialhypercholesterolemiaarareconditionthataffectsapproximately ofthepopulationallanalyseswereconductedinaccordancewiththeoriginalstatisticalanalysisplantheprimary endpointwasthemeanchangeintheintimamediathicknessmeasuredatthreesitesinthecarotidarteriestherightand leftcommoncarotidinternalcarotidandcarotidbulbbetweenpatientstreatedwithezetimibesimvastatinmg versuspatientstreatedwithsimvastatinmgaloneoveratwoyearperiodtherewasnostatisticallysignificant differencebetweentreatmentgroupsontheprimaryendpointtherewasalsonostatisticallysignificantdifference betweenthetreatmentgroupsforeachofthecomponentsoftheprimaryendpointincludingthecommoncarotid arterykeysecondary imaging endpoint showednostatistical difference treatment groupsthe overall incidence rate treatmentrelate adverse event adverse event adverse event lead discon tinuationweregenerallysimilarbetweentreatmentgroupsbothmedicinesweregenerallywelltoleratedoverall thesafetyprofilesofezetimibesimvastatinandsimvastatinaloneweresimilarandgenerallyconsistentwiththeir product label trial significant difference lowdensity lipoprotein ldl cholesterol lower see treatment group ldl cholesterol lower month ezetimibe simvastatinascomparedtoatmonthsonsimvastatinalonethissurrogateendpointstudywasnotpowere design assess cardiovascular clinical event outcomes msp partnership currently conduct improveittrialalargeclinical cardiovascularoutcomestrial comparingvytorinezetimibesimvastatinand simvastatinandincludingmorethanpatientsvytorincontainstwomedicinesezetimibe andsimvastatin vytorin show reduce heart attack stroke simvastatin december february company jointventure partner scheringploughreceivedseveraljointlettersfromthehousecommitteeonenergyandcommerceandthehouse subcommittee oversight investigation letter senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer januarythecompaniesandthemsppartnershipeachreceivedtwosubpoenasfromthenewyorkstate attorneygeneralsofficeseekingsimilarinformationanddocumentsmerckandscheringploughhavealsoeach receivedaletterfromtheofficeoftheconnecticutattorneygeneraldatedfebruaryrequestingdocuments relatedtothemarketingandsaleofvytorinandzetiaandthetimingofdisclosuresoftheresultsofenhancethe companyiscooperatingwiththeseinvestigationsandworkingwithscheringploughtorespondtotheinquiriesin additionsincemidjanuarythecompanyhasbecomeawareoforbeenservedwithapproximatelycivil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia company closely monitor sale vytorin zetia follow release enhanceclinicaltrialresultsinthepressreleaseonjanuarytodatesalesofbothproductsintheus company prior expectation addition wholesaler moderate purchase product reduce inventory level respiratory therapeutic agreement provide joint development marketing united states partner oncedaily fixedcombination tablet contain active ingredient montelukast sodium loratadine montelukast sodium leukotriene receptor antagonist sell merck assingulairandloratadineanantihistamineissoldbyscheringploughasclaritinbothofwhichareindicatedfor thereliefofsymptomsofallergicrhinitisinaugustthepartnersannouncedthatthenewdrugapplication filingformontelukastsodiumloratadinehadbeenacceptedbytheusfoodanddrugadministrationforstandard review partner seek marketing approval medicine treatment allergic rhinitis symptomsinpatientswhowantrelieffromnasalcongestionthecompanyanticipatesfdaactioninthesecond quarter result company interest msp partnership record equity income affiliatesmerckrecognizedequityincomeofmillioninmillioninandmillion financial statement msp partnership include item financial statement schedule astrazeneca lp inthecompanyenteredintoanagreementwithastraabastratodevelopandmarketastra products united states company astra form equallyowne joint venture develop andmarketed mostofastrasnewprescription medicine inthe united states include prilosecthe firstinaclassofmedicationsknownasprotonpumpinhibitorswhichslowstheproductionofacidfromthecellsof stomach lining inthecompanyandastrarestructure jointventurewherebythe companyacquire astras interestinthejointventurerenamedkbiinckbiandcontributedkbisoperatingassetstoanewuslimite partnership name astra pharmaceutical lp partnership company maintain limited partnerinterestthepartnershiprenamedastrazenecalpazlpuponastrasmergerwithzenecagroup plc astrazeneca merger exclusive distributor product kbi retain right merckearnsongoingrevenuebasedonsalesofcurrentandfuturekbiproductsandsuchrevenuewa billionbillionandbillioninandrespectivelyprimarilyrelatingtosalesofnexium aswellasprilosecinadditionmerckearnscertainpartnershipreturnswhicharerecordedinequityincomefrom affiliatessuchreturnsincludeapriorityreturnprovidedforinthepartnershipagreementvariablereturnsbasedin partuponsalesofcertainformerastrausaincproductsandapreferentialreturnrepresentingmercksshareof undistributedazlpgaapearningsthesereturnsaggregatedmillionmillionandmillion respectively astrazeneca merger trigger partial redemption merck limited partnershipinterestinuponthisredemption azlpwilldistributetokbianamountbasedprimarily ona multipleofmercksaverageannualvariablereturnsderivedfromsalesoftheformerastrausaincproductsfor year prior redemption limited partner share agree value conjunction restructure payment million record deferred income astra purchase option asset option buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi product asset option exercisable half exercise price equal net present value march projectedfuturepretaxrevenuetobereceivedbythecompanyfromthenonppiproductstheappraisedvalue merckalsohadtherighttorequireastratopurchasesuchinterestinattheappraisedvalueinfebruary thecompanyadvisedazlpthatitwillnotexercisetheassetoptioninadditioninthecompanygrante astra option buy merck common stock interest kbi merck interest nexium prilosecexercisabletwoyearsafterastraspurchaseofmercksinterestinthenonppiproductstheexerciseof thisoptionbyastraisalsoprovidedforintheyearorifcombinedannualsalesofthetwoproductsfallbelowa minimum providedin case solong astrazenecasoption hasbeen exercise exercisepriceisbasedonthenetpresentvalueofestimatedfuturenetsalesofnexiumandprilosecasdeterminedat time exercise subject certain trueup mechanism alsoasaresultoftheastrazenecamergerinexchangeformercksrelinquishmentofrightstofuture astraproductswithnoexistingorpendinguspatentsatthetimeofthemergerastrapaidmillion advancepaymentwhichissubjecttoatrueupcalculation thetrueupamountinthatmayrequire repaymentofalloraportionofthisamountthetrueupamountisdirectlydependentonthefairmarketvaluein oftheastraproductrightsretainedbythecompanyaccordinglyrecognitionofthiscontingentincomehas beendeferreduntiltherealizableamountisdeterminableininthecompanyreclassifiedthisamountto accruedandothercurrentliabilitiesfromnoncurrentliabilitiesasthistrueupcalculationwilloccurbeforetheend second quarter thesumofthelimitedpartnershareofagreedvaluetheappraisedvalueandthetrueupamountis guaranteedtobeaminimumofbilliondistributionofthelimitedpartnershareofagreedvalueandpayment trueup occur half amount anticipate represent substantial portionofthebillion thesepaymentswillresult inapretax gainestimate tobebillion billionastrazenecaspurchaseofmercksinterestinthenonppiproductsiscontingentupontheexerciseof astrazenecas option payment appraise value occur merial limited merck rhnepoulenc sanowsanofiaventis sacombine animal health poultrygeneticsbusinessestoformmeriallimitedmerialafullyintegratedanimalhealthcompanywhichisa standalonejointventureequallyownedbyeachpartymerialprovidesacomprehensiverangeofpharmaceutical vaccine enhance health wellbeing performance wide range animal specie sale joint venture product follow million fipronil product biological product avermectin product product sanofi pasteur msd inmerckandpasteurmerieuxconnaughtnowsanofipasteursaestablishedaownedjoint venturetomarketvaccinesineuropeandtocollaborateinthedevelopmentofcombinationvaccinesfordistribution europe merck launch newvaccine havebeen approvedfor use eu market spmsd certain western european country gardasil help prevent cervical cancer pre cancerousandlowgradelesionsvulvarandvaginalprecancersandgenitalwartscausedbyhpvtype androtateqtohelpprotectagainstrotavirusgastroenteritisininfantsandchildrenandzostavaxtohelpprevent shingle herpe zoster individual year age old sale joint venture product follow million viral vaccine hepatitis vaccine gardasil vaccines johnson johnsonmerck consumer pharmaceutical company inmerckformedajointventurewithjohnsonjohnsontodevelopandmarketabroadrangeof nonprescriptionmedicinesforusconsumersthisownedjointventurewasexpandedineuropeinand intocanadaininmercksolditsequitystakeinitseuropeanjointventuretojohnsonjohnson merckwillcontinuetobenefitthroughroyaltiesoncertainproductsandalsoregainedtherightstopotentialfuture product switch prescription overthecounter status europe sale joint venture product follow million gastrointestinal product product capital expenditure capital expenditure billion million billion expendituresintheunitedstatesweremillioninmillioninandmillionin expenditure include million production facility million research developmentfacilitie millionforenvironmental projectsandmillionforadministrativesafetyand generalsiteprojectsofwhichapproximatelyrepresentscapitalinvestmentsrelatedtoamultiyearinitiativeto standardize company information system capital expenditure estimate billion depreciation expensewasbillion inbillion inandbillion inofwhich billionbillionandbillionrespectivelyappliedtolocationsintheunitedstatestotaldepreciation expense include accelerate depreciation million million million respectivelyassociate global restructuring program additionallydepreciation expense forreflectsmillionassociatedwiththeclosureoftheterlingsparkbasicresearchcenterseenoteto consolidated financial statement analysis liquidity capital resource mercksstrongfinancialprofileenablesthecompanytofullyfundresearchanddevelopmentfocuson external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cashprovidedbyoperatingactivitieswhichwasbillioninbillioninandbillion continue company primary source fund finance capital expenditure treasury stock purchasesanddividendspaidtostockholdersatdecemberthetotalofworldwidecashandinvestment wasbillionincludingbillionofcashcashequivalentsandshortterminvestmentsandbillionof longterm investment workingcapitallevelsaremorethanadequatetomeettheoperatingrequirementsofthecompanythe ratiosoftotaldebttototalliabilitiesandequityandcashprovidedbyoperationstototaldebtreflectthestrengthof company operate cash flow ability company cover contractual obligation duringthecompanybeganshiftingitsmixofinvestmentsfromshorttermtolongtermresulte inareductionofworkingcapitalinlinewithhistoricallevelsrelativetothelevelatdecemberinto enableexecutionoftheajcarepatriationthecompanychangeditsmixofinvestmentsfromlongtermtoshort termresultinginasignificantincreaseinworkingcapitalasofdecembertheajcacreatedtemporary incentivesthroughdecemberforusmultinationalstorepatriateaccumulatedincomeearnedoutsideof theunitedstatesasofdecemberinconnectionwiththeajcathecompanyrepatriatedbillion duringasaresultthecompanyrecordedanincometaxchargeofmillionintaxesonincomein relatedtothisrepatriationmillionofwhichwaspaidinandtheremainderofwhichwaspaidinthefirst quarter asof december approximately billion ajcarepatriation wasinveste fullycollateralizedovernightrepurchaseagreementsinearlythecompanybeganreinvestingitsrepurchase agreement balance investment duringthecompanyanticipatesthatundertheusvioxxsettlementagreementifparticipation conditionsaremetorwaivedthecompanywillmakepaymentsofuptoapproximatelybillionpursuanttothe settlementagreementalsothecompanyanticipatesmakingpaymentsofapproximatelymillionrelatedto theresolutionofinvestigationsofcivilclaimsbyfederalandstateauthoritiesrelatingtocertainpastmarketingand sellingactivitiesthecompanywillreceivepaymentsinthefirsthalfofforcertainazlprelatedactivitiesas discussedaboveinselectedjointventureandaffiliateinformationdistributionofsuchamountsareanticipate represent substantial portion billion minimum aspreviouslydisclosedtheirshascompleteditsexaminationofthecompanystaxreturnsfortheyear toasaresultoftheexaminationthecompanymadeanaggregatepaymentofbillioninfebruary thispaymentwasoffsetbyiataxrefundofmillionreceivedinforamountspreviouslypaidfor thesemattersandiiafederaltaxbenefitofapproximatelymillionrelatedtointerestincludedinthepayment resultinginanetcashcosttothecompanyofapproximatelybillionintheimpactforyearssubsequent toforitemsreviewedaspartoftheexaminationwasincludedinthepaymentalthoughthoseyearsremainopen inallotherrespectstheclosingoftheirsexaminationdidnothaveamaterialimpactonthecompanysresultsof operation amount previously provide previously disclose merck canadian tax return year examine bythe canada revenue agencycra inoctober craissue companya notice reassessment contain adjustment relate certain intercompany pricing matter result additional canadian provincial tax approximately billion dollar plus interest approximately millionusdollarsinadditioninjulythecraproposedadditionaladjustmentsforrelatingto intercompany pricing matter adjustment increase canadian tax approximately million dollar plus million dollar interest possible crawill propose similaradjustmentsforlateryearsthecompanydisagreeswiththepositionstakenbythecraandbelievesthey arewithoutmeritthecompanyintendstocontesttheassessmentthroughthecraappealsprocessandthecourt ifnecessaryinconnectionwiththeappealsprocessduringthecompanypledgedcollateraltotwofinancial institution provide guarantee cra quebec ministry revenue representingaportionofthetaxandinterestassessedthecollateralisincludedinotherassetsintheconsolidate balance sheet total approximately billion december company previously establishedreservesforthesematterswhiletheresolutionofthesemattersmayresultinliabilitieshigherorlow reserve management believe resolution matter material effect companysfinancialpositionorliquidityhoweveranunfavorableresolutioncouldhaveamaterialeffectonthe company result operation cash flow quarter adjustment record tax injulythecranotifiedthecompanythatitisintheprocessofproposingapenaltyofmillion usdollarsinconnectionwiththenoticethepenaltyisforfailingtoprovideinformationonatimelybasis companyvigorouslydisagree withthe penalty feel isinapplicable andthat appropriate information provide timely basis company pursue appropriate remedy avoid penalty assessedand wasnotifie inearly august craisholde imposition apenalty inabeyance pende review company submission inapplicability penalty irsrecently beganit examination ofthe companystofederal income tax return additionvariousstateandforeigntaxexaminationsareinprogresstaxyearsthatremainsubjecttoexaminationby majortaxjurisdictionsincludegermanyfromitalyandjapanfromandtheunitedkingdomfrom company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt vioxx settlement agreement civil governmental investigation resolution unrecognize tax benefit operating lease paymentsundertheusvioxxsettlementagreementarecontingentuponparticipationconditionsbeingmetorwaivedalsothetimingof suchpaymentsmayvarydependingonthetimingoftheclaimsassessmentprocess asofdecemberthecompanysconsolidatedbalancesheetreflectsaliabilityforunrecognizedtaxbenefitsofbillion includingmillionreflectedasacurrentliabilityduetothehighdegreeofuncertaintyregardingthetimingoffuturecashoutflowsof liabilitiesforunrecognizedtaxbenefitsbeyondoneyearareasonableestimateoftheperiodofcashsettlementforyearsbeyondcannot bemade purchaseobligationsconsistprimarilyofgoodsandservicesthatareenforceableandlegallybindingand include obligation minimum inventory contract research development advertising amount reflectedforresearchanddevelopmentobligationsdonotincludecontingentmilestonepaymentsloanspayable andcurrentportionoflongtermdebtalsoreflectsmillionoflongdatednotesthataresubjecttorepayment attheoptionoftheholdersonanannualbasisrequiredfundingobligationsforrelate tothecompany pension postretirement benefit plan expect material indecemberthecompanyincreasedthecapacityofitsshelfregistrationstatementfiledwiththe security andexchange commissionsec toissuedebt security byan additional billion infebruary thecompanyissuedbillionoftenyearnotesundertheshelfinnovemberthecompany issuedmillionoftwentyyearnotesandmillionoffiveyearnotesundertheshelfthe remain capacity company shelf registration statement approximately billion inaprilthecompanyextendedthematuritydateofitsbillionyearrevolvingcreditfacility april april facility provide backup liquidity company commercial paper borrowingfacility andisforgeneral corporate purposesthecompanyhasnotdrawnfundingfromthisfacility thecompanyslongtermcreditratingsassignedbymoodysinvestorsserviceandstandardpoor aa develop outlook aa stable outlook respectively rating continue allow access tothecapital market andflexibility inobtaine fundsoncompetitiveterm thecompanycontinue maintain conservative financial profile total cash investment billion exceed sum loan payableandlongtermdebtofbillionweplaceourcashandinvestmentsininstrumentsthatmeethighcredit qualitystandardsasspecifiedinourinvestmentpolicyguidelinestheseguidelinesalsolimittheamountofcredit exposure issuer despite strong financial profile certain contingent eventsif realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrange ment involve unconsolidated subsidiary provide financing potentially expose company unre cord financial obligation injulytheboardofdirectorsapprovedpurchasesovertimeofuptobillionofmerckshare totaltreasurystockpurchasedunderthisprograminwasbillionasofdecemberbillion remain stock repurchase authorization approve merck board director financial instrument market risk disclosure foreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment usdollarbase research develop menttotheextentthedollarvalueofcashflowsisdiminishedasaresultofastrengtheningdollarthecompanys ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatilityoffutureforeigncurrencycashflowsandchangesinfairvaluecausedbyvolatilityinforeignexchange rate objective revenue hedging program reduce potential longerterm unfavorable changesinforeignexchangetodecreasetheusdollarvalueoffuturecashflowsderivedfromforeigncurrency denominatedsalesprimarilytheeuroandjapaneseyentoachievethisobjectivethecompanywillpartiallyhedge anticipate thirdpartysalesthatareexpectedtooccuroveritsplanningcycletypicallynomorethanthreeyear intothefuturethecompanywilllayerinhedgesovertimeincreasingtheportionofsaleshedgedasitgetsclos totheexpecteddateofthetransactionsuchthatitisprobablethehedgedtransactionwilloccurtheportionofsale hedge base assessment costbenefit profile consider natural offset exposure revenue exchangeratevolatilitiesandcorrelationsandthecostofhedginginstrumentsthehedgedanticipatedsalesarea specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligationtosellforeigncurrenciesinthefutureatapredeterminedpriceiftheusdollarstrengthensrelativeto thecurrencyofthehedgedanticipatedsalestotalchangesintheoptionscashflowsfullyoffsetthedeclineinthe expectedfutureusdollarcashflowsofthehedgedforeigncurrencysalesconverselyiftheusdollarweaken theoptionsvaluereducestozerobutthecompanybenefitsfromtheincreaseinthevalueoftheanticipatedforeign currencycashflowswhileaweakerusdollarwouldresultinanetbenefitthemarketvalueofthecompany hedgeswouldhavedeclinedbymillionandmillionrespectivelyfromauniformweakeningofthe dollar december market value determine foreign exchange option pricing modelandholdingallfactorsexceptexchangeratesconstantbecause merckprincipally usespurchase localcurrencyputoptionsauniformweakeningoftheusdollarwillyieldthelargestoverallpotentiallossinthe marketvalueoftheseoptionsthesensitivitymeasurementassumesthatachangeinoneforeigncurrencyrelative totheusdollarwouldnotaffect otherforeigncurrencie relativetotheusdollaralthoughnotpredictivein naturethecompanybelievesthatathresholdreflectsreasonablypossibleneartermchangesinmercksmajor foreigncurrencyexposuresrelativetotheusdollarthecashflowsfromthesecontractsarereportedasoperating activity consolidate statement cash flow theprimaryobjectiveofthebalancesheetriskmanagementprogramistoprotecttheusdollarvalueof foreign currency denominate net monetary asset effect volatility foreign exchange occurpriortotheirconversiontousdollarsmerckprincipallyutilizesforwardexchangecontractswhichenable thecompanytobuyandsellforeigncurrencie inthefutureatfixedexchangeratesandeconomically offsetthe consequencesofchangesinforeignexchangeontheamountofusdollarcashflowsderivedfromthenetasset merckroutinelyentersintocontractstofullyoffsettheeffectsofexchangeonexposuresdenominatedindevelope country currency primarily euro japanese yen exposure develop country currency companywillenterintoforwardcontractsonamorelimitedbasisandonlywhenitisdeemedeconomicaltodoso basedonacostbenefitanalysisthatconsidersthemagnitudeoftheexposurethevolatilityoftheexchangerateand thecostofthehedginginstrumentthecompanywillalsominimizetheeffectofexchangeonmonetaryassetsand liability manage operating activity net asset positionsat local level company usesforward contract tohedgethechangesinfairvalue ofcertain foreigncurrencydenominate availableforsale security attributabletofluctuationsinforeigncurrencyexchangeratesasensitivityanalysistochangesinthevalueofthe usdollaronforeigncurrencydenominatedderivativesinvestmentsandmonetaryassetsandliabilitiesindicated thatiftheusdollaruniformlyweakenedbyagainstallcurrencyexposuresofthecompanyatdecember andincomebeforetaxeswouldhavedeclinedbymillionandmillionrespectivelybecause merckisinanetshortpositionrelativetoitsmajorforeigncurrenciesafterconsiderationofforwardcontractsa uniformweakeningoftheusdollarwillyieldthelargestoverallpotentialnetlossinearningsduetoexchange thismeasurementassumesthatachangeinoneforeigncurrencyrelativetotheusdollarwouldnotaffectother foreigncurrenciesrelativetotheusdollaralthoughnotpredictiveinnaturethecompanybelievesthata thresholdreflectsreasonablypossibleneartermchangesinmercksmajorforeigncurrencyexposuresrelativeto dollar cash flow contract report operating activity consolidate statement cash flow interest rate risk management inadditiontotherevenuehedgingandbalancesheetriskmanagementprogramsthecompanymayuse interestrateswapcontractsoncertaininvestingandborrowingtransactionstomanageitsnetexposuretointerest ratechangesandtoreduceitsoverallcostofborrowingthecompanydoesnotuseleveragedswapsandingeneral doesnotleverageanyofitsinvestmentactivitiesthatwouldputprincipalcapitalatriskatdecemberthe company party seven payfloate receivefixe interest rate swap contract designate fair value hedgesoffixedratenotesinwhichthenotionalamountsmatchtheamountofthehedgedfixedratenotesthere weretwoswapsmaturinginwithnotionalamountsofmillioneachoneswapmaturinginwitha notionalamountofmillionandfourswapsmaturinginwithnotionalamountsofmillioneachthe swapseffectivelyconvertthefixedrateobligationstofloatingrateinstrumentsinjanuaryandfebruarythe company terminate interest rate swap contract notional amount million effectivelyconverteditsfixedratenotesduetovariableratedebtasaresultoftheswaptermination thecompanyreceivedmillionincashexcludingaccruedinterestwhichwasnotmaterialthecorresponding gainsrelatedtothebasisadjustmentofthedebtassociatedwiththeterminatedswapcontractshavebeendeferre andwillbeamortizedasareductionofinterestexpenseovertheremainingtermofthenotesthecashflowsfrom contract report operating activity consolidate statement cash flow companysinvestment portfolio include cash equivalent shortterm investment market value significantly impact change interest rate market value company medium tolongterm fixedrate investment ismodestly impact bychange usinterest rate change medium longterm interest rate significant impact market value company fixedrateborrowingswhichgenerallyhavelongermaturitiesasensitivityanalysistomeasurepotentialchange inthemarketvalueofthecompanysinvestmentsdebtandrelatedswapcontractsfromachangeininterestrate indicatedthataonepercentagepointincreaseininterestratesatdecemberandwouldhavepositively impactedthenetaggregatemarketvalueoftheseinstrumentsbymillionandmillionrespectivelya onepercentagepointdecreaseatdecemberandwouldhavenegativelyimpactedthenetaggregate market value million million respectively fair value company debt determine pricing model reflect percentage point shift appropriate yield curve fair value company investment determine combination pricing duration model critical accounting policy matter consolidated financial statement include certain amount base management good estimatesandjudgmentsestimatesareusedindeterminingsuchitemsasprovisionsforsalesdiscountsandreturn depreciable amortizable life recoverability inventory produce preparation product launch amountsrecordedforcontingenciesenvironmentalliabilitiesandotherreservespensionandotherpostretirement benefit plan assumption sharebase compensation assumption amount record connection acqui sitionsimpairmentsoflonglivedassetsandinvestmentsandtaxesonincomebecauseoftheuncertaintyinherent insuchestimatesactualresultsmaydifferfromtheseestimatesapplicationofthefollowingaccountingpolicie result accounting estimate potential significant impact financial statement revenue recognition revenuesfromsalesofproductsarerecognizedwhentitleandriskoflosspassestothecustomerdueto changesintermsandconditionsfordomesticpharmaceuticalsalesinthefourthquarterofrevenuesforthese productspreviouslyrecognizedatthetimeofshipmentwererecognizedattimeofdeliveryconsistentwithmany foreignsubsidiariesandvaccinesalestherewasnosignificantimpactonrevenueinthefourthquarterofasa resultofthesechangesrecognitionofrevenuealsorequiresreasonableassuranceofcollectionofsalesproceed completion performance obligation domestically sale discount issue customer direct discountsatthepointofsaleorindirectlythroughanintermediarywholesalepurchaserknownaschargebacksor indirectlyintheformofrebatesadditionallysalesaregenerallymadewithalimitedrightofreturnundercertain conditionsrevenuesarerecordednetofprovisionsforsalesdiscountsandreturnswhichareestablishedatthetime sale theprovisionforaggregateindirectcustomerdiscountscoverschargebacksandrebateschargebacksare discountsthatoccurwhenacontractedcustomerpurchasesdirectlythroughanintermediarywholesalepurchaser thecontracte customergenerally purchasesproduct atitscontracted price plusamarkup fromthewholesaler wholesaler turn charge company difference price initially pay wholesalerandthecontractpricepaidtothewholesalerbythecustomertheprovisionforchargebacksisbasedon expectedsellthroughlevelsbythecompanyswholesalecustomerstocontractedcustomersaswellasestimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirementswithprivatesectorandpublicsectormedicaidandmedicarepartdbenefitprovidersafterthefinal dispensingoftheproductbyapharmacytoabenefitplanparticipanttheprovisionisbasedonexpectedpayment drive patient usage contract performance benefit provider customer thecompanyassumesafirstinfirstoutmovementofinventorywithinthesupplychainforpurposesof estimate aggregate indirect customer discount accrual addition company use historical customer segmentmixadjustedforotherknowneventsinordertoestimate theexpecte provisionamountsaccrue aggregate indirect customer discount evaluate quarterly basis comparison information providedbythewholesalersandothercustomerstotheamountsaccruedadjustmentsarerecordedwhentrendsor significant event indicate change estimate provision appropriate thecompanycontinuallymonitorsitsprovisionforaggregateindirectcustomerdiscountstherewere nomaterial adjustment toestimate associate withtheaggregateindirect customer discountprovisionin summarizedinformationaboutchangesintheaggregateindirectcustomerdiscountaccrualisasfollow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebatesascurrentliabilitiestheaccruedbalancesrelativetotheseprovisionsincludedinaccountsreceivableand accruedandothercurrentliabilitie weremillion andmillion respectivelyatdecember million million respectively december company maintain return policy allowsit customer return product specified periodpriortoandsubsequenttotheexpirationdategenerallysixmonthsbeforeandtwelvemonthsafterproduct expiration estimate provision return base historical experience actual return additionallythecompanyconsidersfactorssuchaslevelsofinventoryinthedistributionchannelproductdate expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision actual return net sale throughitsdistributionprogram withuswholesaler thecompanyencourage wholesaler toalign purchaseswithunderlyingdemandandmaintaininventorieswithinspecifiedlevelsthetermsoftheprogramallow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reducingproductreturnsinformationprovidedthroughthewholesalerdistributionprogramincludesitemssucha sale trend inventory onhand onorder quantity product return wholesalersgenerallyprovideonlytheabovementioneddatatothecompanyasthereisnoregulatory requirementtoreportlotlevelinformationtomanufacturerswhichisthelevelofinformationneededtodetermine remain shelf life original sale date ofinventorygiven current wholesaler inventorylevelswhichare generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch thecompanycapitalizesinventoriesproducedinpreparationforproductlaunchessufficienttosupport initialmarketdemandtypicallycapitalizationofsuchinventorydoesnotbeginuntiltherelatedproductcandidate areinphaseiiiclinicaltrialsandareconsideredtohaveahighprobabilityofregulatoryapprovalthecompany monitor status respective product regulatory approval process company generallydoesnotdisclosespecifictimingforregulatoryapprovalifthecompanyisawareofanyspecificrisksor contingenciesotherthanthenormalregulatoryapprovalprocessorifthereareanyspecificissuesidentifiedduring theresearchprocessrelatingtosafetyefficacymanufacturingmarketingorlabelingtherelatedinventorywould generallynotbecapitalizedexpirydatesoftheinventoryareimpactedbythestageofcompletionthecompany manage thelevelsofinventory ateach stagetooptimize theshelflife oftheinventory inrelation toanticipate marketdemandinordertoavoidproductexpiryissuesforinventoriesthatarecapitalizedanticipatedfuturesale andshelflivessupporttherealization oftheinventoryvalueastheinventoryshelflifeissufficienttomeetinitial productlaunchrequirementsinventoriesproducedinpreparationforproductlaunchescapitalizedatdecember significant contingency environmental liability companyis involve invariousclaim legal proceeding anature consider normal businessincludingproductliabilityintellectual propertyandcommerciallitigationaswellasadditionalmatter suchasantitrustactionsseenotetotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsfor contingency whenit isprobable aliability hasbeen incur bereasonably estimate theseaccrual areadjustedperiodically asassessmentschangeoradditional information becomesavailable productliabilityclaimsaportionoftheoverallaccrualisactuariallydeterminedandconsiderssuchfactorsaspast experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probableandreasonablyestimableasofjanuarythecompanyhadareserveofmillionsolelyforit future legal defense cost relate vioxx litigation define company spend millionintheaggregateinlegaldefensecostsrelatedtothevioxxlitigationandrecordedadditionalcharge ofmillionaccordinglyasofdecemberthecompanyhadareserveofmillionsolelyforit future legal defense cost relate vioxx litigation company spend million aggregate legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholderlawsuitsiiithevioxxforeignlawsuitsandivthevioxx investigation collectivelythevioxx litigation inthesecondquarterandthirdquarterofthecompanyrecordedchargesofmillionand million respectively increase reserve solely future legal defense cost relate vioxx litigationinincreasingthereservethecompanyconsideredthesamefactorsthatitconsideredwhenitpreviously establishedreservesforthevioxxlitigationonnovembermerckenteredintothesettlementagreement law firm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representatives plaintiff counsel texas new jersey california statecoordinate proceedingstoresolvestateandfederal miandisclaim filedasofthat dateinthe unitedstatesifcertainparticipationconditionsunderthesettlementagreementaremetorwaivedmerckwill payafixedaggregateamountintotwofundsforqualifyingclaimsthatenterintothesettlementprogramasaresult ofenteringintothesettlementagreementthecompanyrecordedapretaxchargeofbillionwhichrepresent fix aggregate pay plaintiff qualify payment settlement program fourthquarterofthecompanyspentapproximatelymillioninvioxxlegaldefensecostswhichresulte inareserveofmillionatdecemberforitsfuturelegaldefensecostsrelatedtothevioxxlitigation afterenteringintothesettlementagreementthecompanyrevieweditsreserveforthevioxxlegaldefensecost allocate approximately million reserve merck anticipate future cost administer settlement program someof significant factor consider reviewof reservewere asfollowsthe actual costsincurredbythecompanythedevelopment ofthecompanyslegaldefensestrategyandstructurein light scope vioxx litigation include settlement agreement expectation settlementagreementwillbeconsummatedbutthatcertainlawsuitswillcontinuetobependingthenumberof case bring company cost outcome complete trial current informationregardinganticipatedtimingprogressionandrelatedcostsofpretrialactivitiesandtrialsinthevioxx productliabilitylawsuitseventssuchasscheduledtrialsthatareexpectedtooccurthroughoutand andtheinherent inability topredict theultimate outcomesofsuchtrial andthedispositionofthevioxxproduct liability lawsuitsnot participate noteligible settlement program limit companysability reasonably estimate legal cost billion reserve settlement program aggregate reserve establish vioxx litigation december approximatelybillionwhilethecompanydoesnotanticipatethatitwillneedtoincreasethereserveevery quarteritwillcontinuetomonitoritslegaldefensecostsandreviewtheadequacyoftheassociatedreservesand maydeterminetoincreaseitsreservesforlegaldefensecostsatanytimeinthefutureifbaseduponthefactorsset forth believe appropriate company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict whetherthistrialwillproceedonscheduleorthetimingofanyoftheothervioxxshareholderlawsuittrialsthe companybelievesthatithasmeritoriousdefensestothevioxxlawsuitsandwillvigorouslydefendagainstthemin viewoftheinherentdifficultyofpredictingtheoutcomeoflitigationparticularlywheretherearemanyclaimant andtheclaimantsseekindeterminatedamagesthecompanyisunabletopredicttheoutcomeofthesemattersand time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation include case verdict judgment enter companyand nowin postverdict proceedingsoronappealineachofthosecasesthecompanybelievesithasstrongpointstoraiseonappealand thereforethatunfavorableoutcomesinsuchcasesarenotprobableunfavorableoutcomesinthevioxxlitigation material adverse effect company financial position liquidity result operation asofdecemberthecompanyhadaremainingreserveofapproximatelymillionsolelyfor future legal defense cost fosamax litigation significant factor consider establishmentofthereserveforthefosamaxlitigationlegaldefensecostswereasfollowstheactualcostsincurred company far development company legal defense strategy structure light creationofthefosamaxmultidistrict litigationthenumberofcasesbeingbroughtagainstthecompanyandthe anticipatedtimingprogressionandrelatedcostsofpretrialactivitiesinthefosamaxlitigationthecompanywill continuetomonitoritslegaldefensecostsandreviewtheadequacyoftheassociatedreservesduetotheuncertain nature litigation company unable estimate cost end company establishedanyreservesforanypotentialliabilityrelatingtothefosamaxlitigationunfavorableoutcomesinthe fosamaxlitigationcouldhaveamaterialadverseeffectonthecompanysfinancialpositionliquidityandresult operation companyis aparty toa number proceeding bring comprehensiveenvironmental response compensation liability act commonly know superfund federal state equiv alentswhenalegitimateclaimforcontributionisassertedaliabilityisinitiallyaccruedbasedupontheestimate transaction cost manage site accrual adjust feasibility study relate cost assessment remedialtechniquesarecompletedandastheextenttowhichotherpotentiallyresponsiblepartiesprpswho jointly severally liable expect contribute determine thecompanyisalsoremediatingenvironmentalcontaminationresultingfrompastindustrialactivityat certain ofit site take active role identify provide cost aworldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiatedestimatesoftheextentofcontaminationateachsitewereinitiallymadeatthepreinvestigationstageand liability forthepotential costofremediation wereaccruedatthattime asmoredefinitiveinformation availableduringthecourseofinvestigationsandorremedialeffortsateachsiteestimateswererefinedandaccrual adjust accordingly estimate related accrual continue refine annually thecompanybelievesthatitisincomplianceinallmaterialrespectswithapplicableenvironmentallaw regulation expenditure remediation environmental liability million estimate million year management opinion liability environmentalmattersthatareprobableandreasonablyestimablehavebeenaccruedandtotaledmillionand millionatdecemberanddecemberrespectivelytheseliabilitiesareundiscounteddo consider potential recovery party pay period remediation applicablesiteswhichareexpectedtooccurprimarilyoverthenextyearsalthoughitisnotpossibletopredict withcertaintytheoutcomeofthesemattersortheultimatecostsofremediationmanagementdoesnotbelievethat reasonably possible expenditure incur excess liability accrue exceed millionintheaggregatemanagementalsodoesnotbelievethattheseexpendituresshouldresultinamaterial adverseeffectonthecompanysfinancialpositionresultsofoperationsliquidityorcapitalresourcesforanyyear sharebased compensation thecompanyrecognizescompensationcostrelatingtosharebasedpaymenttransactionsinnetincome fairvalue measurement method accordance fas r adopt january fasrrequiresallsharebasedpaymentstoemployeesincludinggrantsofstockoptionstoberecognizedin net income compensation expense base fair value requisite service period award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumptionssuchastheriskfreeinterestrateexpectedvolatilityexpecteddividendyieldandexpectedlifeofthe option pension postretirement benefit plan netpensionandotherpostretirement benefitcosttotaledmillioninandmillion pensionandotherpostretirementbenefitplaninformationforfinancialreportingpurposesiscalculateduse actuarialassumptionsincludingadiscountrateforplanbenefitobligationsandanexpectedrateofreturnonplan asset thecompanyreassessesitsbenefitplanassumptionsonaregularbasisforboththepensionandother postretirementbenefitplansthediscountrateisevaluatedannuallyandmodifiedtoreflecttheprevailingmarket rateatdecemberofaportfolioofhighqualityfixedincomedebtinstrumentsthatwouldprovidethefuturecash flowsneededtopaythebenefitsincludedinthebenefitobligationastheycomedueatdecemberthe companychangeditsdiscountratetofromforitsuspensionplansanditsusotherpostretirement benefit plan expect rate return pension postretirement benefit plan represent averagerateofreturntobeearnedonplanassetsovertheperiodthebenefitsincludedinthebenefitobligationareto bepaidindevelopingtheexpectedrateofreturnthecompanyconsiderslongtermcompoundannualizedreturn ofhistoricalmarketdataaswellasactualreturnsonthecompanysplanassetsandappliesadjustmentsthatreflect morerecentcapitalmarketexperienceusingthisreferenceinformationthecompanydevelopsforwardlooking returnexpectationsforeachassetcategoryandaweightedaverageexpectedlongtermrateofreturnforatargete portfolioallocatedacrosstheseinvestmentcategoriestheexpectedportfolioperformancereflectsthecontribution ofactivemanagementasappropriateasaresultofthisanalysisforthecompanysexpectedrateofreturnof remain unchanged pension postretirement benefit plan thetargetinvestmentportfolioofthecompanysuspensionandotherpostretirementbenefitplansis allocate equities international equities fixedincome investment uptoincashand investment theportfoliosequity weight isconsistent withthe longterm nature oftheplansbenefit obligation theexpected annualstandarddeviation ofreturnsofthetarget portfoliowhichapproximatesreflectsboththeequityallocation andthediversificationbenefitsamongthe asset class portfolio invest actuarialassumptionsarebaseduponmanagementsbestestimatesandjudgmentareasonablypossible changeofplusminusbasispointsinthediscountrateassumptionwithotherassumptionsheldconstantwould haveanestimatedmillionfavorableunfavorableimpactonitsusnetpensionandpostretirementbenefit costareasonablypossiblechangeofplusminusbasispointsintheexpectedrateofreturnassumptionwith assumption hold constant estimate million favorable unfavorable impact usnetpensionandpostretirementbenefitcostthecompanydoesnotexpecttohaveaminimumpensionfunde requirementundertheinternalrevenuecodeduringtheprecedinghypotheticalchangesinthediscountrate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expectedandactualreturnsonplanassetsaswellastheeffectsofchangesinactuarialassumptionsarerecorde asacomponentofaccumulatedothercomprehensiveincomeexpectedreturnsarebasedonacalculatedmarket relatedvalueofassetsunderthismethodologyassetgainslossesresultingfromactualreturnsthatdifferfromthe companysexpecte return recognize inthe marketrelated value assetsratably fiveyear period alsonetlossamountsinaccumulatedothercomprehensiveincomeinexcessofcertainthresholdsareamortize net pension postretirement benefit cost average remain service life employee amortizationofnetlossesforthecompanysusplansatdecemberisexpectedtoincreasenetpension postretirement benefit cost approximately million annually acquisition thecompanyaccountsforacquiredbusinessesusingthepurchasemethodofaccountinginaccordance withfasbusinesscombinationswhichrequiresthattheassetsacquiredandliabilitiesassumedberecordedat thedateofacquisitionattheirrespectivefairvaluesanyexcessofthepurchasepriceovertheestimatedfairvalue ofnetassetsacquiredisrecordedasgoodwillifthecompanydeterminestheacquiredcompanyisadevelopment stagecompanywhichhasnotcommenceditsplannedprincipaloperationstheacquisitionwillbeaccountedforas anacquisitionofassetsratherthanasabusinesscombinationandthereforegoodwillwouldnotberecordedthe fairvalueofintangibleassetsincludingacquiredresearchisbasedonsignificantjudgmentsmadebymanagement accordingly significant item company typically obtain assistance party valuation specialist amount allocate acquire research expense date acquisition technological feasibilityhasnotbeenestablishedandnoalternativefutureuseexistsforprojectswhichcanbeusedimmediately research process alternative future use company capitalize intangible asset amortizesthemoveranappropriateusefullifethevaluationsandusefullifeassumptionsarebasedoninformation availableneartheacquisitiondateandarebasedonexpectationsandassumptionsthataredeemedreasonableby managementthejudgmentsmadeindeterminingestimatedfairvaluesassignedtoassetsacquiredandliabilitie assume asset live materially impact company result operation intangible asset include acquire research company typically use income approach whichestimatesfairvaluebasedoneachprojectsprojectedcashflowsfuturecashflowsarepredominatelybase onanetincomeforecastofeachprojectconsistentwithhistoricalpricingmarginsandexpenselevelsofsimilar product revenue estimate base relevant market size growth factor expect industry trend individualprojectlifecyclesandthelifeofeachresearchprojectsunderlyingpatentifanyexpectedrevenuesare thenadjustedfortheprobabilityoftechnicalandmarketingsuccessandtheresultingcashflowsarediscountedata riskadjuste discount rate impairment longlive asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry valuesofitslonglivedassetstobeheldandusedarerecoverableinaccordancewithfasaccountingforthe impairmentsordisposaloflonglive assetsifsuchcircumstance determine toexist estimate ofthe undiscountedfuturecashflowsoftheseassetsorappropriateassetgroupingsiscomparedtothecarryingvalueto determinewhetheranimpairmentexistsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthe difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach thecompanytestsitsgoodwillforimpairmentatleastannuallyinaccordancewithfasgoodwill andotherintangibleassetsusingafairvaluebasedtestgoodwillrepresentstheexcessofacquisitioncostsover fair value net asset business purchase assign reporting unit company segment acquire intangible record cost event circumstance warrant review company assess recoverability future operation intangible undiscounted cash flow derivedfromthelowestappropriateassetgroupingsgenerallythesubsidiarylevelimpairmentsarerecognizedin operatingresultstotheextentthatcarryingvaluesexceedfairvaluewhichisdeterminedbasedonthenetpresent value estimate cash flow impairment investment thecompanyreviewsitsinvestmentsforimpairmentsbasedonthedeterminationofwhetherthedecline market value investment carry value temporary company consider availableevidenceinevaluatingpotentialimpairmentsofitsinvestmentsincludingthedurationandextenttowhich fair value cost company ability intent hold investment tax income company effective tax rate base pretax income statutory tax rate tax planning opportunitiesavailableinthevariousjurisdictionsinwhichthecompanyoperatesanestimatedeffectivetaxrate forayearisappliedtothecompanysquarterlyoperatingresultsintheeventthatthereisasignificantunusualor onetime item recognize expect recognize company quarterly operating result tax attributabletothatitemwouldbeseparatelycalculate andrecordedatthesametimeastheunusualoronetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date accordance fasb interpretation accounting uncertaintyinincometaxesaninterpretationoffasbstatementnowhichmerckadoptedonjanuary thecompanyevaluatestaxpositionstodeterminewhetherthebenefitsoftaxpositionsaremorelikelythan notofbeingsustaineduponauditbasedonthetechnicalmeritsofthetaxpositionfortaxpositionsthataremore likely sustain audit company recognize large benefit greaterthanlikelyofbeingrealizeduponultimatesettlementinthefinancialstatementsfortaxpositionsthat likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectivelysettledthestatuteoflimitationsexpiresorifthemorelikelythannotthresholdismetinasubsequent period note consolidated financial statement taxregulationsrequireitemstobeincludedinthetaxreturnatdifferenttimesthantheitemsarereflecte financial statement time difference create defer tax asset liability defer tax asset generallyrepresentitemsthatcanbeusedasataxdeductionorcreditinthetaxreturninfutureyearsforwhichthe company record tax benefit financial statement company establish valuation allowancesforitsdeferredtaxassetswhentheamountofexpectedfuturetaxableincomeisnotlikelytosupportthe useofthedeductionorcredit deferredtaxliabilitie generally representtaxexpenserecognize inthefinancial statementsforwhichpaymenthasbeendeferredorexpenseforwhichthecompanyhasalreadytakenadeduction tax return recognize expense financial statement previously disclose ajca create temporary incentive multinational repatriate accumulatedincomeearnedoutsideoftheunitedstatesasofdecemberinconnectionwiththeajcathe companyrepatriatedbillionduringseenotetotheconsolidatedfinancialstatementsasaresultof thisrepatriationthecompanyrecordedanincometaxchargeofmillionintaxesonincomeinrelate repatriation charge partially offset million benefit associate decision implement certain tax planning strategy company change intention indefinitely reinv accumulate earning earn subsequent december december foreign earning billionhavebeenretainedindefinitelybysubsidiarycompaniesforreinvestmentnoprovisionwillbemade forincometaxesthatwouldbepayableuponthedistributionofsuchearningsanditisnotpracticabletodetermine relate unrecognized deferred income tax liability recently issue accounting standard inseptemberthefasbissuedstatementnofairvaluemeasurementsfaswhich clarifiesthedefinitionoffairvalueestablishesaframeworkformeasuringfairvalueandexpandsthedisclosure onfairvaluemeasurementsfaswasoriginallyeffectivejanuaryinfebruarythefasbissue staffpositionfspthatdeferre theeffectivedate offasforoneyearfornonfinancial assetsand liabilitiesrecordedatfairvalueonanonrecurringbasistheeffectofadoptionoffasandfsponthe company financial position result operation expect material infebruarythefasbissuedstatementnofasthefairvalueoptionforfinancialasset andfinancialliabilitiesincludinganamendmentoffasbstatementnofaswhichiseffective januaryfaspermitscompaniestochoosetomeasurecertainfinancialassetsandfinancialliabilitiesat fair value unrealize gain loss item fair value option elect report earningsateachsubsequentreportingdatetheeffectofadoptionoffasonthecompanysfinancialposition result operation expect material injunethefasbratifiedtheconsensusreachedbytheemergingissuestaskforceeitfon issuenoaccountingforadvancepaymentsforgoodsorservicesreceivedforuseinfutureresearchand development activity issue effective january apply prospectively new contractsenteredintoonoraftertheeffectivedateissueaddressesnonrefundableadvancepaymentsforgood orservicesthatwillbeusedorrenderedforfutureresearchanddevelopmentactivitiesissuewillrequirethese paymentsbedeferredandcapitalizedandrecognizedasanexpenseastherelatedgoodsaredeliveredortherelate service perform effect adoption issue company financial position result operation expect material indecemberthefasbissuedstatementsnorbusinesscombinationsfasrand noncontrolle interest consolidate financial statementsan amendment arb fas fas r expand scope acquisition accounting transaction control abusinessisobtainedamongotherthingsfasrrequiresthatcontingentconsiderationaswellascontingent asset liability record fair value acquisition date acquire inprocess research developmentbecapitalizedandrecordedasintangibleassetsattheacquisitiondateandalsorequirestransaction cost cost restructure acquire company expense fas require thing noncontrollinginterestsberecordedasequityintheconsolidatedfinancialstatementsfasrandfasare botheffectivejanuarythecompanyisassessingtheimpactsofthesestandardsonitsfinancialposition result operation cautionary factor affect future result thisreportandotherwrittenreportsandoralstatementsmadefromtimetotimebythecompanymay containsocalledforwardlookingstatementsallofwhicharebasedonmanagementscurrentexpectationsand subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan willestimatesforecastsprojectsandotherwordsofsimilarmeaningonecanalsoidentifythembythe factthattheydonotrelatestrictlytohistoricalorcurrentfactsthesestatementsarelikelytoaddressthecompany growth strategy financial result product development product approval product potential development program onemustcarefully consider anysuchstatement shouldunderstand manyfactor cause actualresultstodiffermateriallyfromthecompanysforwardlookingstatementsthesefactorsincludeinaccurate assumptionsandabroadvarietyofotherrisksanduncertaintiesincludingsomethatareknownandsomethatare forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefullyevaluatesuchstatementsinlightoffactorsincludingriskfactorsdescribedinthecompanysfilingswith thesecuritiesandexchangecommissionespeciallyonformskqandkinitemariskfactorsof annual report form kthe company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permittedbytheprivatesecuritieslitigationreformactofoneshouldunderstandthatitisnotpossibleto predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrumentsmarketriskdisclosuresinitemmanagementsdiscussionandanalysisoffinancialcondition result operation item financial statement supplementary datum financial statement theconsolidatedbalancesheetofmerckcoincandsubsidiariesasofdecemberandand therelatedconsolidatedstatementsofincomeofretainedearningsofcomprehensiveincomeandofcashflowsforeach ofthethreeyearsintheperiodendeddecemberthenotestoconsolidatedfinancialstatementsandthereport datedfebruaryofpricewaterhousecoopersllpindependentregisteredpublicaccountingfirmareasfollow consolidatedstatementofincome merck co inc subsidiary year end december millions share amount sale costsexpensesandother materialsandproduction marketingandadministrative researchanddevelopment restructuringcost equityincomefromaffiliate usvioxxsettlementagreementcharge otherincomeexpensenet incomebeforetaxe taxesonincome netincome basicearningspercommonshare earningspercommonshareassumingdilution consolidatedstatementofretainedearning merck co inc subsidiary year end december millions balancejanuary cumulativeeffectofadoptionoffin netincome dividendsdeclaredoncommonstock balancedecember consolidatedstatementofcomprehensiveincome merck co inc subsidiary year end december millions netincome othercomprehensiveincome netunrealizedlossgainonderivativesnetoftaxandnetincomerealization netunrealizedgainoninvestmentsnetoftaxandnetincomerealization benefitplannetgainlossandpriorservicecostcreditnetoftaxandamortization minimumpensionliabilitynetoftax cumulativetranslationadjustmentrelatingtoequityinvesteesnetoftax comprehensiveincome accompany note integral consolidated financial statement consolidate balance sheet merck co inc subsidiary december million asset current asset cash cash equivalent shortterm investment account receivable inventory exclude inventory classify assetssee note prepay expense taxis total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation goodwill intangible net asset liability andstockholder equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxesand noncurrent liability minority interest stockholder equity common stock cent par value authorize share issue share share paidin capital retain earning accumulate comprehensiveloss treasury stock cost share share total stockholder equity accompany note integral consolidated financial statement consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity vioxx settlement agreement charge depreciation amortization defer income taxis equity income affiliate dividend distribution equity affiliate sharebase compensation acquire research taxis pay internal revenue service settlement net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment acquisition subsidiary net cash acquire proceed sale security investment increase restrict cash net cash provide investing activity cash flow financing activity net change shortterm borrowing proceed issuance debt payment debt purchase treasury stock dividend pay stockholder proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note consolidated financial statement merck co inc subsidiarie million share amount nature operation merckisaglobal researchdrivenpharmaceutical companythatdiscoversdevelopsmanufacture marketsabroadrangeofinnovativeproductstoimprovehumanandanimalhealththecompanysoperationsare principallymanagedonaproductsbasisandarecomprisedoftworeportablesegmentsthepharmaceuticalsegment andthevaccinessegmentthepharmaceuticalsegmentincludeshumanhealthpharmaceuticalproductsmarkete directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarilytodrugwholesalersandretailershospitalsgovernmentagenciesandmanagedhealthcareproviderssuch health maintenance organization pharmacy benefit manager institution vaccine segment includeshumanhealthvaccineproductsmarketedeitherdirectlyorthroughajointventuretheseproductsconsist ofpreventivepediatricadolescentandadultvaccinesprimarilyadministeredatphysicianofficesmercksellsthese human health vaccine primarily physicians wholesaler physician distributor government entity companysprofessionalrepresentativescommunicatetheeffectivenesssafetyandvalueofitspharmaceuticaland vaccineproductstohealthcareprofessionalsinprivatepracticegrouppracticesandmanagedcareorganization summaryof accounting policy principle ofconsolidationtheconsolidate financial statement include theaccount ofthecom panyandallofitssubsidiariesinwhichacontrollinginterestismaintainedcontrollinginterestisdeterminedby majorityownershipinterestandtheabsenceofsubstantivethirdpartyparticipatingrightsorinthecaseofvariable interest entity majority exposure expect loss residual return consolidate subsidiarieswheremerckownershipislessthantheoutsidestockholdersinterestsareshownasminority interestsinvestmentsinaffiliatesoverwhichthecompanyhassignificantinfluencebutnotacontrollinginter interest entity own equally company party share control carry equity basis foreign currency translationthe dollar company functional currency cash equivalentscash equivalent comprise certain highly liquid investment original maturity month inventoriessubstantiallyalldomesticinventoriesarevaluedattheloweroflastinfirstoutlifo cost market book tax purpose foreign inventory value low firstin firstout fifo cost market inventory consist currently market product certain product await regulatoryapprovalinevaluate therecoverabilityofinventoriesproducedinpreparation forproductlaunche thecompanyconsiderstheprobabilitythatrevenuewillbeobtainedfromthefuturesaleoftherelatedinventory status product regulatory approval process investmentsinvestment classify availableforsale report fair value unrealize gainsorlossestotheextentnothedgedreportednetoftaxinaccumulatedothercomprehensiveincomeaoci investmentsindebtsecuritiesclassifiedasheldtomaturityconsistentwithmanagementsintentarereportedat costimpairmentlossesarechargedtootherincomeexpensenetforotherthantemporarydeclinesinfairvalue company consider available evidence evaluate potential impairment investment include durationandextenttowhichfairvalueislessthancostandthecompanysabilityandintenttoholdtheinvestment revenuerecognitionrevenuesfromsalesofproductsarerecognizedwhentitleandriskoflosspasse tothecustomerduetochangesintermsandconditionsfordomesticpharmaceuticalsalesinthefourthquarterof revenue product previously recognize time shipment recognize time deliveryconsistentwithmanyforeignsubsidiariesandvaccinesalestherewasnosignificantimpactonrevenuein thefourthquarterofasaresultofthesechangesrecognitionofrevenuealsorequiresreasonableassuranceof collectionofsalesproceedsandcompletionofallperformanceobligationsdomesticallysalesdiscountsareissue customer direct discount pointofsale indirectly intermediary wholesale purchaser knownaschargebacksorindirectly intheformofrebatesadditionallysalesaregenerally madewithalimite right return certain condition revenuesare record net provision sale discount return whichareestablishedatthetimeofsaleaccrualsforchargebacksarereflectedasadirectreductiontoaccount receivable accrual rebate record accrue expense accrue balance relative provision include account receivable accrue current liability million million respectively december million million respectively december companyrecognize revenue sale vaccine federal government placement intostockpilesrelatedtothepediatricvaccinestockpileinaccordancewithsecuritiesandexchangecommission secinterpretationcommissionguidanceregardingaccounting forsalesofvaccinesandbioterrorcoun termeasurestothefederalgovernmentforplacementintothepediatricvaccinestockpileorthestrategicnational stockpile depreciationdepreciationisprovidedovertheestimatedusefullivesoftheassetsprincipallyuse thestraightlinemethodfortaxpurposesacceleratedmethodsareusedtheestimatedusefullivesprimarilyrange year building year machinery equipment office furnishing softwarecapitalizationthecompanycapitalizescertaincostsincurredinconnectionwithobtaine ordevelopinginternaluse softwareincludingexternal direct costsofmaterial andservicesandpayrollcostsfor employee directly involve software development accordance statement position accountingforthecostsofcomputersoftwaredevelopedorobtainedforinternalusecapitalizedsoftwarecost include propertyplant equipment amortize period range year begin asset substantially ready use cost incur preliminary project stage post implementationstageaswellasmaintenanceandtrainingcostsareexpensedasincurredatdecember company approximately million unamortized capitalize software cost relate multiyear initiative standardize information system acquisitionsthecompanyaccountsforacquiredbusinessesusingthepurchasemethodofaccounte inaccordancewithfinancialaccountingstandardsboardfasbstatementnobusinesscombination require asset acquire liability assume record date acquisition respective fair value excess purchase price estimate fair value net asset acquire recordedasgoodwillifthecompanydeterminestheacquiredcompanyisadevelopmentstagecompanywhichhas notcommence itsplannedprincipal operation theacquisition willbeaccounte forasanacquisition ofasset thanasabusinesscombination andtherefore goodwillwouldnotberecorde inaccordancewithfasb interpretation applicability fasb statement business combination account purchase method company allocate amount acquire research expense date acquisition technological feasibility establish alternative future use exist project whichcanbeusedimmediatelyintheresearchprocessthathavealternativefutureusesthecompanycapitalize intangible asset amortize appropriate useful life operating result acquire businessarereflectedinthecompanysconsolidatedfinancialstatementsandresultsofoperationsasofthedateof acquisition goodwillandotherintangiblesgoodwillrepresentstheexcessofacquisitioncostsoverthefairvalue ofnetassetsofbusinessespurchasedgoodwillisassignedtoreportingunitswithinthecompanyssegmentsand evaluate forimpairment onatleastanannualbasisusingafairvaluebasedtestotheracquiredintangiblesare recordedatcostandareamortizedonastraightlinebasisovertheirestimatedusefullivesrangingfromtoyear seenotewheneventsorcircumstanceswarrantareviewthecompanywillassessrecoverabilityfromfuture operationsofotherintangiblesusingundiscountedcashflowsderivedfromthelowestappropriateassetgrouping generally subsidiary level impairment recognize operating result extent carry value exceed fair value determine base net present value estimate future cash flow researchanddevelopmentresearchanddevelopmentisexpensedasincurredupfrontandmilestone payment party connection research development collaboration prior regulatory approvalareexpensedasincurredpaymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalized amortize shorter remaining license product patent life sharebase compensationeffective january company adopt fasb statement r sharebase payment fas r note fas r require sharebase payment employeesincludinggrantsofstockoptionstobeexpensedovertherequisiteserviceperiodbasedonthegrant date fair value award require unvested portion outstanding award adoption recognizedusingthesamefairvalueandattributionmethodologiespreviouslydeterminedunderfasbstatement noaccountingforstockbasedcompensationthecompanyusestheblackscholesvaluationmethodprior toadoptionoffasremployee sharebasedcompensation wasrecognize usingtheintrinsicvalue method whichmeasuressharebasedcompensationexpenseastheamountatwhichthemarketpriceofthestockatthedate grant exceed exercise price accordingly compensation expense recognize company sharebase compensation plan performancebase award restrict stock unit option grant employee certain equity method investee restructuringcoststhecompanyrecordsrestructuringactivitiesinaccordancewithfasbstatement noaccountingforcostsassociatedwithexitordisposalactivitiesassetimpairmentcostsarerecordedin accordance fasb statement accounting impairment disposal longlive asset employee termination benefit cover exist benefit arrangement record accordance fasb statementnoemployersaccountingforpostemploymentbenefitsanamendmentoffasbstatementno andandfasbstatementnoemployersaccountingforsettlementsandcurtailmentsofdefinedbenefit pension plan termination benefit contingency legal defense coststhe company record accrual contingency legal defensecostsexpectedtobeincurredinconnectionwithalosscontingencywhenitisprobablethataliabilityha beenincurredandtheamountcanbereasonablyestimatedinaccordancewithfasbstatementnoaccounte contingency taxis incomedeferre taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax positionstodeterminewhetherthebenefitsoftaxpositionsaremorelikelythannotofbeingsustaineduponaudit basedonthetechnicalmeritsofthetaxpositionfortaxpositionsthataremorelikelythannotofbeingsustaine audit company recognize large benefit great likely realizeduponultimatesettlementinthefinancialstatementsfortaxpositionsthatarenotmorelikelythannotof beingsustaineduponauditthecompanydoesnotrecognizeanyportionofthebenefitinthefinancialstatement use estimatesthe consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount basedonmanagementsbestestimatesandjudgmentsestimatesareusedindeterminingsuchitemsasprovision sale discount return depreciable amortizable life recoverability inventory produce preparationforproductlaunchesamountsrecordedforcontingenciesenvironmentalliabilitiesandotherreserve pension postretirement benefit plan assumption sharebase compensation amount record connection acquisition impairment longlive asset investment tax income uncertainty inherent estimate actual result differ estimate reclassificationscertainreclassificationshavebeenmadetoprioryearamountstoconformwiththe current year presentation recently issue accounting standardsthe fasb recently issue statement fair value measurement fas statement fair value option financial asset financial liabilitiesincluding amendment fasb statement fas statement r business combinationsfasrstatementnononcontrollinginterestsinconsolidatedfinancialstatement anamendmentofarbnofasandratifiedtheconsensusreachedbytheemergingissuestaskforce eitfonissuenoaccountingforadvancepaymentsforgoodsorservicesreceivedforuseinfuture research development activity issue fas clarifie definition fair value establishe framework measure fair value expandsthedisclosuresonfairvaluemeasurementsfaswasoriginallyeffectivejanuaryinfebruary thefasbissuedstaffpositionfspthatdeferredtheeffectivedateoffasforoneyearfor nonfinancialassetsandliabilitiesrecordedatfairvalueonanonrecurringbasistheeffectofadoptionoffas fsp company financial position result operation expect material faswhichiseffectivejanuarypermitscompaniestochoosetomeasurecertain financial assetsandfinancialliabilitiesatfairvalueunrealizedgainsandlossesonitemsforwhichthefairvalueoptionhas beenelectedarereportedinearningsateachsubsequentreportingdatetheeffectofadoptionoffasonthe company financial position result operation expect material eitf issue effective january apply prospectively new contract enteredintoonoraftertheeffectivedateaddressesnonrefundableadvancepaymentsforgoodsorservicesthatwill render future research development activity issue require payment deferredandcapitalizedandrecognizedasanexpenseastherelatedgoodsaredeliveredortherelatedservicesare performedtheeffectofadoptionofissueonthecompanysfinancialpositionandresultsofoperationsisnot expect material fas r expand scope acquisition accounting transaction control businessisobtainedamongotherthingsfasrrequiresthatcontingentconsiderationaswellascontingent asset liability record fair value acquisition date acquire inprocess research developmentbecapitalizedandrecordedasintangibleassetsattheacquisitiondateandalsorequirestransaction cost cost restructure acquire company expense fas require thing noncontrollinginterestsberecordedasequityintheconsolidatedfinancialstatementsfasrandfasare botheffectivejanuarythecompanyisassessingtheimpactsofthesestandardsonitsfinancialposition result operation restructure global restructuring program innovemberthecompanyannouncedtheinitialphaseofaglobalrestructuringprogramdesigne toreducethecompanyscoststructureincreaseefficiencyandenhancecompetitivenesstheinitialstepsinclude theimplementation ofanewsupplystrategybythemerckmanufacturingdivisionwhichisintendedtocreatea lean costeffective customerfocused manufacturing model threeyear period programmerckannouncedplanstosellorclosefivemanufacture sitesandtwopreclinical sitesbytheendof thecompanyhasalsosoldorclose certain otherfacilitie andsoldrelate assetsinconnection withthe restructuringprogramthepretaxcostsofthisrestructuringprogramweremillioninmillion million expect approximately million million throughtheendofwhentheinitialphaseoftheglobalrestructuringprogramisexpectedtobesubstantially completethecumulativepretaxcostsoftheprogramareexpectedtobeapproximatelybilliontobillion approximatelyofthecumulativepretaxcostsarenoncashrelatingprimarilytoaccelerateddepreciationfor thosefacilitiesscheduledforclosuresincetheinceptionoftheglobalrestructuringprogramthroughdecember thecompanyhasrecordedtotalpretaxaccumulatedcostsofbillionandeliminatedapproximately position comprise employee separation elimination contractor vacant position companyhowevercontinuestohirenewemployeesasthebusinessrequiresforsegmentreportingrestructure charge unallocated expense thefollowingtablesummarizesthechargesrelatedtotheglobalrestructuringprogrambytypeofcost separation accelerate year end december cost depreciation total material production research development restructuring cost year end december material production research development restructuring cost year end december material production research development restructuring cost separationcostsareassociatedwithactualheadcountreductionsaswellasthoseheadcountreduction whichwereprobableandcouldbereasonablyestimatedapproximatelypositionspositionsand positionswereeliminatedinandrespectivelythesepositioneliminationsarecomprisedofactual headcount reduction elimination contractor vacant position accelerateddepreciationcostsprimarilyrelatetothefivemerckownedmanufacturingfacilitiesandthe twopreclinicalsitestobesoldorclosedinanefforttoreducecostsandconsolidatethecompanysmanufacture andresearchfacilitiesthroughtheendoffourofthemanufacturingfacilitieshadbeenclosedsoldorhad ceasedoperationsandthetwopreclinicalsiteswereclosedtheremainingfacilitywassoldinjanuaryallof thesitescontinuedtooperateupthroughtherespectiveclosuredatesandsincefuturecashflowsweresufficientto recovertherespectivebookvaluesmerckwasrequiredtoacceleratedepreciationofthesiteassetsratherthanwrite immediately site asset include manufacture research facility equipment activity include million million million respectivelyassociatedwiththeimpairmentofcertainfixedassetsthatwerenolongertobeusedinthebusinessasa result restructure action write additionally activity include million million million respectively relate curtailment settlementandterminationchargesonthecompanyspensionandotherpostretirementbenefitplansseenote otheractivityalsoincludesshutdowncostsandinpretaxgainsofmillionresultingfromthesalesof facility connection global restructuring program restructuring program costreduction program complete company eliminate position record restructuring cost million million relate employee severance benefitsandmillionrelatedtocurtailmentsettlementandterminationchargesonthecompanyspensionand postretirement benefit plan note follow table summarize charge spend relate theglobal restructure program program separation accelerate cost depreciation total restructure reserve january expense payment receipt net noncash activity restructure reserve december expense payment receipt net noncash activity restructure reserve december includesseparationcostsassociatedwiththeglobalrestructuringprogramaswellasamountsfromotherrestructuringprogramstheother restructuringprogramsweresubstantiallycompleteasoftheendofthefirstquarterof includesproceedsfromthesalesoffacilitiesinconnectionwiththeglobalrestructuringprogram thecashoutlaysassociatedwiththeremainingrestructuringreserveareexpectedtobelargelycompletedbytheendof company close basic research center terling park united kingdom anticipation closing company incur additional accelerate depreciation cost million recordedtoresearchanddevelopmentexpenseduringwhichreducedtheassetsofthisresearchcenterdown net realizable value subsequent december research development perform site research collaboration acquisition license agreement merck continue strategy establish strong external alliance complement substantial internal research capability include research collaboration acquisition license preclinical clinical compoundsandtechnologytransferstodrivebothnearandlongtermgrowthduringmercksignedsuch agreement november merck gtx inc gtx announce enter agreement provide research development global strategic collaboration selective androgen receptor modulatorssarmsanewclassofdrugswiththepotentialtotreatagerelatedmusclelosssarcopeniaaswell musculoskeletal condition collaboration include gtxs lead sarm candidate ostarine mk currently evaluate phase ii clinical trial treatment muscle loss patient cancer establish broad sarm collaboration gtx merck pool programsandpartnertodiscoverdevelopandcommercializecurrentaswellasfuturesarmmoleculesaspartof thisglobalagreementmerckwillberesponsibleforallfuturecostsassociatedwithongoingdevelopmentandif approvedcommercializationofostarineandotherinvestigationalsarmsresultingfromthecollaborationunder thetermsofthecollaborationagreementandrelatedstockpurchaseagreementgtxandmerckwillcombinetheir respective sarm research programs gtx receive upfront payment million record merckasresearchanddevelopmentexpenseandwillalsoreceivemillioninresearchreimbursementstobe paidovertheinitialthreeyearsofthecollaborationinadditionmerckmadeaninvestmentofmillioningtx commonstockgtxwillalsobeeligibletoreceiveuptomillioninfuturemilestonepaymentsassociatedwith thedevelopmentandapprovalofadrugcandidate ifmultiple indicationsreceiveregulatoryapprovaladditional milestone received development approval collaboration drug candidate gtx receive royalty result worldwide product revenue november merck dynavax technologies corporation dynavax announce globallicenseanddevelopmentcollaborationagreementtojointlydevelopvanovelinvestigationalhepatitisb vaccinewhichiscurrentlybeingevaluatedinamulticenterphaseiiiclinicaltrialinvolvingadultsandinpatient ondialysisunderthetermsoftheagreementmerckreceivesworldwideexclusiverightstovwillfundfuture vaccine development responsible commercialization dynavax receive initial payment millionwhichthecompanyrecordedasresearchanddevelopmentexpenseandwillbeeligibletoreceive uptomillionindevelopmentandsalesmilestonepaymentsanddoubledigittieredroyaltiesonglobalsalesof v september merck complete acquisition novacardia inc novacardia privately heldclinicalstagepharmaceuticalcompanyfocusedoncardiovasculardiseasethisacquisitionaddedrolofylline mknovacardiasinvestigationalphaseiiicompoundforacuteheartfailuretomerckspipelinemerck acquire outstanding equity novacardia total purchase price million include millionofcashandinvestmentsonhandatclosingwhichwaspaidthroughtheissuanceofmillionshare ofmerckcommonstocktotheformernovacardiashareholdersbasedonmercksaverageclosingstockpricefor thefivedayspriortoclosingoftheacquisitioninconnectionwiththeacquisitionthecompanyrecordedacharge million acquire research associate rolofylline acquisition date technological feasibilityhadnotbeenestablishedandnoalternativefutureuseexistedthechargewhichisnotdeductiblefortax purposeswasrecordedinresearchanddevelopmentexpenseandwasdeterminedbaseduponthepresentvalueof expectedfuturecashflowsresultingfromthistechnologyadjustedfortheprobabilityofitstechnicalandmarkete successutilizinganincomeapproachreflectinganappropriateriskadjusteddiscountrateoftheongoe activity respect future development rolofylline expect material company research development expense remain purchase price allocate cash investment millionadeferredtaxassetrelatingtoanetoperatinglosscarryforwardofmillionandothernetasset million novacardia development stage company commence plan principal operation transaction account acquisition asset business combinationandthereforegoodwillwasnotrecordednovacardiasresultsofoperationshavebeenincludedin company consolidate financial result acquisition date injulymerckandariadpharmaceuticalsincariadannouncedthattheyhadenteredinto global collaboration jointly develop commercialize deforolimus mk ariad novel mtor inhibitorforuseincancereachpartywillfundofthecostofglobaldevelopmentofmkexceptthat merckwillfundofthecostofexusdevelopmentthatisspecifictothedevelopmentorcommercialization ofmkoutsidetheusthatisnotcurrentlypartoftheglobaldevelopmentplantheagreementprovidedfor aninitialpaymentofmilliontoariadwhichthecompanyrecordedasresearchanddevelopmentexpense uptomillion inmilestone payment toariadbase onthe successful development ofmkin multiplecancerindicationsincludingmillionpaidfortheinitiationofthephaseiiiclinicaltrialinmetastatic sarcomas million pay initiation phaseii phase iiiclinical trial additional million base achievement significant sale threshold million estimate contributionsbymercktoglobaldevelopmentuptomillionininterestbearingrepayabledevelopmentcost advance merck cover portion ariad share globaldevelopment cost ariad pay million global development cost potential commercial return profit share royalty pay merck outside ariad distribute sell mk cancer indication ariad merck copromote receive income sale outside merck distribute sell promote mk merck pay ariadtiered doubledigit royalty endmarket sale mk ondecembermerckcompletedtheacquisitionofsirnatherapeuticsincsirnaforper shareincashforatotalvalueofapproximatelybillionwhichincludedthepurchaseofalloutstandingsirna shareswarrantsandstockoptionstheaggregatepurchasepriceofbillionwaspaidonjanuaryand accordinglyisreflecte asaliability withinaccruedandothercurrent liability inthe companysconsolidate balance sheet december sirna publiclyheld biotechnology company leader developinganewclassofmedicinesbasedonrnainterferencernaitechnologywhichcouldsignificantly alterthetreatmentofdiseasernaibasedtherapeuticsselectivelycatalyzethedestructionofthernatranscribe fromanindividualgenetheacquisitionofsirnaisexpectedtoincreasemercksabilitytousernaitechnologyto turnoffatargetedgeneinahumancellpotentiallyrenderinginoperativeageneresponsiblefortriggeringaspecific diseasethetransactionwasaccountedforunderthepurchasemethodofaccountinginwhichtheassetsacquire andtheliabilitiesassumedfromsirnaatthedateofacquisitionwererecordedattheirrespectivefairvaluesasofthe acquisition date company consolidate financial statement determination fair value require managementtomakesignificantestimatesandassumptionstheexcessofthepurchasepriceoverthefairvalueof acquire net asset record goodwill million goodwill fully allocate pharmaceutical segment deductible tax purpose company record charge millionforacquiredresearchassociatedwithsirnascompoundscurrentlyunderdevelopmentforwhich attheacquisitiondatetechnologicalfeasibilityhadnotbeenestablishedandnoalternativefutureuseexistedthe acquiredresearchchargerelatedtothedevelopmentoftreatmentsforboththehepatitisbandhepatitiscviruse whichwereandcurrently remain inpreclinical development aswellaslicense agreement heldbysirnathe charge deductible tax purpose record research development expense determine baseduponthepresentvalueofexpectedfuturecashflowsofnewproductcandidatesresultingfrom technology adjust probability technical marketing success utilize income approach reflectingappropriateriskadjusteddiscountratesoftotheongoingactivitywithrespecttoeachof compoundsunder development isnotexpecte tobematerial tothe companysresearch anddevelopment expense allocation purchase price result recognition intangible asset million relate defer tax liability million asset liabilities netofmilliontheintangibleassetrelatestosirnasdevelopedtechnologythatcanbeusedimmediatelyin theresearch anddevelopmentprocessandhasalternativefutureusesthisintangible assetisbeingamortize research development expense straightline basis seven year useful life pro forma financial informationisnotrequiredbecausesirnashistoricalfinancialresultsarenotsignificantwhencomparedwiththe company financial result transaction close december accordingly sirnas operating result include company result operation begin january november company expand scope exist strategic collaboration foxhollow technology inc foxhollow atherosclerotic plaque analysis acquire stake foxhollow exist strategic collaboration enter provide foxhollow receive upfrontpaymentwiththeopportunityforadditionalpaymentsifthecollaborationcontinuedunderthetermsofthe expandedcollaborationagreementpaymentsaremadetofoxhollowoverfouryearsinexchangeforfoxhollow agreement collaborate exclusively merck specify disease area merck provide funding foxhollow year year collaboration program term research activity conduct foxhollow merck direction foxhollow receive milestone payment successful development drug product diagnostic test utilize result collaboration royalty octoberevincevaglobalmedicaldevicecompanyfocusedoncatheterbasedtechnologiesforthe endovascular treatment vascular disease disorder merge foxhollow time foxhollow whollyowne subsidiary ev connection merger company share foxhollow wereconvertedintosharesofevcommonstocktheinvestmentinevisrecordedasacostmethodinvestmentin december consolidated balance sheet june company acquire outstanding equity glycofi inc glycofi approximatelymillionincashmillionpurchasepricenetofmillioninsharesalreadyownedandnet transaction cost glycofi privatelyheld biotechnology company leader field yeast glycoengineere addition specific carbohydrate modification protein yeast optimizationofbiologicdrugmoleculesglycofistechnologyplatformisusedinthedevelopmentofglycoprotein asthe optimization ofaglycoprotein targetinconnection withthe acquisition companyrecorde charge million acquire research associate glycofis technology platform research development process acquisition date technological feasibility establishedandnoalternativefutureuseexistedthischargeisnotdeductiblefortaxpurposesthetechnologyis currently beingutilize inmerckspipeline ofbiologic thechargewasrecorde inresearch anddevelopment expenseandwasdeterminedbaseduponthepresentvalueofexpectedfuturecashflowsofnewproductcandidate resultingfromthistechnologyadjustedfortheprobabilityofitstechnicalandmarketingsuccessutilizinganincome approach reflect appropriate riskadjuste discount rate company record million intangible assetmillion netofdeferre taxesrelate toglycofisdevelopedtechnology canbeuse immediatelyintheresearchanddevelopmentprocessandhasalternativefutureusesthisintangibleassetisbee amortizedtoresearchanddevelopmentexpenseonastraightlinebasisoverafiveyearusefullifetheremaine netassetsacquiredinthistransactionwerenotmaterialbecauseglycofiwasadevelopmentstagecompanythat hadnotcommenceditsplannedprincipaloperationsthetransactionwasaccountedforasanacquisitionofasset business combination goodwill record glycofis result operation include company consolidate financial result acquisition date inmaythecompanyacquiredalloftheequityofabmaxisincabmaxisforapproximately million cash abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody mab product human therapeutic diagnostic abmaxis develop validate breakthrough antibody engineering technology platform abmaxis insilico immuni zationwhichhasalternativefutureusestothecompanywithnosignificanttechnologicalorengineeringrisksat thedateofacquisitioninconnectionwiththeacquisitionthecompanyallocatedsubstantiallyallofthepurchase price abmaxis technology platform record intangible asset million million net defer taxesthisintangible assetisbee amortize toresearch anddevelopment expenseonastraightline basisoverafiveyearusefullifetheremainingnetassetsacquiredinthistransactionwerenotmaterialbecause abmaxis development stage company commence plan principal operation transaction account acquisition asset business combination goodwillwasnotrecordedabmaxisresultsofoperation havebeeninclude withthecompanysconsolidate financial result acquisition date merck idera pharmaceutical idera announce form broad collaboration research develop commercialize idera tolllike receptor agonist use combination merck therapeutic prophylactic vaccine development oncology infectious disease alzheimersdiseaseadditionallyinmerckandambriliabiopharmaincambriliaabiopharmaceutical companydevelopinginnovativetherapeuticsinthefieldsofcancerandinfectiousdiseasesannouncedtheyentere exclusive licensing agreement grant merck worldwide right ambrilias hivaid protease inhibitorprogramalsoinneuromedpharmaceutical ltdandmercksignedaresearchcollaboration license agreement research develop commercialize novel compound treatment pain neurological disorder agensys inc agensys cancer biotechnology company merck announce formation global alliance jointly develop commercialize agspsca agensys fully human mab toprostatestemcellantigenalsoinmerckenteredintoanagreementwithgeroncorporationtodevelopa cancervaccineagainsttelomeraseanenzymeactiveinmostcancercellsthatmaintainstelomerelengthattheends chromosome allow cancer grow metastasize long period time financial instrument foreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment usdollarbase research develop menttotheextentthedollarvalueofcashflowsisdiminishedasaresultofastrengtheningdollarthecompanys ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatilityoffutureforeigncurrencycashflowsandchangesinfairvaluecausedbyvolatilityinforeignexchange rate objective revenue hedging program reduce potential longerterm unfavorable changesinforeignexchangetodecreasetheusdollarvalueoffuturecashflowsderivedfromforeigncurrency denominatedsalesprimarilytheeuroandjapaneseyentoachievethisobjectivethecompanywillpartiallyhedge anticipate thirdpartysalesthatareexpectedtooccuroveritsplanningcycletypicallynomorethanthreeyear intothefuturethecompanywilllayerinhedgesovertimeincreasingtheportionofsaleshedgedasitgetsclos totheexpecteddateofthetransactionsuchthatitisprobablethatthehedgedtransactionwilloccurtheportionof saleshedgedisbasedonassessmentsofcostbenefitprofilesthatconsidernaturaloffsettingexposuresrevenueand exchangeratevolatilitiesandcorrelationsandthecostofhedginginstrumentsthehedgedanticipatedsalesarea specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligationtosellforeigncurrenciesinthefutureatapredeterminedpriceiftheusdollarstrengthensrelativeto thecurrencyofthehedgedanticipatedsalestotalchangesintheoptionscashflowsfullyoffsetthedeclineinthe expectedfutureusdollarcashflowsofthehedgedforeigncurrencysalesconverselyiftheusdollarweaken theoptionsvaluereducestozerobutthecompanybenefitsfromtheincreaseinthevalueoftheanticipatedforeign currency cash flow thedesignatedhedgerelationshipisbasedontotalchangesintheoptionscashflowsaccordinglythe entirefairvaluechangeintheoptionsisdeferredinaociandreclassifiedintosaleswhenthehedgedanticipate revenueisrecognizedthehedgerelationshipishighlyeffectiveandhedgeineffectivenessisdeminimisthefair valuesofpurchasedcurrencyoptionsarereportedinaccountsreceivableorotherassetsthecashflowsfromthese contract report operating activity consolidate statement cash flow theprimaryobjectiveofthebalancesheetriskmanagementprogramistoprotecttheusdollarvalueof foreign currency denominate net monetary asset effect volatility foreign exchange occurpriortotheirconversiontousdollarsmerckprincipallyutilizesforwardexchangecontractswhichenable thecompanytobuyandsellforeigncurrencie inthefutureatfixedexchangeratesandeconomically offsetthe consequencesofchangesinforeignexchangeontheamountofusdollarcashflowsderivedfromthenetasset merckroutinelyentersintocontractstofullyoffsettheeffectsofexchangeonexposuresdenominatedindevelope country currency primarily euro japanese yen exposure develop country currency companywillenterintoforwardcontractsonamorelimitedbasisandonlywhenitisdeemedeconomicaltodoso basedonacostbenefitanalysisthatconsidersthemagnitudeoftheexposurethevolatilityoftheexchangerateand thecostofthehedginginstrumentthecompanywillalsominimizetheeffectofexchangeonmonetaryassetsand liability manage operating activity net asset position local level foreigncurrencydenominatedmonetaryassetsandliabilitiesareremeasuredatspotratesineffectonthe balance sheetdatewiththeeffectsofchangesinspotratesreportedinotherincomeexpensenettheforward contractsarenotdesignatedashedgesandaremarkedtomarketthroughotherincomeexpensenetaccordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward differencesthesedifferencesarenotsignificantduetotheshorttermnatureofthecontractswhichtypicallyhave average maturity inception year company use forward contract hedge change fair value certain foreign currency denominatedavailableforsalesecuritiesattributabletofluctuationsinforeigncurrencyexchangerateschangesin thefairvalueofthehedgedsecuritiesduetofluctuationsinspotratesareoffsetinotherincomeexpensenetby thefairvaluechangesintheforwardcontractsattributabletospotratefluctuationshedgeineffectivenesswasnot material change contract fair value spotforward difference exclude fromthedesignated hedgerelationship andrecognize inotherincome expensenetthese amount significant year end december thefairvaluesofforwardexchangecontractsarereportedinthefollowingfourbalancesheetlineitem accountsreceivablecurrentportionofgainpositionotherassetsnoncurrentportionofgainpositionaccrue andothercurrentliabilitie currentportionoflosspositionordeferredincometaxesandnoncurrentliabilitie noncurrentportionoflosspositionthecashflowsfromthesecontractsarereportedasoperatingactivitiesinthe consolidated statement cash flow interest rate risk management company use interest rate swap contract certain investing borrowing transaction manageitsnetexposuretointerestratechangesandtoreduceitsoverallcostofborrowingthecompanydoesnot use leveraged swap general leverage investment activity principal capital risk atdecemberthecompanywasapartytosevenpayfloatingreceivefixedinterestrateswap contractsdesignatedasfairvaluehedgesoffixedratenotesinwhichthenotionalamountsmatchtheamountofthe hedgedfixedratenotestherearetwoswapsmaturinginwithnotionalamountsofmillioneachone swap mature notional million swap mature notional amountsofmillioneachtheswapseffectivelyconvertthefixedrateobligationstofloatingrateinstrument thefairvaluechangesinthenotesarefullyoffsetininterestexpensebythefairvaluechangesintheswapcontract fair value contract report account receivable asset accrue current liabilitiesordeferredincometaxesandnoncurrentliabilitiesthecashflowsfromthesecontractsarereporteda operating activity consolidate statement cash flow fair value financial instrument summarize carry value fair value companys financial instrument decemberandfairvalueswereestimatedbasedonmarketpriceswhereavailableordealerquote carry value fair value carry value fair value asset cash cash equivalent shortterm investment longterm investment purchase currency option forward exchange contract interest rate swap liabilitie loan payable current portion longterm debt longterm debt write currency option forward exchange contract asummaryofthedecembercarryingvaluesandfairvaluesofthecompanysinvestmentsandgross unrealize gain loss companys availableforsale investment record net tax aoci follow gross unrealized carry fair value value gain loss corporate note bond government agency security mortgagebacke security municipal security assetbacke security foreign government bond commercial paper debt security equity security theamountofgrossunrealize lossesthatwereinacontinuouslosspositionformorethanmonths de minimis gross unrealize carry fair value value gain loss corporate note bond government agency security commercial paper municipal security mortgagebacke security assetbacke security foreign government bond repurchase agreement debt security equity securities availableforsaledebtsecuritiesmaturingwithinoneyeartotaledbillionatdecemberof remain debt security billion mature year availableforsale investment december december include million andmillionrespectivelyofaaaratedmortgagebackedsecuritiesissuedorunconditionallyguaranteeda payment principal interest government agency million million respectively assetbacke security substantially highlyrate standard poor rate aaaor moodysinvestorsserviceratingofaaasecuredprimarilybycreditcardautoloanandhomeequity receivables weightedaverage live primarily year concentration credit risk aspartofitsongoingcontrolproceduresthecompanymonitorsconcentrationsofcreditriskassociate withcorporateissuersofsecuritiesandfinancialinstitutionswithwhichitconductsbusinessweplaceourcashand investmentsininstrumentsthatmeethighcreditqualitystandardsasspecifiedinourinvestmentpolicyguideline credit riskisminimal ascredit exposurelimit areestablishe toavoidaconcentration withanysingleissueror institution customer represent aggregate approximately onesixth company account receivableatdecemberthecompanymonitorsthecreditworthinessofitscustomerstowhichitgrant credit term normal course business bad debt minimal company normally require collateral security support credit sale inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost recognize inventory asset inventory value lifo method comprise approximately inventory december respectively amount recognize asset comprise entirely raw materialsandworkinprocessinventoriesrepresentinginventoriesforproductsnotexpectedtobesoldwithinone year majority vaccine intangible intangible december consist patent product right total acquire cost patent product right total accumulate amortization reflect intangible record connection acquisition sirna glycofi abmaxis seenoteaggregateamortizationexpensewasmillioninmillioninandmil lion estimate aggregate amortization expense year follow million million million million million joint venture equity method affiliate equityincomefromaffiliatesreflectstheperformanceofthecompanysjointventuresandotherequity method affiliate comprise follow year end december merckscheringplough astrazeneca lp primarilyreflectsresultsfrommeriallimitedsanofipasteurmsdandjohnsonjohnsonmerckconsumerpharmaceuticalscompany merckscheringplough company scheringplough corporation scheringplough collectively ner enter agreement create separate equallyowne partnership develop market unitedstatesnewprescriptionmedicinesinthecholesterolmanagement andrespiratorytherapeuticareasthese agreementsgenerallyprovideforequalsharingofdevelopmentcostsandforcopromotionofapprovedproductsby company cholesterolmanagement partnership agreement expand include countriesoftheworldexcludingjapaninezetimibethefirstinanewclassofcholesterolloweringagent waslaunchedintheunitedstatesaszetiamarketedasezetroloutsidetheunitedstatesinacombination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states cholesterol agreement provide share operating income generate merck scheringplough cholesterol partnership msp partnership base percentage vary product saleslevelandcountryintheusmarketthepartnersshareprofitsonzetiaandvytorinsalesequallywiththe exception million annual zetia sale scheringplough receive great share profitsoperatingincomeincludesexpensesthatthepartnershavecontractuallyagreedtosharesuchasaportion ofmanufacturingcostsspecificallyidentifiedpromotioncostsincludingdirecttoconsumeradvertisinganddirect identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msppartnership share partner market administrative expense include certain sale force cost certain manufacturing costsare include inequity income affiliate howeverthese cost reflect inthe overall result company certain research development expense generally share equally partner adjust earn milestone note information respect litigation involve msp partnership partner relate sale promotion zetia vytorin respiratory therapeutic agreement provide joint development marketing united states partner oncedaily fixedcombination tablet contain active ingredient montelukast sodium loratadine montelukast sodium leukotriene receptor antagonist sell merck assingulairandloratadineanantihistamineissoldbyscheringploughasclaritinbothofwhichareindicatedfor thereliefofsymptomsofallergicrhinitisinaugustthepartnersannouncedthatthenewdrugapplication filingformontelukastsodiumloratadinehadbeenacceptedbytheusfoodanddrugadministrationfdafor standardreviewthepartnersareseekingusmarketingapprovalofthemedicinefortreatmentofallergicrhinitis symptom patient whowant relief nasal congestion summarize financial information msp partnership follow year end december sale vytorin zetia material production cost expense net income taxis merck share income taxis december total asset total liability mercksshareofthemsppartnershipsincomebeforetaxesdiffersfromtheequityincomerecognizedfromthemsppartnershipprimarily duetothetimingofrecognitionofcertaintransactionsbetweenthecompanyandthemsppartnership amountsarecomprisedalmostentirelyofcurrentbalance astrazeneca lp merck enter agreement astra ab astra develop market astra productsunderaroyaltybearinglicenseinthecompanystotalsalesofastraproductsreachedalevelthat triggeredthefirststepintheestablishmentofajointventurebusinesscarriedonbyastramerckincamiin whichmerckandastraeachownedasharethisjointventureformedindevelopedandmarketedmost astrasnewprescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining inmerckandastracompletedtherestructuringoftheownershipandoperationsofthejointventure company acquire astras interest ami rename kbi inc kbi contribute kbis operatingassetstoanewuslimitedpartnershipastrapharmaceuticalslpthepartnershipinexchangefora limitedpartnerinterestastracontributedthenetassetsofitswhollyownedsubsidiaryastrausainctothe partnershipinexchangeforageneralpartnerinterestthepartnershiprenamedastrazeneca lpazlp uponastrasmergerwithzenecagroupplctheastrazenecamergerbecametheexclusivedistributorof products kbi retain right maintain limited partner interest azlp merck consent protective right intendedtopreserveitsbusinessandeconomicinterestsincludingrestrictionsonthepowerofthegeneralpartnerto makecertaindistributionsordispositionsfurthermoreinlimitedeventsofdefaultadditionalrightswillbegrante tothecompanyincludingpowerstodirecttheactionsoforremoveandreplacethepartnershipschiefexecutive officerandchieffinancialofficermerckearnsongoingrevenuebasedonsalesofcurrentandfuturekbiproduct revenuewa billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return providedforinthepartnershipagreementvariablereturnsbasedinpartuponsalesofcertainformerastrausa inc product preferential return represent merck share undistribute azlp gaap earning astrazeneca merger trigger partial redemption mercks limited partnership interest redemption azlp distribute kbi base primarily multiple merck average annual variablereturnsderivedfromsalesoftheformerastrausaincproductsforthethreeyearspriortotheredemption limited partner share agree value conjunction restructure payment million record deferred income astra purchase option asset option buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi product asset option exercisable half exercise price equal net present value march project future pretax revenue receive company kbi product appraise value merckalsohadtherighttorequireastratopurchasesuchinterestinattheappraisedvalueinfebruary thecompanyadvisedazlpthatitwillnotexercisetheassetoptioninadditioninthecompanygrante astra option buy merck common stock interest kbi merck interest nexium prilosecexercisabletwoyearsafterastraspurchaseofmercksinterestinthenonppiproductstheexerciseof thisoptionbyastraisalsoprovidedforintheyearorifcombinedannualsalesofthetwoproductsfallbelowa minimum providedin case solong astrazenecasoption hasbeen exercise exercisepriceisbasedonthenetpresentvalueofestimatedfuturenetsalesofnexiumandprilosecasdeterminedat time exercise subject certain trueup mechanism theastrazenecamergerconstitutedatriggereventunderthekbirestructuringagreementsasa resultofthemergerinexchangeformercksrelinquishmentofrightstofutureastraproductswithnoexistingor pendinguspatentsatthetimeofthemergerastrapaidmilliontheadvancepaymentwhichissubject trueup calculation require repayment portion determine trueup calculation trueup directly dependent onthe fair market value oftheastraproductrightsretainedbythecompanyaccordinglyrecognitionofthiscontingentincomehas beendeferreduntiltherealizableamountisdeterminableininthecompanyreclassifiedthisamountto accruedandothercurrentliabilitiesfromnoncurrentliabilitiesasthistrueupcalculationwilloccurbeforetheend second quarter undertheprovisionsofthekbirestructuringagreementsbecauseatriggereventhasoccurredthesum ofthelimitedpartnershareofagreedvaluetheappraisedvalueandthetrueupamountisguaranteedtobea minimumofbilliondistributionofthelimitedpartnershareofagreedvalueandpaymentofthetrueup amountwilloccurinthefirsthalfofandsuchamountsareanticipatedtorepresentasubstantialportionofthe billionthesepaymentswillresultinapretaxgainestimatedtobebilliontobillionastrazenecas purchase ofmercksinter inthenonppiproductsiscontingent upontheexercise ofastrazenecasoptionin payment appraise value occur connection restructure ami company assume billion par value preferredstockobligationwithadividendrateofperannumwhichiscarriedbykbiandincludedinminority interestswhileasmallportionofthepreferredstockcarriedbykbiisconvertibleintokbicommonsharesnone ofthepreferredsecuritiesareconvertibleintothecompanyscommonsharesandthereforetheyarenotinclude ascommonsharesissuableforpurposesofcomputingearningspercommonshareassumingdilutionseenote merial limited merck rhnepoulenc sanowsanofiaventis sacombine animal health poultrygeneticsbusinessestoformmeriallimitedmerialafullyintegratedanimalhealthcompanywhichisa standalonejointventureequallyownedbyeachpartymerialprovidesacomprehensiverangeofpharmaceutical vaccine enhance health wellbeing performance ofawide range animal specie merial sale billion billion billion sanofi pasteur msd inmerckandpasteurmrieuxconnaughtnowsanofipasteursaestablishedanequallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion million million johnson johnsonmerck consumer pharmaceutical company inmerckformedajointventurewithjohnsonjohnsontodevelopandmarketabroadrangeof nonprescriptionmedicinesforusconsumersthisownedventurewasexpandedintoeuropeinandinto canada merck sell equity stake european joint venture johnson johnson merckwillcontinuetobenefitthroughroyaltiesoncertainproductsandalsoregainedtherightstopotentialfuture productsthatswitchfromprescriptiontooverthecounterstatusineuropesalesofproductsmarketedbythejoint venture million million million investment affiliate account equity method include joint venture totaledbillionatdecemberandbillionatdecembertheseamountsarereportedin asset summarizedinformationforthoseaffiliatesexcludingthemsppartnershipdisclosedseparatelyabove follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability noncurrent liability loan payable longterm debt commitment duringthecompanyreclassifiedthebillionastranotedueinfromlongtermdebtto loan payable current portion longterm debt loan payable december include millionandmillionrespectivelyoflongdatednotesthataresubjecttorepaymentattheoptionof holder annual basis loan payable december include million note annualinterestrateresetswhichwereredeemedbythecompanyinuponnotificationfromtheremarkete agent overall rise interest rate exercise annual option remarket note additionallyloanspayableatdecemberincludedmillionoffixedratenoteswhichmaturedin indecemberaforeignsubsidiaryofthecompanyenteredintoanmonthmillionlineofcredit withafinancialinstitutionatdecemberandborrowingsunderthelineofcreditweremillion andmillionrespectivelyandareincludedinloanspayabletheweightedaverageinterestrateforallofthese borrowing include loan payable december respectively longterm debt december consist note note debenture note debenture note debenture astra note variablerate borrowing thecompanywasapartytointerestrateswapcontractswhicheffectivelyconvertthe fixedrate note floatingrate instrument note inseptember thecompanyredeemed itsmillionvariablerate borrowingsthat wereduein present table december consist primarily million million respectively borrowing variable rate average respectivelyoftheseborrowingsmillionaresubjecttorepaymentattheoptionoftheholdersbeginningin million subject repayment option holder begin year include foreign borrowing vary rate aggregate maturity longterm debt year follow billion million million million million rental expense company operating lease net sublease income million theminimumaggregaterentalcommitmentsundernoncancellableleasesareasfollowsmillion million million millionmillionandthereaftermillion company significant capital lease contingency environmental liability companyis involve invariousclaim legal proceeding anature consider normal businessincludingproductliabilityintellectual propertyandcommerciallitigationaswellasadditionalmatter suchasantitrustactionsthecompanyrecordsaccrualsforcontingencie whenitisprobablethataliability beenincurredandtheamountcanbereasonablyestimatedtheseaccrualsareadjustedperiodicallyasassessment changeoradditionalinformationbecomesavailableforproductliabilityclaimsaportionoftheoverallaccruali actuarially determinedandconsiderssuchfactorsaspastexperiencenumberofclaimsreportedandestimatesof claim incur report individually significant contingent loss accrue probable reasonablyestimablelegaldefensecostsexpectedtobeincurredinconnectionwithalosscontingencyareaccrue probable reasonably estimable thecompanysdecisiontoobtaininsurancecoverageisdependentonmarketconditionsincludingcost andavailabilityexistingatthetimesuchdecisionsaremadeasaresultofanumberoffactorsproductliability insurancehasbecomelessavailablewhilethecosthasincreasedsignificantlythecompanyhasevaluateditsrisk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august includingliabilityforproductsfirstsoldafterthatdatethecompanywillcontinuetoevaluateitsinsuranceneed cost availability benefit product liability insurance future vioxx litigation product liability lawsuit previously disclose individual putative class action file company stateandfederalcourtsallegingpersonalinjuryandoreconomiclosswithrespecttothepurchaseoruseofvioxx allsuchactionsfiledinfederalcourtarecoordinatedinamultidistrictlitigationintheusdistrictcourtforthe easterndistrictoflouisianathemdlbeforedistrictjudgeeldonefallonanumberofsuchactionsfiledin statecourtarecoordinatedinseparatecoordinatedproceedingsinstatecourtsinnewjerseycaliforniaandtexas andthecountiesofphiladelphiapennsylvaniaandwashoeandclarkcountiesnevadaasofdecember thecompanyhadbeenservedorwasawarethatithadbeennamedasadefendantinapproximatelylawsuit whichincludeapproximatelyplaintiffgroupsallegingpersonalinjuriesresultingfromtheuseofvioxxand approximately putative class action allege personal injury andor economic loss action discussedinthisparagrapharecollectivelyreferredtoasthevioxxproductliabilitylawsuitsoftheselawsuit approximately lawsuit represent approximately plaintiff group slate federalmdlandapproximatelylawsuitsrepresentingapproximatelyplaintiffgroupsareincludedin coordinate proceed new jersey superior court judge carol e higbee inadditiontothevioxxproductliability lawsuitsdiscussedabovetheclaim ofoverplaintiff hadbeendismissedasofdecember ofthesetherehavebeenoverplaintiffswhoseclaimswere dismissedwithprejudiceietheycannotbebroughtagaineitherbyplaintiffsthemselvesorbythecourtsover additionalplaintiffshavehadtheirclaimsdismissedwithoutprejudiceiesubjecttotheapplicablestatuteof limitation bring merck enter tolling agreement tolling agreement mdl plaintiff steer committeepscthatestablishedaproceduretohalttherunningofthestatuteoflimitationstollingastocertain category ofclaim allegedly arisingfromthe useofvioxx bynonnewjerseycitizens tolling agreement appliedtoindividualswhohavenotfiledlawsuitsandmay ormaynoteventually filelawsuitsandonlytothose claimantswhoseektotollclaimsalleginginjuriesresultingfromathromboticcardiovasculareventthatresultsina myocardialinfarctionmiorischemicstrokeisthetollingagreementprovidedcounseladditionaltimeto evaluate potential claim tolling agreement require toll claim file federal court decemberapproximatelyclaimantshadenteredintotollingagreementsthepartiesagreedthat april deadline filing tolling agreement additional tolling agreement accept november merck announce enter agreement settlement agreement law firm comprise executive committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceedingstoresolvestateandfederalmiandisclaimsfiledasofthatdateintheunitedstatesthesettlement agreementwhichalsoappliestotolledclaimswassignedbythepartiesafterseveralmeetingswiththreeofthe fourjudgesoverseeingthecoordination ofmorethanpercent ofthecurrentclaim inthevioxx litigation definedbelowthesettlementagreementappliesonlytouslegalresidentsandthosewhoallegethattheirmior occur united states certain participation condition settlement agreement meet condition waivedbymerckmerckwillpayafixedaggregateamountofbillionintotwofundsforqualifyingclaimsthat enter resolution process settlement program individual claimant examine admin istrator ofthe settlement program todetermine qualification base onobjectivedocumented fact provide claimantsincludingrecordssufficientforascientificevaluationofindependentriskfactorstheconditionsinthe settlementagreementalsorequireclaimantstopassthreegatesaninjurygaterequiringobjectivemedicalproofof anmioriseachasdefinedinthesettlementagreementadurationgatebasedondocumentedreceiptofatleast vioxx pill proximity gate require receipt pill sufficient number proximity event support presumption ingestion vioxx day claim injury settlement agreement provide merck admit causation fault merck payment obligationsunderthesettlementagreementwillbetriggeredonlyifamongotherconditionslawfirmsonthe federalandstatepscsandfirmsthathavetriedcasesinthecoordinatedproceedingselecttorecommendenrollmentin theprogramtopercentoftheirclientswhoallegeeithermiorisandbymarchsubjecttoextension plaintiffsenrollinthesettlementprogramatleastpercentofeachofallcurrentlypendingandtolledimiclaim iiisclaimsiiieligiblemiandisclaimstogetherwhichinvolvedeathandiveligiblemiandisclaimstogether allege month use company right towaive participation condition underthesettlementagreementmerckwillcreateseparatefundsintheamountofbillionformi claimsandmillionforisclaimsoncetriggeredmerckstotalpaymentforbothfundsofbillionisafixe amounttobeallocatedamongqualifyingclaimantsbasedontheirindividualevaluationwhileatthistimetheexact numberofclaimantscoveredbythesettlementagreementisunknownthetotaldollaramountisfixedpaymentsto individual qualifying claimantscould beginas early august pay period time merck retain right terminate process payment claimant defend claim individuallyattrialifanyoftheaforementionedparticipationconditionsinthesettlementagreementarenotmet settlement agreement announce november judges federal mdl california texasandnewjerseystate coordinate proceedingsentered aseriesoforderstheorderstem porarily stay respective litigation require plaintiff register claim january requireplaintiffswithcasespendingasofnovembertopreserveandproducerecordsandserveexpert reportsandrequireplaintiffswhofilethereaftertomakesimilarproductionsonanaccelerate schedulethe clark county nevada coordinate proceeding generally stay asoffebruarymorethanplaintiffshadsubmittedregistrationmaterialsincludingmore thanplaintiffswhoallegeanmiorisinadditionasoffebruarymorethanclaimantshave startedsubmittingenrollmentmaterialstheregistrationandenrollmentmaterialscurrentlyarebeingevaluatedfor eligibilityaccuracyandcompletenesstheclaimsadministratorcontinuestoreceivenewmaterialsfromplaintiffs company previously disclose outcome vioxx product liability lawsuit try prior september chart followingset forth result trial certain significant ruling occur fourth quarter respect vioxx product liability lawsuit october jury kozic v merck case try state court tampa florida found unanimously favor merck count reject claim company wasliable plaintiff heart attackindecemberplaintifffiledanappealbutagreedtoanorderstayingallotherposttrialactivitypende entry settlement program january judge victoria chaney declare mistrial consolidated trial case appellvmerckandarrigalevmerckwhichhadcommencedonoctoberincaliforniastatecourtinlos angelesafterthejuryindicatedthatitcouldnotreachaverdictjudgechaneyhadrescheduledtheretrialofthe combine trial appell arrigale january case stay inaprilinatrialinvolvingtwoplaintiffsthomasconaandjohnmcdarbyinsuperiorcourtof newjerseylawdivisionatlanticcountythejuryreturnedasplitverdictthejurydeterminedthatvioxxdidnot substantially contribute heart attack mr cona substantially contribute heart attack mr mcdarby jury conclude case merck violate new jerseys consumer fraud statute whichallowsplaintiffstoreceivetheirexpensesforpurchasingthedrugtrebledaswellasreasonableattorney fee jury award million compensatory damage mr mcdarby wife plaintiffinthat case punitivedamage million onjune judge higbee deny merck motion new trial june judge higbee award approximately million aggregate attorneysfeesandcoststhecompanyhasappealedthejudgmentsinbothcasesandtheappellatedivisionheld oral argument case january onmarchajuryfoundformerckonallcountsinschwallervmerckwhichwastriedinstate court madison county illinois plaintiff move new trial plaintiff file supplementalmotionforanewtrialonseptemberondecemberjudgestacksignedaconsent order stay posttrial activity case march ondecemberthejuryinalbrightvmerckacasetriedinstatecourtinbirminghamalabama returnedaverdictformerckonallcountsplaintiffappeale injulytothealabamasupremecourtbutin december plaintiff agree stay appeal pende entry settlement program april judge randy wilson presides texas vioxx coordinate proceeding dismissedthefailuretowarnclaimofplaintiffrubyledbetterwhosecasewasscheduledtobetriedonmay judge wilson rely texas statute enact provide failure warn regardingaprescriptionmedicineifthemedicineisdistributedwithfdaapprovedlabelingthereisanexception inthestatuteifrequiredmaterial andrelevantinformationwaswithheldfromthefdathatwouldhaveledtoa different decision approve labeling judge wilson find exception preempt federal law fda find information withhold judge wilson currently preside approximatelyvioxxsuitsintexasinwhichaprincipalallegationisfailuretowarnjudgewilsoncertifie thedecisionforanexpeditedappealtothetexascourtofcivilappealsplaintiffshaveappealedthedecisionon october merck file motion abate hearing appeal supreme courts decision warner lambert v kent decide october texas court appealsdeniedmercksmotiontoabatethepartiesarecurrentlybriefingtheappealthecompanyexpectsoral argument set spring injulyindohertyvmerckinsuperiorcourtofnewjerseylawdivisionatlanticcountyajury returnedaverdictinfavorofthecompanyonallcountsthejuryrejectedaclaimbytheplaintiffthathernearly threeyearsofvioxxusecausedherheartattackthejuryalsofoundinmercksfavorontheplaintiffsconsumer fraudclaimplaintifffiledamotionforanewtrialinaugustondecemberjudgehigbeedenie plaintiff motion new trial prejudice light plaintiff express intention participate settlement program aconsolidatedtrialhermansvmerckandtheretrialofhumestonvmerckbeganonjanuaryin thecoordinatedproceedinginnewjerseysuperiorcourtbeforejudgehigbeehumestonvmerckwasfirsttriedin resultinginajuryverdictinfavorofmerckonnovemberhoweveronaugustjudgehigbee set aside november jury verdict order new trial thegroundsof newly discover evidence thehermanshumestontrialwasseparatedintotwophasesageneralphaseregardingmercksconduct aplaintiffspecific phaseonmarchthe juryfoundformerckinthegeneral phaseonthe hermans failuretowarnclaimandtheconsumerfraudclaimwassubsequentlysubmittedtojudgehigbeefordecisionon march jury find plaintiff humeston case award compensatory damage mr humeston million mrs humeston million jury awardedmillioninpunitivedamagesmerckhasmovedforajudgmentnotwithstandingtheverdictanew trialorreductionoftheawardtheseandotherposttrialmotionsarecurrentlypendingondecember court dismiss motion new trial prejudice herman onjulythenewjerseyappellate divisionunanimouslyupheldjudgehigbeesdismissalof vioxxproductliabilitylawsuitsbroughtbyresidentsoftheunitedkingdomplaintiffshadaskedthenewjersey supremecourttoreviewthedecisiononnovemberthenewjerseysupremecourtdeclinedtoreview decision merckvoluntarilywithdrewvioxxfromthemarketonseptembermoststateshavestatutesof limitationsforproductliabilityclaimsofnomorethanthreeyearswhichrequirethatclaimsmustbefiledwithinno morethanthreeyearsaftertheplaintiffslearnedorcouldhavelearnedoftheirpotentialcauseofactionasaresult somemayviewseptemberasasignificantdeadlineforfilingvioxxcasesitisimportanttonotehowever thatthelawregardingstatutesoflimitation canbecomplexandvariable dependingonthefactsandapplicable lawsomestateshavelongerstatutesoflimitationstherearealsoargumentsthatthestatutesoflimitationsbegan run september new jersey superior court judge higbee federal district court judge fallonhaveissuedordersincasesfromnewjerseyandeightotherjurisdictionsrulingthatthestatutoryperiodfor makingvioxxpersonalinjuryclaimshaspassedjudgehigbeesorderwasissuedonoctoberandjudge fallon issue november thefollowingchartsetsforththeresultsofallusvioxxproductliabilitytrialstodatejurieshavenow decidedinfavorofthecompanytimesandinplaintiffsfavorfivetimesonemerckverdictwassetasidebythe courtandhasnotbeenretriedanothermerckverdictwassetasideandretriedleadingtooneofthefiveplaintiff verdictstherehavebeentwounresolvedmistrialswithrespecttothefiveplaintiffsverdictsmerckhasfiledan appealorsoughtjudicialreviewineachofthosecasesandinoneofthosefiveafederaljudgereducedthedamage award trial certain plaintiff trial list eligible settlement program stateor federal verdictdate plaintiff court result comment aug ernst texas verdict forplaintiff juryawardedplaintiffmillion thecourtreducedamountto approximately million plus interest thejudgmentisnowon appeal novand humeston newjersey verdict formerck inthetrial thejuryfoundfor march thenjudgesetaside merck inaugustthecourtset theverdictorderinga asidetheverdict andorderedanew newtrialwhich trialforjanuary resultedinaverdict attheconclusion ofthetrial forplaintiff thejuryawardedplaintiffatotalof million indamage thejury alsoawardedplaintiffthenominal sumofontheir consumer fraudactclaim merckhasmove forajudgmentnotwithstande verdict areducedverdictamount foranewtrialthesemotionsarestill pende decand plunkett federal verdict formerck merckprevailedinthefebruary feb judgethensetaside retrial thecourtsetasidethe theverdict februaryverdict inmay nodatehasbeensetforanewtrial april mcdarby nj verdict forplaintiff plaintiffwasawardedmillion damagesinjunethecourt awardedplaintiffsinthisandthe conaclaim triedwithit approximately million inattorney feesandcost merckhasappeale thejudgmentinclude theawardof attorneysfeesandcost stateor federal verdictdate plaintiff court result comment april cona nj verdict formerckon thejuryfoundformerckonthe failuretowarnclaim failuretowarnclaim thejury awardedplaintiffthenominalsumof forhisconsumerfraudact claim injunethecourt awardedplaintiffsinthisandthe mcdarbyclaim try withit approximately million inattorney feesandcost merckhasappeale thejudgmentinclude theawardof attorneysfeesandcost april garza texas verdict forplaintiff judgereducedmillion juryaward tomillion plusinterestmerck filedanappealonmarch july doherty nj verdict formerck thecourtdeniedthemotion fornew trialwithoutprejudice pende plaintiffsentryintothesettlement program aug grossberg california verdict formerck plaintiffsmotionforanewtrial deniedandhissubsequentappealwas dismiss aug barnett federal verdict forplaintiff juryawardedplaintiffmillion damagesthejudgeruledtheaward wasgrosslyexcessiveandreduce theawardtomillion merckha appeal thejudgmenttothecourtof appeals sept smith federal verdict formerck nov mason federal verdict formerck dec dedrick federal verdict formerck plaintiffsmotionforanewtrial deniedinmay dec albright alabama verdict formerck plaintiffappealed injulytothe alabamasupremecourtbutin decemberplaintiffagreedto stayhisappealpendinghisentryinto thesettlement program jan arrigaleappell california mistrialdeclare juryfaile toreturnverdictsincase thejurydeadlocke filedbytwoplaintiffswhoallege vioxxcontributedtotheirheart attack thesecasesarenowstaye march hermans newjersey verdict formerckon thejuryfoundformerckonthe thefailuretowarn failuretowarnclaim thepartie claim submittedtheconsumerfraudact claim tothecourtforresolutionthis remainspendingbutsubjecttothe stay march schwaller illinois verdict formerck plaintiffmovedforanewtrial decemberjudgestack signedaconsentorderstayingall posttrialactivityinthecaseuntil march oct kozic florida verdict formerck indecemberplaintifffiledan appealbutagreedtoanorderstaye allotherposttrialactivitypendinghis entryintothesettlement program lawsuit aspreviouslydisclosedonjulyanewjerseystatetrialcourtcertifiedanationwideclassof thirdpartypayorssuchasunionsandhealthinsuranceplansthatpaidinwholeorinpartforthevioxxusedbytheir planmembersorinsuredsthenamedplaintiffinthatcasesoughtrecoveryofcertain vioxxpurchasecostsplus penaltiesbasedonallegationsthatthepurportedclassmemberspaidmoreforvioxxthantheywouldhavehadthey know product allege risk march new jersey superior court appellate division affirm class certification order september new jersey supreme court reverse certificationofanationwideclassactionofthirdpartypayorsfindingthatthesuitdoesnotmeettherequirement class action claim certain individual thirdparty payor remain pende new jersey court counselpurportingtorepresentalargenumberofthirdpartypayorshasthreatenedtofilenumerousadditionalsuch action activity pende case currently stay pende court putative class action purportedly bring behalf individual purchaser user vioxx claim reimbursement allege economic loss entitlement medical monitoring case early procedural stage class certifiedinnewjerseythetrialcourtdismissedthecomplaintinthecaseofsinclairapurportedstatewidemedical monitoringclasstheappellatedivisionreversedthedismissalandtheissueisnowonappealtothenewjersey supreme court court hear argument october aspreviouslyreportedthecompanyhasalsobeennamedasadefendantinseparatelawsuitsbroughtby theattorneysgeneralofsevenstatesandthecityofnewyorkacoloradotaxpayerhasalsofiledaderivativesuit onbehalfofthestateofcoloradonamingthecompanytheseactionsallegethatthecompanymisrepresentedthe safety vioxx seek recovery cost vioxx purchase reimburse state agency iireimbursementofallsumspaidbythestateanditsagenciesformedicalservicesforthetreatmentofperson injure vioxx iii damage common law theory andor iv remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty addition company name lawsuit contain similar allegationsfiledbygovernmentalentitiesseekingthereimbursementofallegedmedicaidexpendituresforvioxx lawsuit class action file santa clara county california behalf similarly situate californiacountiesandanactionfiledbyeriecountynewyorkwiththeexceptionofthecasefiledbytexas remain texas state court currently schedule trial september new york attorney general erie county case pende transfer rest action describe paragraph transfer federal mdl experience significant activity date shareholder lawsuit aspreviouslydisclosedinaddition tothevioxx productliability lawsuitsthecompanyandvarious current officer director defendant invarious putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx securitieslawsuitspendinginfederalcourthavebeentransferredbythejudicialpanelonmultidistrictlitigation jpml united states district court district new jersey district judge stanley r chesler forinclusion inanationwide mdlthe shareholder mdljudgechesler hasconsolidate vioxx securitieslawsuitsforallpurposestheputativeclassactionwhichrequesteddamagesonbehalfofpurchasersof companystockbetweenmayandoctoberallegedthatthedefendantsmadefalseandmisleade statement vioxx inviolation section band ofthe securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assertedclaimsundersectionaofthesecuritiesandexchangeactagainstcertaindefendantsrelatingtotheir salesofmerckstockandundersectionsandofthesecuritiesactofagainstcertaindefendantsbase statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan onapril judge chesler grant defendant motion dismissthecomplaintwithprejudiceplaintiffshaveappealedjudgecheslersdecisiontotheunitedstatescourt appeals circuit inoctoberadutchpensionfundfiledacomplaintinthedistrictofnewjerseyallegingviolation offederalsecuritieslawsaswellasviolationsofstatelawagainstthecompanyandcertainofficerspursuanttothe casemanagementordergoverningtheshareholdermdlthecasewhichisbasedonthesameallegationsasthe vioxxsecuritieslawsuitswasconsolidatedwiththevioxxsecuritieslawsuitsdefendantsmotiontodismissthe pensionfundscomplaintwasfiledonaugustinseptemberthedutchpensionfundfiledanamende complaintratherthanrespondingtodefendantsmotiontodismissinadditioninsixnewcomplaintswere file district new jersey behalf foreign institutional investor allege violation federalsecuritieslawsaswellasviolationsofstatelawagainstthecompanyandcertainofficersdefendantsare notrequiredtorespondtothesecomplaintsuntilafterthethirdcircuitissuesadecisiononthesecuritieslawsuit currently appeal aspreviouslydisclosedonaugustacomplaintwasfiledinoregonstatecourtbythestateof oregonthroughtheoregonstatetreasureronbehalfoftheoregonpublicemployeeretirementfundagainstthe companyandcertaincurrentandformerofficersanddirectorsunderoregonsecuritieslawatrialdatehasbeenset october aspreviouslydisclosedvariousshareholderderivativeactionsfiledinfederalcourtweretransferredto shareholder mdlandconsolidate forall purposesbyjudgechesler thevioxx derivativelawsuit mayjudgecheslergranteddefendantsmotiontodismissanddeniedplaintiffsrequestforleavetoamend complaint plaintiff appeal argue judge chesler err deny plaintiff leave amend complaintwithmaterialsacquiredduringdiscoveryonjulytheunitedstatescourtofappealsforthe thirdcircuitreversedthedistrictcourtsdecisiononthegroundsthatjudgecheslershouldhaveallowedplaintiff use discovery material try establish demand futility remand case district courtsconsideration ofwhetherevenwiththeadditional material plaintiffsrequesttoamendtheircomplaint futile plaintiff file brief support request leave amend complaint november motion pende addition previously disclose putative class action file federal court employeeretirementincomesecurityacterisaagainstthecompanyandcertaincurrentandformerofficer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim behalf certain company current employee participant certain company retirement plan breach fiduciarydutythelawsuitsmakesimilarallegationstotheallegationscontainedinthevioxxsecuritieslawsuit july judge chesler grant deny defendant motion dismiss erisa complaintinoctoberplaintiffsmovedforcertificationofaclassofindividualswhowereparticipantsinand beneficiariesofthecompanysretirementsavingsplansatanytimebetweenoctoberandseptember plan account include investment merck common stock fund andor merck common stock motion pende previously disclose october individual shareholder demand company board legal action mr raymond gilmartin chairman president chief executiveofficerandotherindividualsforallegedlycausingdamagetothecompanywithrespecttotheallegedly improper marketing vioxx december special committee board director retain honorable johnsmartin jrof debevoiseplimpton llp toconduct anindependent investigationofamong thing allegation set forth inthe demand judgemartinsreport wasmade public inseptember basedonthespecialcommitteesrecommendationmadeaftercarefulconsiderationofthemartinreportandthe impactthatderivativelitigationwouldhaveonthecompanytheboardrejectedthedemandonoctober shareholder file lawsuit state court atlantic county nj current executive directorsofthecompanyallegingthattheboardsrejectionoftheirdemandwasunreasonableandimproperand defendant breach duty company allow vioxx market international lawsuit aspreviouslydisclosedinadditiontothelawsuitsdiscussedabovethecompanyhasbeennamedasa defendantinlitigationrelatingtovioxxinvariouscountriescollectivelythevioxxforeignlawsuitsineurope canada brazil argentina australia turkey israel additional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future insurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible co insurancethisinsuranceprovidescoverageforlegaldefensecostsandpotential damageamountsinconnection withthevioxxproductliabilitylawsuitsthecompanysinsurancecoveragewithrespecttothevioxxlawsuit adequate cover defense cost loss previously disclose company upper level excess insurer provide excess insurance potentiallyapplicabletoallofthevioxxlawsuitshadcommencedanarbitrationseekingamongotherthingsto cancel policy tovoid oftheir obligation policy toraise coverage issueswith respecttothevioxxlawsuitsaspreviouslydisclosedinnovemberthetribunalinthearbitrationruledinthe companysfavororderingtheupperlevelexcessinsurerstocomplywiththeirobligationsunderthepoliciesthe companyrecordedamilliongaininthefourthquarterasaresultofcertainothersettlementsandthetribunal decisioninadditionpriortorecordingthegaininthefourthquarterofasaresultofsettlementswithand payment certain insurer company previously receive insurance proceed approx imately million company claim resolve low level excess insurerstoobtainreimbursementforamountspaidinconnectionwithvioxxproductliabilitylawsuitsasaresult ofsettlementsthathavealreadybeenmadethecompanywillnotrecoverthefullamountofthelimitsdiscussedin paragraph section resolution claim low level insurer affect total insurance recover claim remain coverage approximately million fromthelowerlevelexcessinsurersthecompanyhasnoadditional insuranceforthevioxxproduct liability lawsuit thecompanyhasdirectorsandofficersinsurancecoverageapplicabletothevioxxsecuritieslawsuit andvioxxderivativelawsuitswithstatedupperlimitsofapproximatelymillionthecompanyhasfiduciary insurance vioxx erisalawsuit state upper limit approximately million asa resultofthearbitration additional insurancecoveragefortheseclaimsshouldalsobeavailable ifneededunder upperlevelexcesspoliciesthatprovidecoverageforavarietyofriskstherearedisputeswiththeinsurersaboutthe availabilityofsomeorallofthecompanysinsurancecoveragefortheseclaimsandtherearelikelytobeadditional disputestheamountsactuallyrecoveredunderthepoliciesdiscussedinthisparagraphmaybelessthanthestated upper limit investigation aspreviouslydisclosedinnovemberthecompanywasadvisedbythestaffofthesecthatitwas commencinganinformalinquiryconcerningvioxxonjanuarythecompanyannouncedthatitreceive notice thesecissuedaformalnotice ofinvestigationalsothecompanyhasreceivedsubpoenasfromthe usdepartmentofjusticethedojrequestinginformationrelatedtothecompanysresearchmarketingand sellingactivitieswithrespecttovioxxinafederalhealthcareinvestigationundercriminalstatutesinadditionas previouslydisclosedinvestigationsarebeingconductedbylocalauthoritiesincertaincitiesineuropeinorderto determine anycriminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company receive number civil investigative demand cid fromagroupofattorneysgeneralfromstatesandthedistrictofcolumbiawhoareinvestigatingwhetherthe company violate state consumer protection law market vioxxthe company cooperate attorney general respond cid inadditionthecompanyreceivedasubpoenainseptemberfromthestateofcaliforniaattorney generalseekingdocumentsandinformationrelatedtotheplacementofvioxxoncaliforniasmedicalformulary company cooperate attorney general respond subpoena reserve asdiscussedaboveonnovembermerckenteredintothesettlement agreementwiththelaw firm comprise executive committee psc federal vioxx mdl representative plaintiffscounselinthetexasnewjerseyandcaliforniastatecoordinatedproceedingstoresolvestateandfederal miandisclaimsfiledasofthatdateintheunitedstatesthesettlementagreementwhichalsoappliestotolle claimswassignedbythepartiesafterseveralmeetingswiththreeofthefourjudgesoverseeingthecoordinationof percent current claim vioxx litigation settlement agreement apply uslegalresidentsandthosewhoallegethattheirmiorisoccurredintheunitedstatesasaresultofenteringinto settlement agreement company record pretax charge billion represent fix aggregate pay plaintiff qualify payment settlement program company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict whetherthistrialwillproceedonscheduleorthetimingofanyoftheothervioxxshareholderlawsuittrialsthe companybelievesthatithasmeritoriousdefensestothevioxxlawsuitsandwillvigorouslydefendagainstthemin viewoftheinherentdifficultyofpredictingtheoutcomeoflitigationparticularlywheretherearemanyclaimant andtheclaimantsseekindeterminatedamagesthecompanyisunabletopredicttheoutcomeofthesemattersand time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation include case verdict judgment enter companyand nowin postverdict proceedingsoronappealineachofthosecasesthecompanybelievesithasstrongpointstoraiseonappealand thereforethatunfavorableoutcomesinsuchcasesarenotprobableunfavorableoutcomesinthevioxxlitigation material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probableandreasonablyestimableasofdecemberthecompanyhadareserveofmillionsolelyfor itsfuturelegaldefensecostsrelatedtothevioxxlitigationduringthecompanyspentmillioninthe aggregate legal defense cost relate vioxx litigation record additional charge million thusasofdecemberthecompanyhadareserveofmillionsolelyforitsfuturelegaldefensecost relate vioxx litigation company spend approximately million aggregate legal defense cost worldwiderelate toithevioxx productliability lawsuitsiithevioxx shareholderlawsuitsiiithevioxx foreignlawsuitsandivthevioxxinvestigationscollectivelythevioxxlitigationinthesecondquarterand thirdquarterofthecompanyrecordedchargesofmillionandmillionrespectivelytoincreasethe reserve solely future legal defense cost relate vioxx litigation increase reserve company consider factor consider previously establish reserve vioxx litigationinthefourthquarterthecompanyspentapproximatelymillioninvioxxlegaldefensecostswhich result ina reserveof million december itsfuture legal defense costsrelate vioxx litigation enter settlement agreement company review reserve vioxx legal defense cost allocate approximately million reserve merck anticipate future cost administerthesettlementprogramsomeofthesignificantfactorsconsideredinthereviewofthereservewereas followstheactualcostsincurredbythecompanythedevelopmentofthecompanyslegaldefensestrategyand structureinlightofthescopeofthevioxxlitigationincludingthesettlementagreementandtheexpectationthat thesettlementagreementwillbeconsummatedbutthatcertainlawsuitswillcontinuetobependingthenumberof case bring company cost outcome complete trial current informationregardinganticipatedtimingprogressionandrelatedcostsofpretrialactivitiesandtrialsinthevioxx productliabilitylawsuitseventssuchasscheduledtrialsthatareexpectedtooccurthroughoutand inherent inability predict ultimate outcome trial disposition vioxx product liability lawsuitsnot participate noteligible settlement program limit companysability reasonably estimate legal cost billion reserve settlement program aggregate reserve establish vioxx litigation december approximatelybillionthevioxxreserveasofdecemberbillionofthevioxxreserve include accrued current liability consolidate balance sheet company anticipate need increase reserve quarter continuetomonitoritslegaldefensecostsandreviewtheadequacyoftheassociatedreservesandmaydetermineto increaseitsreservesforlegaldefensecostsatanytimeinthefutureifbaseduponthefactorssetforthitbelievesit appropriate product liability litigation previously disclose company defendant product liability lawsuit united states involvingfosamaxthefosamaxlitigationasofdecemberapproximatelycaseswhichinclude approximatelyplaintiffgroupshadbeenfiledandwerependingagainstmerckineitherfederalorstatecourt includingcaseswhichseekclassactioncertificationaswellasdamagesandmedicalmonitoringintheseaction plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasivedentalproceduressuchastoothextractionordentalimplantsandordelayedhealinginassociationwith use fosamaxonaugust jpmlordere fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdlforcoordinatedpretrialproceedingsthefosamaxmdlhasbeentransferredtojudgejohnkeenaninthe unitedstatesdistrictcourtforthesoutherndistrictofnewyorkasaresultofthejpmlorderapproximately case judge keenan judge keenan issue case management order set forth schedulegoverningtheproceedingswhichfocusesprimarilyuponresolvingtheclassactioncertificationmotionsin andcomplete factdiscoveryinaninitial groupofcasesbyaugustbriefingandargumenton plaintiffsmotionsforcertificationofmedicalmonitoringclasseswerecompletedinandjudgekeenanissue order deny motion january january judge keenan issue order dismiss prejudice class claim assert class action lawsuitsfile merck soughtpersonalinjurydamagesandormedicalmonitoringreliefonaclasswidebasisdiscoveryisongoinginboth thefosamaxmdllitigationaswellasinvariousstatecourtcasesthecompanyintendstodefendagainstthese lawsuit asofdecemberthecompanyhadaremainingreserveofapproximatelymillionsolelyfor future legal defense cost fosamax litigation significant factor consider establishmentofthereserveforthefosamaxlitigationlegaldefensecostswereasfollowstheactualcostsincurred company far development company legal defense strategy structure light creationofthefosamaxmdlthenumberofcasesbeingbroughtagainstthecompanyandtheanticipatedtime progression relate cost pretrial activity fosamax litigation company continue monitoritslegaldefensecostsandreviewtheadequacyoftheassociatedreservesduetotheuncertainnatureof litigationthecompanyisunabletoestimateitscostsbeyondthecompanyhasnotestablishedanyreserve foranypotentialliabilityrelatingtothefosamaxlitigationunfavorableoutcomesinthefosamaxlitigationcould material adverse effect company financial position liquidity result operation commercial litigation previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidatedclassactioncomplaintwhichaggregatedtheclaimspreviouslyfiledinvariousfederaldistrictcourt action alsoexpande number ofmanufacturer toinclude somewhich like companyhadnotbeen defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissaltheplaintiffsfiledanamendedconsolidatedclassactioncomplaintwhichdidnotnamethecompanyas defendant company pharmaceutical manufacturer defendant similar complaint pendinginfederalandstatecourtbroughtindividuallybyanumberofcountiesinthestateofnewyorkfortyof thecountycaseshavebeenconsolidatedthecompanywasdismissedfromthesuffolkcountycasewhichwasthe firstofthenewyorkcountycasestobefiledinadditionasofdecemberthecompanywasadefendant state case bring attorney general state defend aspreviouslydisclosedinjanuarythedojnotifiedthefederalcourtinneworleanslouisiana thatitwasnotgoingtointerveneatthattimeinapendingfederalfalseclaimsactcasethatwasfiledundersealin december company court issue order unseal complaint file physicianinlouisianaandorderedthatthecomplaintbeservedthecomplaintwhichallegedthatthecompany discount pepcid certain louisiana hospital lead increase cost medicaid dismiss amendedcomplaintwasfiledundersealandthecasehasbeenadministrativelyclosedbythecourtuntilthesealis liftedthestateoflouisianahasfileditsownamendedcomplaintincorporatingtheallegationscontainedinthe sealedamendedcomplaintaspartoftheresolutionofthegovernmentinvestigationsdiscussedbelowthesealin case lift case dismiss inaprilthecompanywasnamedinaquitamlawsuitunderthenevadafalseclaimsactthesuit inwhichthenevadaattorneygeneralhasintervenedallegesthatthecompanyinappropriately offerednominal pricing marketing pricing inducement certain customer fail comply obligation medicaid good price scheme relate arrangement company motion todismissthis action wasdenie bythe district court thismatter hasalsobeen dismissedaspart ofthe resolution government investigation december february company jointventure partner scheringploughreceivedseveraljointlettersfromthehousecommitteeonenergyandcommerceandthehouse subcommittee oversight investigation letter senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer januarythecompaniesandthemsppartnershipeachreceivedtwosubpoenasfromthenewyorkstate attorneygeneralsofficeseekingsimilarinformationanddocumentsmerckandscheringploughhavealsoeach receivedaletterfromtheofficeoftheconnecticutattorneygeneraldatedfebruaryrequestingdocuments relatedtothemarketingandsaleofvytorinandzetiaandthetimingofdisclosuresoftheresultsofenhancethe companyiscooperatingwiththeseinvestigationsandworkingwithscheringploughtorespondtotheinquiriesin additionsincemidjanuarythecompanyhasbecomeawareoforbeenservedwithapproximatelycivil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia unfavorable outcome result government investigation consumer fraud litigation material adverse effect company financial position liquidity result operation governmental proceeding previously disclose company receive subpoena doj connection investigationofthecompanysmarketingandsellingactivitiesincludingnominalpricingprogramsandsample company report receive cid attorney general texas company marketing selling activity relate texas previously disclose company receive cid attorney general texas ask additional information company marketingandsellingactivitiesrelatedtotexasincludingwithrespecttocertainofitsnominalpricingprogram sample april company receive subpoena office inspector general district columbia connection investigation company interaction physicians districtofcolumbiamarylandandvirginiainnovemberthecompanyreceivedaletterrequestfromthe doj connection investigation company pricing pepcid february company announce enter agreement government settle federal andstatecivilcasesallegingviolationsofthemedicaidrebate statuteaswellasfederal andstate falseclaimsactsinconnectionwithcertainnominalpricingprogramsandsalesandmarketingactivitiesbetween andtoresolvethesemattersthecompanyagreedtopayapproximatelymillionplusinterestand reasonable feesandexpensestothefederal governmentstatesparticipating inthemedicaidprogram andthe district columbia fourth quarter company record pretax charge million connection anticipate resolution investigation investigation describe precede paragraph resolve settlement agreement settlement describe arise civil action file seal district court locatedinphiladelphiaandneworleansbothactionscontainedallegationsinvolvingpastpricingprogramsthe philadelphiasettlementrelatestopastprogramsinwhichthecompanyofferedhospitalssignificantlydiscounte price certain medication include mevacor vioxx zocor philadelphia matter government allegedthatthecompanyimproperlyexcludedcertaindiscountsthosewhichwerenominalinamountfrom itsbestpricereportedtomedicaidunderthemedicaidrebateagreementthephiladelphiaactionalsorelatedto certainmarketingandsalesprogramsconductedbetweenandthephiladelphiasettlementaccountsfor million plus interest total settlement new orleans settlement resolve civil action contain allegation involve pricing discount offeredtohospitalsforpepcidtheoriginalpricingprogramknownastheflexprogramwaslaunchedinand continue operate flexnp program termination april new orleans settlement account million plus interest total settlement inconnectionwiththesesettlementsthecompanyenteredintoacorporateintegrityagreementwiththe department ofhealth andhumanservice whichincorporate companysexiste comprehensivecompli ance program govern pharmaceutical sale marketing activity united states aspreviouslydisclosedthecompanyhadreceivedaletterfromdojadvisingitoftheexistenceofacivil complaintbroughtunderthequitamprovisionsofthefalseclaimsactallegingthatthecompanyviolatedcertain rulesrelatedtoitscalculationsofbestpriceandotherfederalpricingbenchmarkcalculationscertainofwhichmay affect company medicaid rebate obligation doj inform company intend intervene action close investigation lawsuit dismiss company cooperate investigation addition investigation time time federal state foreign regulator authority seek information practice pharmaceuticalindustryorthecompanysbusinesspracticesininquiriesotherthantheinvestigationsdiscussedin section feasible predict outcome inquiry vaccine litigation aspreviouslydisclosedthecompanywasapartyinclaimsbroughtundertheconsumerprotectionact ofintheunitedkingdomwhichallegethatcertainchildrensufferfromavarietyofconditionsasaresultof vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mump rubella include companysmmrii condition include autism orwithout inflam matoryboweldiseaseepilepsyencephalitisencephalopathyguillainbarresyndromeandtransversemyelitisall oftheremainingcaseshavebeendiscontinuedorstruckoutbythecourtandthegrouplitigationhasconclude therearenoclaimsoutstandingagainstmerckaspreviouslydisclosedthecompanyisalsoapartytoindividual class action product liability lawsuit claim united states involve pediatric vaccine eg hepatitis b vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december therewere approximately activethimerosal relate lawsuitswith approximately plaintiff defen dant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case currently schedule trial company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation thecompanyhasbeensuccessfulinhavingcasesofthistypeeitherdismissedorstayedontheground thattheactionisprohibitedunderthenationalchildhoodvaccineinjuryactthevaccineactthevaccineact prohibitsanypersonfromfilingormaintainingacivilactioninstateorfederalcourtseekingdamagesagainsta vaccinemanufacturerforvaccinerelatedinjuriesunlessapetitionisfirstfiledintheunitedstatescourtoffederal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturerthepetitionermusteitherapursuehisorherpetitiontoconclusioninvaccinecourtandthentimely fileanelectiontoproceedwithacivilactioninlieuofacceptingthevaccinecourtsadjudicationofthepetitionor btimelyexercisearighttowithdrawthepetitionpriortovaccinecourtadjudicationinaccordancewithcertain statutorilyprescribedtimeperiodsthecompanyisnotapartytovaccinecourtproceedingsbecausethepetition bring united states department health human service companyisawarethat approximately casespende inthevaccine courtinvolve allegationsthatthimerosalcontainingvaccinesandorthemmriivaccinecauseautismspectrumdisordersnot thimerosalcontaine vaccine involve vaccine court proceeding company vaccine companyisthesolesourceofthemmriivaccinedomesticallyinjunethespecialmasterspresidingover thevaccine courtproceedingsheldatwoandahalfweekhearinginwhichbothpetitioner andthegovernment present evidence ontheissueofwhetherthecombination ofmmriivaccine andthimerosal invaccine causeautismspectrumdisordersandwhetheritdidcauseautismspectrumdisorderinthepetitioner inthatcase twoshorteradditionalevidentiaryhearingsofthattypeaddressingthatissuewereheldinthefallofruling inthesethreecasesareexpectedinaccordingtothevaccinecourtitexpectstoholdevidentiaryhearingsin sixadditionalsocalledtestcasesbyseptemberaddressingtheissueofwhetherthimerosalinvaccinesor mmr ii vaccine cause autism spectrum disorder cause disorder petitionersthevaccinecourthasindicatedthatitintendstousetheevidencepresentedatthesetestcasehearing guide adjudication remain autism spectrum disorder case patent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application andaswiththe fdaseeke tomarket generic formsofthecompanysproductspriortothe expiration relevant patent own company generic pharmaceutical manufacturer submit andastothefdaseekingtomarketintheunitedstatesagenericformoffosamaxpropeciaprilosecnexium singulairtrusoptcosoptandprimaxinpriortotheexpirationofthecompanysandastrazenecasinthecaseof prilosec nexium patent concern product addition anda submit fda seekingtomarketintheunitedstatesagenericformofzetiapriortotheexpirationofscheringploughspatent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market genericformofprilosecthecompanyhasfiledpatentinfringementsuitsinfederalcourtagainstcompaniesfile andas generic alendronate fosamax finasteride propecia dorzolamide trusopt montelukast singulair dorzolamidetimolol cosopt imipenemcilastatin primaxin astrazeneca company file patent infringement suit federal court company file andas generic omeprazole prilosecandesomeprazolenexiumalsothecompanyandscheringploughhavefiledapatentinfringement suitinfederalcourtagainstcompaniesfilingandasforgenericezetimibezetiasimilarpatentchallengesexist incertainforeignjurisdictionsthecompanyintendstovigorouslydefenditspatentswhichitbelievesarevalid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product infebruaryscheringploughreceivedanoticefromagenericcompanyindicatingthatithadfile anandaforzetiaandthatitischallengingtheuspatentsthatarelistedforzetiamerckandscheringplough market zetia ajoint venture mspsingapore companyllc onmarch scheringplough mspsingaporecompanyllcfiledapatentinfringementsuitagainstglenmarkpharmaceuticalsincusaandits parent corporation glenmark lawsuit automatically stay fda approval glenmark anda month adverse court decision whichever occur early aspreviouslydisclosedinjanuarythecompanyreceivedaletterfromranbaxylaboratoriesltd ranbaxystatingthatithadfiledanandaseekingapprovalofagenericversionofmercksprimaxininapril company file patent infringement suit ranbaxy aspreviouslydisclose infebruarythe companyreceivedanotice fromtevapharmaceutical tevaageneric companyindicating hadfiledanandaformontelukast andthat ischallenge uspatent islistedforsingulaironaprilthe companyfiledapatent infringement action teva lawsuit automatically stay fda approval tevas anda month adverse court decision whichever occur early previously disclose january court appeal federal circuit washingtondcfoundthecompanyspatentclaimsforonceweeklyadministrationoffosamaxtobeinvalidthe companyexhaustedalloptionstoappealthisdecisioninbasedonthecourtofappealsdecisionfosamax lostmarketexclusivityintheunitedstatesinfebruaryfosamaxplusdwilllosemarketingexclusivityinthe unitedstatesinaprilasaresultoftheseeventsthecompanyexpectssignificantdeclinesinusfosamax fosamax plus sale inmaythefederalcourtofcanadatrialdivisionissuedadecisionrefusingtobartheapprovalof generic alendronate groundsthat merck patent weekly alendronate likely invalid decision cannotbeappealedandgenericalendronatewaslaunchedincanadainjuneinjulymerckwassuedin federal court canada apotex corp apotex seek damage lose sale generic weekly alendronate patent proceeding aspreviouslydisclosedinseptemberthecompanyappealedadecisionoftheoppositiondivision oftheeuropeanpatentofficeepothatrevokedthecompanyspatentineuropethatcoverstheonceweekly administration alendronate march board appeal epo uphold decision opposition division revoke patent march epo issue patent europe companythatcoverstheonceweeklyadministrationofalendronateunderitstermsthisnewpatentiseffective untiljulyoppositionshavebeenfiledintheepoagainstthispatentadditionallymerckhasbroughtpatent infringementsuitsinvariouseuropeanjurisdictionsbaseduponthispatentmercksbasicpatentcoveringtheuseof alendronate hasbeen challenge european country company receive adverse decision germany holland united kingdom decision united kingdom upheld appeal company appeal decision germany holland inadditionaspreviouslydisclosedinjapanafteraproceedingwasfiledchallengingthevalidityofthe company japanese patent onceweekly administration alendronate patent office invalidate patent decision appeal onjanuarythecompanysuedhitechpharmacalcoinchitechofamityville new yorkforpatentinfringementinresponsetohitechsapplicationtothefdaseekingapprovalofagenericversion merck ophthalmic drug trusopt cosopt treat elevated intraocular pressure patientswithopenangleglaucomaorocularhypertensioninthelawsuitmercksuedtoenforceapatentcovere active ingredient dorzolamide present trusopt cosopt district court enter judgmentinmercksfavorwhichwasupheldonappealthepatentcoveringdorzolamideprovidesexclusivityfor trusopt cosopt october include month pediatric exclusivity time companyexpectssignificantdeclinesinussalesoftheseproductsmerckhaselectednottoenforcetwoother patent list fda cover combination dorzolamide timolol active ingredient cosopt inthecaseofomeprazoleonmaythetrialcourtissuedadecisionwithrespecttofourgeneric company sell generic omeprazole court find impax laboratories inc apotex product infringedastrazenecasformulationpatentswhileproductsmadebymylanlaboratoriesandlekpharmaceutical andchemicalcodddidnotinfringethecompaniesfoundtohaveinfringedwereorderedoffthemarketuntil october expiration pediatric exclusivity period companyand astrazeneca receivednotice inoctober ranbaxy file andafor esomeprazolemagnesiumtheandacontainsparagraphivchallengestopatentsonnexiumonnovember thecompanyandastrazenecasuedranbaxyintheunitedstatesdistrictcourtinnewjerseyaccordingly fdaapprovalofranbaxysandaisstayedformonthsuntilapriloruntilanadversecourtdecisionif whichever occur early company astrazeneca receive notice january ivax pharmaceuticals inc subsequently acquire teva file anda esomeprazole magnesium andacontainsparagraphivchallengestopatentsonnexiumonmarchthecompanyandastrazeneca suedtevaintheunitedstatesdistrictcourtinnewjerseyaccordinglyfdaapprovaloftevasandaisstaye month september adverse court decision whichever occur early january company astrazeneca sue dr reddys district court new jersey base drreddysfilingofanandaforesomeprazolemagnesiumaccordinglyfdaapprovalofdrreddysandais stay month july adverse court decision whichever occur early europe company aware company seek registration generic losartan activeingredientforcozaarthecompanyhaspatentrightstolosartanvialicensefromeidupontdenemour andcompanydupontthecompanyandduponthavefiledpatentinfringementproceedingsagainstvarious company portugal spain norway austria aspreviouslydisclosedinthethirdquarterofthecompanyresolvedcertainpatentdisputeswhich result net gain company litigation innovemberanindividualshareholderdeliveredalettertothecompanysboardallegingthatthe company sustain damage company adoption ofit change control separation benefit planthecicplaninnovembertheshareholdermadeademandontheboardtotakelegalactionagainst theboardscurrentorformermembersforallegedlycausingdamagetothecompanywithrespecttotheadoptionof cic plan response demand letter independent member board determine novemberboardmeetingthattheboardwouldtaketheshareholdersrequestunderconsiderationafter careful consideration bythe board shareholder wasadvise board determine totake legal action february individual shareholder deliver letter company board director demandingthattheboardtakelegalactionagainsttheresponsibleindividualstorecovertheamountspaidbythe company resolve governmental investigation referred previously disclose august united states district court district new jerseygrantedamotionbythecompanymedcohealthsolutionsincmedcohealthandcertainofficersand directorstodismissashareholderderivativeactioninvolvingclaimsrelatedtothecompanysrevenuerecognition practiceforretailcopaymentspaidbyindividualstowhommedcohealthprovidespharmaceuticalbenefitsaswell asotherallegationsthecomplaintwasdismissedwithprejudiceplaintiffsappealedthedecisionondecember theuscourtofappealsforthethirdcircuitupheldmostofthedistrictcourtsdecisiondismissingthe suit send issue company board director properly refuse shareholder demand relate company treatment retail copayment district court reconsideration differentlegalstandardplaintiffsmovedtoremandtheiractiontostatecourtonaugustandthedistrict courtgrante motion onfebruary theshareholder derivativesuitwaspendingbefore superior court new jersey chancery division hunterdon county remain issue dismiss prejudice favor medco health merck individual defendant july aspreviouslydisclosedpriortothespinoffofmedcohealththecompanyandmedcohealthagreedto settleonaclassactionbasisaseriesoflawsuitsassertingviolationsoferisathegruercasesthecompany medcohealthandcertainplaintiffscounselfiledthesettlementagreementwiththefederaldistrictcourtinnew york case commence number plaintiff include participant number pharmaceutical benefitplansforwhichmedcohealthisthepharmacybenefitmanageraswellastrusteesofsuchplanshavebeen consolidatedmedcohealthandthecompanyagreedtotheproposedsettlementinordertoavoidthesignificant costanddistractionofprolongedlitigationtheproposedclasssettlementhasbeenagreedtobyplaintiffsinfiveof thecasesfiledagainstmedcohealthandthecompanyundertheproposedsettlementthecompanyandmedco health agree pay total million medco health agree modify certain business practicesortocontinuecertainspecifiedbusinesspracticesforaperiodoffiveyearsthefinancialcompensationi intend benefit member settlement class include erisa plan medco health administer pharmacy benefit anytime december district court hold hearing hear objectionstothefairnessoftheproposedsettlementandapprovedthesettlementinbuthasnotyetdetermined number class member plan haveproperly elect toparticipate inthe settlement settlement becomesfinalonlyifandwhenallappealshavebeenresolvedcertainclassmemberplanshaveindicatedthatthey willnotparticipateinthesettlementcasesinitiatedbythreesuchplansandtwoindividualsremainpendinginthe southern district new york plaintiff case assert claim base erisa federalandstatelawsthatarethesameasorsimilartotheclaimsthathadbeenassertedbysettlingclassmembersin gruer case company medco health name defendant case notice appeal file appellate court hear oral argument decembertheappellatecourtissuedadecisionvacatingthedistrictcourtsjudgmentandremandingthe casestothedistrictcourttoallowthedistrictcourttoresolvecertainjurisdictionalissuesahearingwasheldto address suchissuesonfebruary district court issue rule onaugust resolve jurisdictional issuesinfavorofthe settle plaintiffstheclass member theother party hadpreviously appeal district court judgment renew appeals october renew appeal affirmedinpartandvacatedinpartbythefederalcourtofappealstheappealscourtremandedtheclasssettlement proceeding district court afterthespinoffofmedcohealthmedcohealthassumedsubstantiallyalloftheliabilityexposurefor matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involvingthecompanywhicharependingwhileitisnotfeasibletopredicttheoutcomeofsuchproceedingsor theproceedingsdiscussedinthisnoteintheopinionofthecompanyallsuchproceedingsareeitheradequately coveredbyinsuranceorifnotsocoveredshouldnotultimatelyresultinanyliabilitythatwouldhaveamaterial adverseeffectonthefinancialpositionliquidityorresultsofoperationsofthecompanyotherthanproceedingsfor separate assessment provide note environmental matter companyis aparty toa number proceeding bring comprehensiveenvironmental response compensation liability act commonly know superfund federal state equiv alentstheseproceedingsseektorequiretheoperatorsofhazardouswastedisposalfacilitiestransportersofwaste site generator hazardous waste dispose site clean site reimburse governmentforcleanupcoststhecompanyhasbeenmadeapartytotheseproceedingsasanallegedgeneratorof waste dispose site case government allege defendant jointly severally liableforthecleanupcostsalthoughjointandseveralliabilityisallegedtheseproceedingsarefrequentlyresolve sothattheallocationofcleanupcostsamongthepartiesmorenearlyreflectstherelativecontributionsofthepartie tothesitesituationthecompanyspotentialliabilityvariesgreatlyfromsitetositeforsomesitesthepotential liabilityisdeminimisandforothersthecostsofcleanuphavenotyetbeendeterminedwhileitisnotfeasibleto predict theoutcome ofmanyoftheseproceedingsbroughtbyfederal orstate agency orprivate litigant inthe opinionofthecompanysuchproceedingsshouldnotultimatelyresultinanyliabilitywhichwouldhaveamaterial adverseeffect onthe financial position result operation liquidity capital resource companythe companyhastakenanactiveroleinidentifyingandprovidingforthesecostsandsuchamountsdonotincludeany reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party merck enter consent decree decree united states america pennsylvaniadepartmentofenvironmentalprotectionandthepennsylvaniafishandboatcommissionresolve government claim assert enforcement action united states america commonwealth pennsylvania v merck co inc response previously disclose accidental release gallon potassiumthiocyanatefromthesiteinjunethatresultedinafishkillinthewissahickoncreekaswellasthe dischargeofmaterialsonaugustandthatcausedfoaminginthecreekpursuanttothetermsofthe decreemerckwillpaycivilpenaltiesintheamountofmillionfundsupplementalenvironmentalproject intheamountofmillionandimplementonsiteremedialmeasuresintheamountofmillionamotionto enter decree pende court previously disclose september approximately plaintiff file amend complaint merck defendant united states district court eastern district california assertingclaimsunderthecleanwateracttheresourceconservationandrecoveryactaswellasnegligence andnuisancethesuitseeksdamagesfordiminutionofpropertyvaluemedicalmonitoringandotherallegedreal personal property damage associate groundwater soil contamination find site merck subsidiary merce california company intend defend claim inmanagementsopiniontheliabilitie forallenvironmental matter thatareprobableandreasonably estimable accrue total million million december respectivelytheseliabilitiesareundiscounteddonotconsiderpotentialrecoveriesfromotherpartiesandwillbe paidoutovertheperiodsofremediationfortheapplicablesiteswhichareexpectedtooccurprimarilyoverthenext yearsalthoughitisnotpossibletopredictwithcertaintytheoutcomeofthesemattersortheultimatecostsof remediationmanagementdoesnotbelievethatanyreasonablypossibleexpendituresthatmaybeincurredinexcess oftheliabilitiesaccruedshouldexceedmillionintheaggregatemanagementalsodoesnotbelievethatthese expendituresshouldresultinamaterialadverseeffectonthecompanysfinancialpositionresultsofoperation liquidity capital resource year stockholder equity otherpaidincapitalincreasedbymillioninmillioninandmillionin theincreaseinreflectstheissuanceofsharesrelatedtotheacquisitionofnovacardiaseenotethe increasesinallperiodsalsoreflecttheimpactofsharesissueduponexerciseofstockoptionsandrelatedincometax benefit issuance restrict share addition increase reflect impact recognize sharebased compensation expense result adoption fas r note summary treasury stock transaction share millions follow share cost share cost share cost balance january purchase issuance balance december issuedprimarilyunderstockoptionplan atdecemberandmillionsharesofpreferredstockwithoutparvaluewereauthorize issue sharebased compensation plan thecompanyhassharebasedcompensationplansunderwhichemployeesnonemployeedirectorsand employee certain company equity method investee grant option purchase share companycommon stockatthefair market value atthe time ofgrantinaddition tostockoptionsthecompany grant performance share unit psus restrict stock unit rsus certain management level employee plan approve company shareholder december million share authorize future grant company sharebase compensation plan company settle employee sharebase compensation award primarily treasury share employeestockoptionsaregrantedtopurchasesharesofcompanystockatthefairmarketvalueatthe timeofgranttheseawardsgenerallyvestonethirdeachyearoverathreeyearperiodwithacontractualtermof yearsrsusarestockawardsthataregrantedtoemployeesandentitletheholdertosharesofcommonstockas theawardsvestaswellasnonforfeitabledividendequivalentsthefairvalueoftheawardsisdeterminedandfixe onthegrantdatebasedonthecompanysstockpricepsusarestockawardswheretheultimatenumberofshare issuedwillbecontingent onthecompanysperformanceagainstapresetobjectiveorsetofobjectivesthefair valueofeachpsuisdeterminedonthedateofgrantbasedonthecompanysstockpriceovertheperformance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate numberofsharesissuedthecompanydidnotrecognizecompensationexpenseinconnectionwithpsusin orbothpsuandrsupayoutswillbeinsharesofcompanystockaftertheendofthevestingorperformance period generally year subject term applicable award effective january company adopt fas r employee sharebase compensation expense previously recognize intrinsic value method measure sharebase compensation expense market price stock date grant exceed exercise price fasrrequirestherecognitionofthefairvalueofsharebasedcompensationinnetincomewhichthecompany recognizesonastraightlinebasisovertherequisiteserviceperiodadditionallythecompanyelectedthemodifie prospective transition method adopt fas r prior period retrospectively adjustedunderthismethodtheprovisionsforfasrapplytoallawardsgrantedormodifiedafterjanuary addition unrecognized expense award vest date adoption recognize net income relevant period date adoption effective january companyadopte fasbstaffpositionrtransition election relate accounting forthe taxeffect sharebase payment award provide company optional shortcut method calculate historical pool windfall tax benefit adopt fas r follow table provide amount sharebased compensation cost record consolidated statement income substantially amount related rsus year end december pretax sharebase compensation expense income tax benefit total sharebased compensation expense net tax fasrrequiresthecompanytopresentproformainformationforperiodspriortotheadoptionasif thecompanyhadaccountedforemployeesharebasedcompensationunderthefairvaluemethodofthatstatement forpurposesofproformadisclosuretheestimatedfairvalueofawardsatthedateofgrantincludingthosegrante retirementeligible employee amortize expense requisite service period follow table illustrate effect net income earning common share company apply fair value method recognize employee sharebase compensation year end december year end december net income report compensation expense net tax report fair value method pro forma net income earning common share basic report basic pro forma assume dilution report assume dilution pro forma theproformaamountsandthefairvalueofeachoptiongrantwereestimatedonthedateofgrantusing blackschole option pricing model adoption fas r compensation expense recognize immediately award grant retirementeligible employee period grant date date retirement eligibility achieve approach know nonsubstantive vest period approach company apply approach stock option grant retirementeligible employeestheeffectonproformaearningspershareassumingdilutionfortheyearendeddecembera provide table significant pro forma compensation expense calculate blackschole model utilize assumptionsbasedonhistoricaldatasuchthatexpensewasdeterminedusingseparateexpectedtermassumption foreachvestingtrancheasaresultproformacompensationexpenseforanystockoptionsgrantedafterjanuary butprior tojanuarywascalculate usingthe accelerated amortization method prescribe infasb interpretationnoaccountingforstockappreciationrightsandothervariablestockoptionorawardplans uponadoptionoffasreffectivejanuarythecompanyrecognizescompensationexpenseusingthe straightline method thecompanycontinuestousetheblackscholesoptionpricingmodelforoptiongrantsafteradoptionof fasrinapplyingthismodelthecompanyusesbothhistoricaldataandcurrentmarketdatatoestimatethe fair value option blackschole model require assumption include expect term optionsriskfreeratevolatilityanddividendyieldtheexpectedtermrepresentstheexpectedamountoftimethat optionsgrantedareexpectedtobeoutstandingbasedonhistoricalandforecastedexercisebehaviortheriskfree rateisbasedontherateatgrantdateofzerocouponustreasurynoteswithatermequaltotheexpectedtermof option expect volatility estimate blend historical imply volatility historical componentisbasedonhistoricalmonthlypricechangestheimpliedvolatilityisobtainedfrommarketdataonthe company trade option theweightedaveragefairvalueofoptionsgrantedinandwasand option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative company stock option plan option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term value balance december grant exercise forfeit outstanding december exercisable december additional information pertain companysstock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option asummaryofthecompanysnonvestedrsusandpsussharesinthousandsatdecemberis follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste december grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relatedtononvestedstockoptionsrsuandpsuawardswhichwillberecognizedoveraweightedaverageperiod year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan thecompanyhasdefinedbenefitpensionplanscoveringeligibleemployeesintheunitedstatesandin certainofitsinternationalsubsidiariespensionbenefitsintheunitedstatesarebasedonaformulathatconsider final average pay year credit service addition company provide medical dental life insurancebenefitsprincipallytoitseligibleusretireesandsimilarbenefitstotheirdependentsthroughitsother postretirement benefit plan company use december measurement date substantially pension plan postretirement benefit plan thenetcostforthecompanyspensionandotherpostretirementbenefitplansconsistedofthefollowe component postretirement pension benefit benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net pension postretirement cost thenetpensioncostattributabletousplansincludedintheabovetablewasmillion million million cost health care life insurance benefit active employee million million million inconnectionwiththecompanysrestructuringactionsseenotemerckrecordedterminationcharge pension postretirement benefit plan relate expand eligibility certain employee exit company connection restructuring activity company record curtailment loss pension plan curtailment gain postretirement benefitplansandcurtailment lossesinonitspensionandotherpostretirement benefitplans amendment change participant contribution postretirement benefit plan generate curtailment gain inadditionthecompanyrecordedsettlementlossesinandandasettlementgaininon certain ofitsdomestic pensionplansresulte fromemployee elect toreceivetheirpensionbenefitsaslump sum payment effectivedecemberthecompanyadoptedfasbstatementnoemployersaccounte fordefinedbenefitpensionandotherpostretirementplansanamendmentoffasbstatementsnoand rfasexceptfortherequirementtomeasureplanassetsandbenefitobligationsasofthecompany fiscalyearendwhichiseffectiveasofdecemberfasrequiredthecompanytofullyrecognizethe fund status benefit plan overfunde plan recognize asset underfunde plan recognize liability previously unrecognized net lossesand unrecognized plan change recognize component aoci note summarizedinformationaboutthechangesinplanassetsandbenefitobligationthefundedstatusandthe amount record december follow postretirement pension benefit benefit fair value plan asset january actual return plan asset company contribution benefit pay plan asset fair value plan asset december benefit obligation january service cost interest cost actuarial gain loss benefit pay plan amendment curtailment termination benefit benefit obligation december fund status december recognize asset accrue current liability defer income taxis noncurrent liability thefairvalue ofuspensionplanassetsinclude inthepreceding tablewasbillion inand thepensionbenefitobligationofusplansincludedinthistablewasbillioninandbillionin weight average asset allocation investment portfolio pension postre tirement benefit plan december follow postretirement pension benefit benefit target target equities international equity fixedincome investment real estate investment cash cash equivalent thetargetinvestmentportfoliosforthecompanyspensionplansaredeterminedbycountrybasedonthe natureoftheliabilitiesandconsideringthedemographiccompositionoftheplanparticipantsaverageageyearsof service active versus retiree status accordance local regulation investment include insurancecontractsforcertaininternationalpensionplansthetargetinvestmentportfolioassetallocationforthe company postretirement benefit plan consistent longterm nature plan benefit obligation diversify asset class portfolio invest contributionstothepensionplansandotherpostretirementbenefitplansduringareexpectedtobe million million respectively expect benefit payment follow pension postretirement benefit benefit expect benefit paymentsarebasedonthesameassumptionsusedtomeasure thebenefitobligation include estimate future employee service atdecember andtheaccumulate benefitobligation wasbillion andbillion respectively pension plan december accumulate benefit obligation uspensionplanswasbillionthecompanyrecordedaminimumpensionliabilityrepresentingtheextentto accumulate benefit obligation exceed plan asset certain company pension plan million prior adoption fas december forpensionplanswithbenefitobligationsinexcessofplanassetsatdecemberandthefair valueofplanassetswasmillionandmillionrespectivelyandthebenefitobligationwasbillion billion respectively plan accumulate benefit obligation excess plan asset decemberandthefairvalueofplanassetswasmillionandmillionrespectivelyandthe accumulate benefit obligation million million respectively net loss amount reflect experience differential primarily relate difference expectedandactualreturnsonplanassetsaswellastheeffectsofchangesinactuarialassumptionsarerecorde asacomponentofaocinetlossamountsinexcessofcertainthresholdsareamortizedintonetpensionandother postretirementbenefitcostovertheaverageremainingservicelifeofemployeestheestimatednetlossandprior service cost credit amount amortize aociinto net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan thecompanyreassessesitsbenefitplanassumptionsonaregularbasistheweightedaverageassumption usedindeterminingpensionplananduspensionandotherpostretirement benefitplaninformationareasfollow pension postretirement pension plan benefit plan december net cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate usedforotherpostretirementbenefitplan expect rate return pension postretirement benefit plan represent averagerateofreturntobeearnedonplanassetsovertheperiodthebenefitsincludedinthebenefitobligationareto bepaidandisdeterminedonacountrybasisindevelopingtheexpectedrateofreturnwithineachcountrythelong term historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return countrys target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return remain unchanged pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate aonepercentage pointchange inthe health care costtrendratewouldhavehad thefollowingeffect percentage point increase decrease effect total service interest cost component effect benefit obligation income expense net year end december interest income interest expense exchange gain minority interest net thechangeinothernetduringprimarilyreflectsachargerelatedtotheresolutionofcertaincivil governmentalinvestigationsseenotepartiallyoffsetbythefavorableimpactofgainsonsalesofassetsand product divestiture net gain settlement certain patent dispute increase interest income inreflectsinterestincomegenerate fromthecompanysinvestmentportfolioderivedfromhigher interest rate high average investment portfolio balance interest pay million million million taxis income reconciliation company effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning taxexemption puerto rico operation state taxis acquire research american jobscreation act otherincludesthetaxeffectofminorityinterestscontingencyreservesresearchcreditsexportincentivesandmiscellaneousitem thetaxratereconciliationpercentageofforforeignearningsreflectsthechangeinmixof foreignanddomesticearningsprimarilyresultingfromthebillionusvioxxsettlementagreementcharge pretax loss income consist year end december pretax loss income domestic foreign taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation advance payment equity investment pension postretirement benefit compensation relate vioxx litigation reserve unrecognized tax benefit net operating loss subtotal valuation allowance total defer taxis net deferred income taxis recognize prepay expense taxis asset income taxis payable deferred income taxis noncurrent liability company net operating loss nol carryforward number jurisdiction significantofwhichistheunitedkingdomwithnolcarryforwardsofmillionwhichhavenoexpiration datethevaluationallowanceinbothyearsprimarilyrelatestocertaincanadiannolcarryforwardsresultingfrom legal entity reorganization incometaxespaidinandwerebillionbillionandbillionrespectively stockoptionexercisesreducedincometaxespaidbymillioninstockoptionexercisesdidnothavea significant impact taxis pay onjanuarythecompanyadoptedtheprovisionsoffasbinterpretationnoaccountingfor uncertainty income taxesan interpretation fasb statement fin fin prescribe recognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementofatax position take expect take tax return fin require company determine benefitsoftaxpositionsaremorelikelythannotofbeingsustaineduponauditbasedonthetechnicalmeritsofthe taxpositionfortaxpositionsthataremorelikelythannotofbeingsustaineduponauditthecompanyrecognize thelargestamountofthebenefitthatisgreaterthanlikelyofbeingrealize uponultimate settlement inthe financialstatementsfortaxpositionsthatarenotmorelikelythannotofbeingsustaineduponauditthecompany doesnotrecognizeanyportionofthebenefitinthefinancialstatementsasaresultoftheimplementationoffin company recognize million decrease exist liability unrecognized tax benefit correspond increase january retain earning balance asofjanuaryaftertheimplementationoffinthecompanysliabilityforunrecognizedtax benefitswasbillionexcludingliabilitiesforinterestandpenaltiesifthecompanyweretorecognizethese benefitstheincometaxprovisionwouldreflectafavorablenetimpactofbillioninadditionatjanuary liabilitiesforaccruedinterestandpenaltiesrelatingtotheunrecognizedtaxbenefitstotaledbilliona ofdecemberthecompanysconsolidatedbalancesheetreflectsaliabilityforunrecognizedtaxbenefit ofbillionifthecompanyweretorecognizethesebenefitstheincometaxprovisionwouldreflectafavorable net impact billion accrue interest penalty include consolidated balance sheet billionasofdecemberthedeclinesfromjanuarywereprimarilyduetothesettlementwith internal revenue service irs discuss reconciliation begin end unrecognized tax benefit follow balance january addition relate prior year position reduction tax position prior year addition relate current year position settlement lapse statute limitation balance december thecompanyrecognizesinterestandpenaltiesassociatedwithuncertaintaxpositionsasacomponentof taxis income consolidate statement income amount million aspreviouslydisclosedtheirshascompleteditsexaminationofthecompanystaxreturnsfortheyear toasaresultoftheexaminationthecompanymadeanaggregatepaymentofbillioninfebruary thispaymentwasoffsetbyiataxrefundofmillionreceivedinforamountspreviouslypaidfor thesemattersandiiafederaltaxbenefitofapproximatelymillionrelatedtointerestincludedinthepayment resultinginanetcashcosttothecompanyofapproximatelybillionintheimpactforyearssubsequent toforitemsreviewedaspartoftheexaminationwasincludedinthepaymentalthoughthoseyearsremainopen inallotherrespectstheclosingoftheirsexaminationdidnothaveamaterialimpactonthecompanysresultsof operation amounts previously provide thecompanyisintheprocessofreportingtheresultsoftheirsadjustmentsfortheyearsthrough state tax authority result additional tax interest payment million million respectively equivalent reduction balance unrecognize tax benefit accrue interest itisanticipatedthattheamountofunrecognizedtaxbenefitswillchangeinthenextmonthshowever thesechangesarenotexpectedtohaveasignificantimpactontheresultsofoperationscashflowsorthefinancial position company previously disclose merck canadian tax return year examine bythe canada revenue agencycra inoctober craissue companya notice reassessment contain adjustment relate certain intercompany pricing matter result additional canadian provincial tax approximately billion dollar plus interest approximately millionusdollarsinadditioninjulythecraproposedadditionaladjustmentsforrelatingto intercompany pricing matter adjustment increase canadian tax approximately million dollar plus million dollar interest possible crawill propose similaradjustmentsforlateryearsthecompanydisagreeswiththepositionstakenbythecraandbelievesthey arewithoutmeritthecompanyintendstocontesttheassessmentthroughthecraappealsprocessandthecourt ifnecessaryinconnectionwiththeappealsprocessduringthecompanypledgedcollateraltotwofinancial institution provide guarantee cra quebec ministry revenue representingaportionofthetaxandinterestassessedthecollateralisincludedinotherassetsintheconsolidate balance sheet total approximately billion december company previously establishedreservesforthesematterswhiletheresolutionofthesemattersmayresultinliabilitieshigherorlow reserve management believe resolution matter material effect companysfinancialpositionorliquidityhoweveranunfavorableresolutioncouldhaveamaterialeffectonthe company result operation cash flow quarter adjustment record tax injulythecranotifiedthecompanythatitisintheprocessofproposingapenaltyofmillion usdollarsinconnectionwiththenoticethepenaltyisforfailingtoprovideinformationonatimelybasis companyvigorouslydisagree withthe penalty feel isinapplicable andthat appropriate information provide timely basis company pursue appropriate remedy avoid penalty assessedand wasnotifie inearly august craisholde imposition apenalty inabeyance pende review company submission inapplicability penalty irsrecently beganit examination ofthe companystofederal income tax return connectionwiththeexaminationthecompanyisconsideringthepossibilityofaprefilingagreementwiththeir assure certainty respect time deductibility certain legal settlement accrue additionvariousstateandforeigntaxexaminationsareinprogresstaxyearsthatremainsubjecttoexaminationby majortaxjurisdictionsincludegermanyfromitalyandjapanfromandtheunitedkingdomfrom december foreign earning billion havebeen retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant expire respectively american job creation act ajcacreatedtemporaryincentivesforusmultinationalstorepatriateaccumulatedincomeearnedoutsidethe unitedstatesasofdecemberinaccordancewiththeajcathecompanyrepatriatedbilliondure thecompanyrecordedanincometaxchargeofmillionintaxesonincomeinrelatedtothis repatriationmillionofwhichwaspaidinandtheremainderwaspaidinthefirstquarterofthe company change intention indefinitely reinv accumulate earning earn subsequent december earning share theweightedaveragecommonsharesusedinthecomputationsofbasicearningspercommonshareand earning common share assume dilution share million follow year end december average common share outstanding common share issuable average common share outstanding assume dilution issuableprimarilyundersharebasedcompensationplan inandmillionmillionandmillionrespectivelyofcommonshare issuableunderthecompanyssharebasedcompensationplanswereexcludedfromthecomputationofearningsper common share assume dilution effect antidilutive comprehensive income component comprehensive income follow pretax tax tax year end december net unrealized loss derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net gain loss prior service cost credit arise period net loss prior service cost credit amortization include net periodic benefit cost benefit plan cumulative translation adjustment relate equity investee year end december net unrealized loss derivative net loss realization derivative net unrealized gain investment net loss realization investment minimum pension liability cumulative translation adjustment relate equity investee year end december net unrealized gain derivative net loss realization derivative net unrealized loss investment net loss realization investment minimum pension liability cumulative translation adjustment relate equity investee netofapplicableminorityinterest pretaxnetgainlossandpriorservicecostcreditarisingduringtheperiodweremillionandmillionrespectivelyfor pensionplansandweremillionandmillionrespectivelyforotherpostretirementbenefitplans pretaxamortizationofnetlossandpriorservicecostcreditwasmillionandmillionrespectivelyrelatingtopensionplan andmillionandmillionrespectivelyrelatingtootherpostretirementbenefitplan component accumulate comprehensive loss follow december net unrealized loss derivative net unrealized gain investment pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service cost cumulative translation adjustment relate equity investee atdecembermillionofthenetunrealizedlossonderivativesisassociatedwithoption maturinginthenextmonthswhichhedgeanticipatedforeigncurrencydenominatedsalesoverthatsameperiod segment reporting company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine segment thepharmaceuticalsegmentincludeshumanhealthpharmaceuticalproductsmarketedeitherdirectlyor joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine segment include human health vaccine product market directly joint venture product consist preventivepediatricadolescentandadultvaccinesprimarilyadministeredatphysicianofficesmercksellsthese human health vaccine primarily physicians wholesaler physician distributor government entity vaccinessegmentincludesthevastmajorityofthecompanysvaccinesalesbutexcludescertainsalesofvaccine bynonussubsidiariesmanagedbyandincludedinthepharmaceuticalsegmentalargecomponentofpediatric adolescent vaccine sell center disease control prevention vaccine child program fund government allotherincludesothernonreportablehumanandanimalhealthsegmentstheaccountingpoliciesfor thesegmentsdescribedabovearethesameasthosedescribedinnoterevenuesandprofitsforthesesegmentsare follow pharmaceutical vaccine total year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization inaccordancewithsegmentreportingrequirementsvaccinessegmentrevenuesexcludemillionmillionandmillionin andrespectivelyofvaccinesalesbycertainnonussubsidiariesmanagedbyandincludedinthepharmaceuticalsegment segment profit comprise segment revenue certain element material production costsandoperatingexpensesinclude componentsofequity income lossfromaffiliatesanddepreciation amortization expense internal management reporting present chief operating decision maker companydoesnotallocatethevastmajorityofindirectproductioncostsresearchanddevelopmentexpensesand general andadministrativeexpensesaswellasthecostoffinancingtheseactivitiesseparatedivisionsmaintain responsibility formonitore andmanaging thesecostsincluding depreciation relate tofixedassetsutilize division include segment profit reconciliation total segment revenue consolidate sale follow year end december segment revenue revenue revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale include segment result sale company product follow year end december singulair cozaarhyzaar fosamax zocor cosopttrusopt primaxin januvia cancidas vasotecvaseretic maxalt proscar propecia arcoxia crixivanstocrin emend invanz janumet pharmaceutical vaccine gardasil rotateq zostavax proquadmmr iivarivax hepatitis vaccine vaccine presentednetofdiscountsandreturn otherpharmaceuticalprimarilyincludessalesofotherhumanpharmaceuticalproductsandrevenuefromthecompanysrelationshipwith astrazenecalpprimarilyrelatingtosalesofnexiumaswellasprilosecrevenuefromastrazenecalpwasbillionbillionand billioninandrespectivelyinotherpharmaceuticalalsoreflectscertainsupplysalesincludingsupplysale associatedwiththecompanysarrangementwithdrreddyslaboratoriesforthesaleofgenericsimvastatin theseamountsdonotreflectsalesofvaccinessoldinmostmajoreuropeanmarketsthroughthecompanysjointventuresanofipasteur msdtheresultsofwhicharereflectedinequityincomefromaffiliate otherprimarilyincludesotherhumanandanimalhealthjointventuresupplysalesandothermiscellaneousrevenue consolidated revenue geographic area derive follow year end december united states europe middle east africa japan reconciliation total segment profit consolidate income taxis follow year end december segment profit profit adjustment unallocate interest income interest expense equity income affiliate depreciation amortization research development vioxx settlement agreement charge expense net profit primarily comprise miscellaneous corporate profit operating profit relatedtodivestedproductsorbusinessesandothersupplysalesadjustmentsrepresenttheeliminationoftheeffect ofdoublecountingcertain itemsofincomeandexpenseequityincomefromaffiliatesincludestaxespaidatthe joint venture level portion equity income report segment profit expense net include expensesfromcorporate andmanufacture costcenter andothermiscellaneous income expensenet longlive assets geographic area locate follow year end december united states europe middle east africa japan longlivedassetsarecomprisedofpropertyplantandequipmentnetgoodwillandintangibleassetsnet company disaggregate asset product service basis internal management report information present report independent register public accounting firm board director shareholders merck co inc opinion accompany consolidated balance sheet relate consolidated statement income retainedearningsofcomprehensiveincomeandofcashflowspresentfairlyinallmaterialrespectsthefinancialpositionof merckcoincanditssubsidiariesatdecemberanddecemberandtheresultsoftheiroperationsand theircashflowsforeachofthethreeyearsintheperiodendeddecemberinconformitywithaccountingprinciple generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespect effective internal control financial reporting december base criterion establish internal controlintegratedframework issuedbythecommittee sponsoringorganizationsofthe treadwaycommission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting includedinmanagementsreportunderitemaourresponsibilityistoexpressopinionsonthesefinancialstatementsand company internal control financial reporting base integrated audits conduct audits accordancewiththestandardsofthepubliccompanyaccountingoversightboardunitedstatesthosestandardsrequire plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respectsourauditsofthefinancialstatementsincludedexaminingonatestbasisevidencesupportingtheamountsand disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reportingincludedobtaininganunderstandingofinternalcontroloverfinancialreportingassessingtheriskthatamaterial weaknessexistsandtestingandevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassesse risk audits include perform procedure consider necessary circumstance believethatourauditsprovideareasonablebasisforouropinion discuss note consolidated financial statement company change manner account sharebase compensation discuss note consolidated financial statement company change manner account define benefit pension postretirement plan discuss note consolidated financial statement company change manner account unrecognized tax benefit acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliability financial reporting preparation financial statement external purpose accordance generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand procedure pertain maintenance record reasonable detail accurately fairly reflect transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsarerecordeda necessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccountingprinciplesand thatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsofmanagementand directorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetectionofunauthorize acquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancialstatement inherent limitation internal control financial reporting prevent detect misstate mentsalsoprojectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmay inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february b supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount th q rd q nd q st q sale material production cost market administrative expense research development expense restructure cost equity income affiliate vioxx product liability settlement charge income expense net loss income taxis net loss income basic loss earning common share loss earning common share assume dilution sale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income taxis net income basic earning common share earning common share assume dilution amountsforincludetheimpactoftheusvioxxsettlementagreementchargeacivilgovernmentalinvestigationschargeandan insurancearbitrationgainseenotethefourthquartertaxprovisioninadditiontotheseitemsalsoreflectsthefavorableimpactsof adjustmentsrelatingtocertainfederalandstatetaxitem amountsforthirdandsecondquarterandfourthandthirdquarterincludetheimpactofadditionalvioxxlegaldefensereserves seenoteamountsforfourthquarterincludetheimpactoffosamaxlegaldefensereservesseenote amountsforthirdquarterandfourthandsecondquarterincludeacquiredresearchexpensesassociatedwithacquisitionssee note amountsforincludeanetgainonthesettlementsofcertainpatentdispute amountsforincludegainsonsalesofassetsandproductdivestiture amountsforandincludetheimpactofrestructuringactionsseenote item change disagreement accountant account financial disclosure applicable item control procedure managementofthecompanywiththeparticipation ofitschiefexecutiveofficerandchieffinancial officerevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresbasedontheirevaluation asoftheendoftheperiodcoveredbythisformkthecompanyschiefexecutiveofficerandchieffinancial officerhaveconclude thatthecompanysdisclosurecontrolsandprocedure asdefinedinrulesae de security exchange act amend act effective managementisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancialreporte assuchtermisdefinedinruleafoftheactmanagementconductedanevaluationoftheeffectivenessofinternal control financial reporting base framework internal controlintegrate framework issue committeeofsponsoringorganizationsofthetreadwaycommissioncosobasedonthisevaluationmanage mentconcludedthatinternalcontroloverfinancialreportingwaseffectiveasofdecemberbasedoncriteriain internalcontrolintegratedframeworkissuedbycosopricewaterhousecoopersllpanindependentregistered publicaccountingfirmhasperformeditsownassessmentoftheeffectivenessofthecompanysinternalcontrolover financial reportinganditsattestationreport isinclude inthisformkfile change internal control financial reporting period cover report havematerially affect reasonably likely materially affect companysinternal control overfinancialreportingaspreviouslydisclosedthecompanyisundergoingamultiyearinitiativetostandardizea number information system october company implement sap environment selectedbusinessprocessesatalimitednumberofitsnonuslocationsthisinitiativeaswellasthecompany plantomovecertaintransactionprocessingactivitiesintosharedserviceenvironmentswillsupporteffortstocreate lean organization management report management responsibility financial statement responsibility integrity objectivity company financial statement rest managementthefinancialstatementsreportonmanagementsstewardshipofcompanyassetsthesestatement areprepare inconformity withgenerally accept accounting principle andaccordinglyinclude amountsthat arebasedonmanagementsbestestimatesandjudgmentsnonfinancialinformationincludedintheannualreport prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection traininganddevelopmentofoperatingandfinancialmanagersanorganizationthatprovidesappropriatedivisionof responsibility communication aim assure company policy procedure understand throughouttheorganizationastaffofinternalauditorsregularlymonitorstheadequacyandapplicationofinternal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition companyhascompliance programsincludinganethical businesspractice programtoreinforce thecompany longstanding commitment high ethical standard conduct business financial statement financial information include inthe annual report onform k fairlypresentinallmaterialrespectsthecompanysfinancialconditionresultsofoperationsandcashflowsour formalcertificationtothesecuritiesandexchangecommissionisincludedinthisformkfilinginadditionin maythecompanysubmittedtothenewyorkstockexchangenyseacertificateoftheceocertifye aware violation company nyse corporate governance list standard management report internal control financial reporting managementisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancialreporting assuchtermisdefinedinexchangeactruleafmanagementconductedanevaluationoftheeffectivenessof internalcontroloverfinancialreportingbasedontheframeworkininternalcontrolintegratedframeworkissuedby committee sponsor organization treadway commission coso base evaluation managementconcludedthatinternalcontroloverfinancialreportingwaseffectiveasofdecemberbasedon criteriaininternalcontrolintegratedframeworkissuedbycosopricewaterhousecoopersllpanindependent register public accounting firm perform assessment effectiveness company internal control financial reportinganditsattestationreport isincludedinthisform kfile peter n kellogg richard clark executive vice president chairman president chief financial officer chief executive officer item b information iii item director executive officer corporate governance require information director nominee incorporate reference discussion underitemelectionofdirectorsofthecompanysproxystatementfortheannualmeetingofstockholderstobe heldaprilinformationonexecutiveofficersissetforthinpartiofthisdocumentonpagesthrough require information compliance section security exchange act incorporate byreference fromthediscussionundertheheadingsectionabeneficialownershipreporte complianceofthecompanysproxystatementfortheannualmeetingofstockholderstobeheldapril thecompanyhasadoptedacodeofconductourvaluesandstandardsapplicabletoallemployee includingtheprincipalexecutiveofficerprincipalfinancialofficerandprincipalaccountingofficerthecodeof conduct available company website wwwmerckcomaboutcorporategovernance company intendstopostonthiswebsiteanyamendmentstoorwaiversfromitscodeofconductaprintedcopywillbe sentwithoutchargetoanystockholderwhorequestsitbywritingtothechiefethicsofficerofmerckcoinc merck drive whitehouse station nj therequiredinformationontheidentificationoftheauditcommitteeandtheauditcommitteefinancial expertisincorporatedbyreferencefromthediscussionundertheheadingboardcommitteesofthecompany proxy statement annual meeting stockholder hold april item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity awards fiscal yearend tableoptionexercisesandstockvestedtableretirementplanbenefitsandrelatedpensionbenefitstable nonqualifieddeferredcompensationandrelatedtablespotentialpaymentsonterminationorchangeincontrol include discussion subheading separation separation plan payment benefit estimate table individual agreement change control change control payment benefit estimate tableaswellasallfootnoteinformationtothevarioustablesofthecompanysproxystatement fortheannual meeting stockholder hold april require information director compensation incorporate reference discussion undertheheadingdirectorcompensationandrelateddirectorcompensationtableandscheduleofdirector feestableofthecompanysproxystatementfortheannualmeetingofstockholderstobeheldapril require information underthe headings compensation committee interlock andinsider partic ipation compensation benefit committee report incorporate reference company proxy statement annual meeting stockholder hold april item security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan incorporate reference discussion head equity compensation plan information companysproxystatement forthe annual meeting stockholder hold april information withrespecttosecurityownershipofcertainbeneficialownersandmanagementisincorporatedbyreferencefrom discussion head security ownership certain beneficial owner management company proxy statement annual meeting stockholder hold april item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting stockholder hold april require information director independence incorporate reference discussion head independence director company proxy statement annual meeting stockholder hold april item principal accountant fee service information require item incorporate reference discussion audit committee beginning caption preapproval policy service independent register public accounting firm fee companys proxy statement annual meeting stockholder hold april iv item